þ
|
Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
o
|
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Delaware
|
|
75-3108137
|
State of Incorporation
|
|
IRS Employer Identification No.
|
|
|
|
11825 N. Pennsylvania Street
|
|
|
Carmel, Indiana 46032
|
|
(317) 817-6100
|
Address of principal executive offices
|
|
Telephone
|
Title of each class
|
|
Name of Each Exchange on which Registered
|
Common Stock, par value $0.01 per share
|
|
New York Stock Exchange
|
Rights to purchase Series C Junior Participating Preferred Stock
|
|
New York Stock Exchange
|
PART I
|
|
Page
|
Item 1.
|
||
Item 1A.
|
||
Item 1B.
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
|
||
|
|
|
PART II
|
|
|
Item 5.
|
||
Item 6.
|
||
Item 7.
|
||
Item 7A.
|
||
Item 8.
|
||
Item 9.
|
||
Item 9A.
|
||
Item 9B.
|
||
|
|
|
PART III
|
|
|
Item 10.
|
||
Item 11.
|
||
Item 12.
|
||
Item 13.
|
||
Item 14.
|
||
|
|
|
PART IV
|
|
|
Item 15.
|
||
Item 16.
|
•
|
Bankers Life,
which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices. The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company ("Bankers Life"). Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plans ("PDP") products in exchange for a fee.
|
•
|
Washington National,
which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite. These products are marketed through Performance Matters Associates, Inc. ("PMA", a wholly owned subsidiary) and through independent marketing organizations and insurance agencies including worksite marketing. The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.
|
•
|
Colonial Penn
,
which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing. The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn").
|
•
|
Long-term care in run-off
consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC").
|
•
|
Maximize our product portfolio to ensure it meets our customers’ needs for integrated products and advice covering a broad range of their financial needs
|
•
|
Position marketing and our distribution channels to respond effectively to evolving customer preferences
|
•
|
Expand and enhance elements of our broker-dealer and registered investment advisor program
|
•
|
Increase the speed-to-market for new products that are a good fit for our customers
|
•
|
Make strategic, measured changes to our business practices to improve our competitive advantage
|
•
|
Continue to invest in technology partnerships that will support our field force and relationships with our customers
|
•
|
Maintain our strong capital position and favorable financial metrics
|
•
|
Work to increase our return on equity
|
•
|
Maintain pricing discipline
|
•
|
Maintain an active enterprise risk management process
|
•
|
Utilize excess cash flow to maximize returns
|
•
|
Maintain a competitive dividend payout ratio
|
•
|
Reduce relative legacy long-term care exposure
|
•
|
Attract, retain and develop the best talent to help us drive sustainable growth, and provide them with development opportunities
|
•
|
Recruit, develop and retain our agent force
|
|
2017
|
|
2016
|
|
2015
|
||||||
Health:
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
1,213.4
|
|
|
$
|
1,235.3
|
|
|
$
|
1,242.3
|
|
Washington National
|
642.5
|
|
|
628.4
|
|
|
619.6
|
|
|||
Colonial Penn
|
2.0
|
|
|
2.4
|
|
|
3.0
|
|
|||
Long-term care in run-off
|
16.9
|
|
|
4.7
|
|
|
—
|
|
|||
Total health
|
1,874.8
|
|
|
1,870.8
|
|
|
1,864.9
|
|
|||
Annuities:
|
|
|
|
|
|
||||||
Bankers Life
|
1,030.6
|
|
|
970.0
|
|
|
803.0
|
|
|||
Washington National
|
.9
|
|
|
1.5
|
|
|
2.4
|
|
|||
Total annuities
|
1,031.5
|
|
|
971.5
|
|
|
805.4
|
|
|||
Life:
|
|
|
|
|
|
||||||
Bankers Life
|
462.4
|
|
|
461.1
|
|
|
446.0
|
|
|||
Washington National
|
30.0
|
|
|
29.4
|
|
|
27.7
|
|
|||
Colonial Penn
|
289.6
|
|
|
277.8
|
|
|
259.9
|
|
|||
Total life
|
782.0
|
|
|
768.3
|
|
|
733.6
|
|
|||
Total premium collections
|
$
|
3,688.3
|
|
|
$
|
3,610.6
|
|
|
$
|
3,403.9
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Medicare supplement:
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
739.4
|
|
|
$
|
739.3
|
|
|
$
|
739.4
|
|
Washington National
|
51.6
|
|
|
61.0
|
|
|
72.6
|
|
|||
Colonial Penn
|
1.9
|
|
|
2.3
|
|
|
2.7
|
|
|||
Total
|
792.9
|
|
|
802.6
|
|
|
814.7
|
|
|||
Long-term care:
|
|
|
|
|
|
||||||
Bankers Life
|
445.3
|
|
|
468.6
|
|
|
476.6
|
|
|||
Long-term care in run-off
|
16.9
|
|
|
4.7
|
|
|
—
|
|
|||
Total
|
462.2
|
|
|
473.3
|
|
|
476.6
|
|
|||
Supplemental health:
|
|
|
|
|
|
||||||
Bankers Life
|
22.6
|
|
|
21.2
|
|
|
19.2
|
|
|||
Washington National
|
589.1
|
|
|
565.5
|
|
|
544.8
|
|
|||
Total
|
611.7
|
|
|
586.7
|
|
|
564.0
|
|
|||
Other:
|
|
|
|
|
|
||||||
Bankers Life
|
6.1
|
|
|
6.2
|
|
|
7.1
|
|
|||
Washington National
|
1.8
|
|
|
1.9
|
|
|
2.2
|
|
|||
Colonial Penn
|
.1
|
|
|
.1
|
|
|
.3
|
|
|||
Total
|
8.0
|
|
|
8.2
|
|
|
9.6
|
|
|||
Total health premium collections
|
$
|
1,874.8
|
|
|
$
|
1,870.8
|
|
|
$
|
1,864.9
|
|
|
|
|
|
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Fixed index annuity:
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
964.7
|
|
|
$
|
868.1
|
|
|
$
|
706.6
|
|
Washington National
|
.6
|
|
|
1.2
|
|
|
1.9
|
|
|||
Total fixed index annuity premium collections
|
965.3
|
|
|
869.3
|
|
|
708.5
|
|
|||
Other fixed interest annuity:
|
|
|
|
|
|
||||||
Bankers Life
|
65.9
|
|
|
101.9
|
|
|
96.4
|
|
|||
Washington National
|
.3
|
|
|
.3
|
|
|
.5
|
|
|||
Total fixed interest annuity premium collections
|
66.2
|
|
|
102.2
|
|
|
96.9
|
|
|||
Total annuity premium collections
|
$
|
1,031.5
|
|
|
$
|
971.5
|
|
|
$
|
805.4
|
|
•
|
The index to be used.
|
•
|
The time period during which the change in the index is measured. At the end of the time period, the change in the index is applied to the account value. The time period of the contract ranges from 1 to 4 years.
|
•
|
The method used to measure the change in the index.
|
•
|
The measured change in the index is multiplied by a "participation rate" (percentage of change in the index) before the credit is applied. Some policies guarantee the initial participation rate for the life of the contract, and some vary the rate for each period.
|
•
|
The measured change in the index may also be limited by a "cap" before the credit is applied. Some policies guarantee the initial cap for the life of the contract, and some vary the cap for each period.
|
•
|
The measured change in the index may also be limited to the excess in the measured change over a "margin" before the credit is applied. Some policies guarantee the initial margin for the life of the contract, and some vary the margin for each period.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Interest-sensitive life products:
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
162.5
|
|
|
$
|
175.0
|
|
|
$
|
169.1
|
|
Washington National
|
19.1
|
|
|
18.0
|
|
|
15.6
|
|
|||
Colonial Penn
|
.2
|
|
|
.3
|
|
|
.2
|
|
|||
Total interest-sensitive life premium collections
|
181.8
|
|
|
193.3
|
|
|
184.9
|
|
|||
Traditional life:
|
|
|
|
|
|
||||||
Bankers Life
|
299.9
|
|
|
286.1
|
|
|
276.9
|
|
|||
Washington National
|
10.9
|
|
|
11.4
|
|
|
12.1
|
|
|||
Colonial Penn
|
289.4
|
|
|
277.5
|
|
|
259.7
|
|
|||
Total traditional life premium collections
|
600.2
|
|
|
575.0
|
|
|
548.7
|
|
|||
Total life insurance premium collections
|
$
|
782.0
|
|
|
$
|
768.3
|
|
|
$
|
733.6
|
|
•
|
provide largely stable investment income from a diversified high quality fixed income portfolio;
|
•
|
maximize and maintain a stable spread between our investment income and the yields we pay on insurance products;
|
•
|
sustain adequate liquidity levels to meet operating cash requirements, including a margin for potential adverse developments;
|
•
|
continually monitor and manage the relationship between our investment portfolio and the financial characteristics of our insurance liabilities such as durations and cash flows; and
|
•
|
maximize total return through active strategic asset allocation and investment management.
|
•
|
purchasing options on equity indices with similar payoff characteristics; and
|
•
|
adjusting the participation rate to reflect the change in the cost of such options (such cost varies based on market conditions).
|
Name of Reinsurer
|
Reinsurance receivables
|
|
Ceded life insurance inforce
|
|
A.M. Best rating
|
||||
Jackson National Life Insurance Company ("Jackson") (a)
|
$
|
1,408.2
|
|
|
$
|
696.3
|
|
|
A+
|
Wilton Reassurance Company ("Wilton Re")
|
305.5
|
|
|
1,215.5
|
|
|
A+
|
||
RGA Reinsurance Company (b)
|
228.0
|
|
|
101.3
|
|
|
A+
|
||
Munich American Reassurance Company
|
3.6
|
|
|
494.8
|
|
|
A+
|
||
Swiss Re Life and Health America Inc.
|
2.9
|
|
|
628.1
|
|
|
A+
|
||
SCOR Global Life USA Reinsurance Company
|
1.4
|
|
|
86.0
|
|
|
A+
|
||
All others (c)
|
225.6
|
|
|
230.6
|
|
|
|
||
|
$
|
2,175.2
|
|
|
$
|
3,452.6
|
|
|
|
(a)
|
In addition to the life insurance business, Jackson has assumed certain annuity business from our insurance subsidiaries through a coinsurance agreement. Such business had total insurance policy liabilities of $1.1 billion at
December 31, 2017
.
|
(b)
|
RGA Reinsurance Company has assumed a portion of the long-term care business of Bankers Life on a coinsurance basis.
|
(c)
|
No other single reinsurer represents more than 3 percent of the reinsurance receivables balance or has assumed greater than 2 percent of the total ceded life insurance business inforce.
|
•
|
grant and revoke business licenses;
|
•
|
regulate and supervise sales practices and market conduct;
|
•
|
establish guaranty associations;
|
•
|
license agents;
|
•
|
approve policy forms;
|
•
|
approve premium rates and premium rate increases for some lines of business such as long-term care and Medicare supplement;
|
•
|
establish reserve requirements;
|
•
|
prescribe the form and content of required financial statements and reports;
|
•
|
determine the reasonableness and adequacy of statutory capital and surplus;
|
•
|
perform financial, market conduct and other examinations;
|
•
|
define acceptable accounting principles; and
|
•
|
regulate the types and amounts of permitted investments.
|
•
|
reserve requirements;
|
•
|
risk-based capital ("RBC") standards;
|
•
|
codification of insurance accounting principles;
|
•
|
investment restrictions;
|
•
|
restrictions on an insurance company's ability to pay dividends;
|
•
|
credit for reinsurance; and
|
•
|
product illustrations.
|
•
|
statutory net gain from operations or statutory net income for the prior year; or
|
•
|
10 percent of statutory capital and surplus at the end of the preceding year.
|
•
|
between the current year and the prior year; and
|
•
|
for the average of the last 3 years.
|
Guaranteed
|
|
Fixed interest and fixed
|
|
Universal
|
|
|
||||||
rate
|
|
index annuities
|
|
life
|
|
Total
|
||||||
> 5.0% to 6.0%
|
|
$
|
.4
|
|
|
$
|
13.4
|
|
|
$
|
13.8
|
|
> 4.0% to 5.0%
|
|
32.2
|
|
|
281.9
|
|
|
314.1
|
|
|||
> 3.0% to 4.0%
|
|
924.3
|
|
|
47.3
|
|
|
971.6
|
|
|||
> 2.0% to 3.0%
|
|
2,120.9
|
|
|
206.5
|
|
|
2,327.4
|
|
|||
> 1.0% to 2.0%
|
|
801.8
|
|
|
21.6
|
|
|
823.4
|
|
|||
1.0% and under
|
|
4,668.8
|
|
|
352.6
|
|
|
5,021.4
|
|
|||
|
|
$
|
8,548.4
|
|
|
$
|
923.3
|
|
|
$
|
9,471.7
|
|
Weighted average
|
|
1.79
|
%
|
|
2.78
|
%
|
|
1.88
|
%
|
•
|
The first hypothetical scenario assumes immediate and permanent reductions to current interest rate spreads on interest-sensitive products. We estimate that a pre-tax charge of approximately $42 million would occur if assumed spreads related to our interest-sensitive life and annuity products immediately and permanently decreased by 10 basis points.
|
•
|
A second scenario assumes that new money rates remain at their current level indefinitely. We estimate that this scenario would: (i) result in a pre-tax charge of approximately $2 million related to an increase in deficiency reserves related to life contingent payout annuities; and (ii) reduce the margins in the long-term care block in run-off by approximately $8 million but not result in a charge because margins would continue to be positive (based on our 2017 comprehensive actuarial review).
|
•
|
The third hypothetical scenario assumes current new money rates increase such that our current portfolio yield remains level. We estimate that this scenario would: (i) result in a pre-tax charge of approximately $1 million related to an increase in deficiency reserves related to life contingent payout annuities; and (ii) reduce the margins in the long-term care block in run-off by approximately $4 million but not result in a charge because margins would continue to be positive (based on our 2017 comprehensive actuarial review).
|
•
|
One scenario assumes that the new money rates available to invest cash flows from our long-term care block in the Bankers Life segment remain at their current level of 5.42 percent indefinitely. This scenario would reduce margins by approximately $105 million but would not result in a charge because margins would continue to be positive (based on our 2017 comprehensive actuarial review).
|
•
|
An additional scenario assumes that current new money rates available to invest cash flows from our long-term care block in the Bankers Life segment immediately decrease to approximately 3.50 percent and remain at that level indefinitely. This scenario would reduce margins in this block by approximately $410 million and would result in a pre-tax charge of approximately $95 million (based on our 2017 comprehensive actuarial review).
|
•
|
The value of our investment portfolio has been materially affected in the past by changes in market conditions which resulted in substantial changes in realized and/or unrealized losses. Future adverse capital market conditions could result in additional realized and/or unrealized losses.
|
•
|
Changes in interest rates also affect our investment portfolio. In periods of increasing interest rates, life insurance policy loans, surrenders and withdrawals could increase as policyholders seek higher returns. This could require us to sell invested assets at a time when their prices may be depressed by the increase in interest rates, which could cause us to realize investment losses. Conversely, during periods of declining interest rates, we could experience increased premium payments on products with flexible premium features, repayment of policy loans and increased percentages of policies remaining inforce. We could obtain lower returns on investments made with these cash flows. In addition, prepayment rates on investments may increase so that we might have to reinvest those proceeds in lower-yielding investments. As a consequence of these factors, we could experience a decrease in the spread between the returns on
|
•
|
The attractiveness of certain of our insurance products may decrease because they are linked to the equity markets and assessments of our financial strength, resulting in lower profits. Increasing consumer concerns about the returns and features of our insurance products or our financial strength may cause existing customers to surrender policies or withdraw assets, and diminish our ability to sell policies and attract assets from new and existing customers, which would result in lower sales and fee revenues.
|
•
|
changes in interest rates and credit spreads, which can reduce the value of our investments as further discussed in the risk factor entitled "Changing interest rates may adversely affect our results of operations";
|
•
|
changes in patterns of relative liquidity in the capital markets for various asset classes;
|
•
|
changes in the perceived or actual ability of issuers to make timely repayments, which can reduce the value of our investments. This risk is significantly greater with respect to below-investment grade securities, which comprised 13 percent of the cost basis of our available for sale fixed maturity investments as of
December 31, 2017
; and
|
•
|
changes in the estimated timing of receipt of cash flows. For example, our structured securities, which comprised
25 percent
of our available for sale fixed maturity investments at
December 31, 2017
, are subject to variable prepayment on the assets underlying such securities, such as mortgage loans. When asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage
|
•
|
subsidiary debt;
|
•
|
liens;
|
•
|
restrictive agreements;
|
•
|
restricted payments during the continuance of an event of default;
|
•
|
disposition of assets and sale and leaseback transactions;
|
•
|
transactions with affiliates;
|
•
|
change in business;
|
•
|
fundamental changes;
|
•
|
modification of certain agreements; and
|
•
|
changes to fiscal year.
|
•
|
non-payment;
|
•
|
breach of representations, warranties or covenants;
|
•
|
cross-default and cross-acceleration;
|
•
|
bankruptcy and insolvency events;
|
•
|
judgment defaults;
|
•
|
actual or asserted invalidity of documentation with respect to the Revolving Credit Agreement;
|
•
|
change of control; and
|
•
|
customary ERISA defaults.
|
•
|
incur certain subsidiary indebtedness without also guaranteeing the Notes;
|
•
|
create liens;
|
•
|
enter into sale and leaseback transactions;
|
•
|
issue, sell, transfer or otherwise dispose of any shares of capital stock of any Insurance Subsidiary (as defined in the Indenture); and
|
•
|
consolidate or merge with or into other companies or transfer all or substantially all of the Company’s assets.
|
•
|
statutory net gain from operations or statutory net income for the prior year, or
|
•
|
10 percent of statutory capital and surplus as of the end of the preceding year.
|
Officer
|
With CNO
|
Positions with CNO, Principal
|
Name and Age (a)
|
Since
|
Occupation and Business Experience (b)
|
Bruce Baude, 53
|
2012
|
Since July 2012, executive vice president, chief operations and technology officer. From 2008 to 2012, Mr. Baude was chief operating officer at Univita Health.
|
Gary C. Bhojwani, 50
|
2016
|
Since January 2018, chief executive officer. From April 2016 to December 2017, president of CNO. From April 2015 until joining CNO, chief executive officer of GCB, LLC, an insurance and financial services consulting company that he founded. Mr. Bhojwani served as a member of the board of management at Allianz SE, Chairman of Allianz of America, Allianz Life Insurance Company, and Fireman’s Fund Insurance Company from 2012 to January 1, 2015. From 2007 to 2012, he served as president of Allianz Life Insurance Company of North America.
|
Yvonne K. Franzese, 59
|
2017
|
Since November 2017, executive vice president and chief human resources officer of CNO. From 2016 until joining CNO, chief human capital officer of TCF Bank. From 2007 to 2016, Ms. Franzese held various human resource positions at Allianz, including the chief human resources role for Allianz of North America.
|
Erik M. Helding, 45
|
2004
|
Since April 2016, executive vice president and chief financial officer. From August 2012 to April 2016, senior vice president, treasury and investor relations. Prior to August 2012, Mr. Helding was vice president, financial planning and analysis and he has held various finance positions since joining CNO in 2004.
|
Eric R. Johnson, 57
|
1997
|
Since September 2003, executive vice president and chief investment officer of CNO and president and chief executive officer of 40|86 Advisors, CNO's wholly-owned registered investment advisor. Since January 2018, executive in charge of corporate development activities. Mr. Johnson has held various investment management positions since joining CNO in 1997.
|
John R. Kline, 60
|
1990
|
Since July 2002, senior vice president and chief accounting officer. Mr. Kline has served in various accounting and finance capacities with CNO since 1990.
|
Christopher J. Nickele, 61
|
2005
|
Since August 2014, executive vice president and chief actuary. From October 2005 until August 2014, executive vice president, product management and from May 2010 until March 2014, president, Other CNO Business.
|
Matthew J. Zimpfer, 50
|
1998
|
Since June 2008, executive vice president and general counsel. Mr. Zimpfer has held various legal positions since joining CNO in 1998.
|
(a)
|
The executive officers serve as such at the discretion of the Board of Directors and are elected annually.
|
(b)
|
Business experience is given for at least the last five years.
|
ITEM 5.
|
MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
|
Period
|
Market price
|
|
Dividends
|
||||||||
|
High
|
|
Low
|
|
declared and paid
|
||||||
2016:
|
|
|
|
|
|
||||||
First Quarter
|
$
|
18.71
|
|
|
$
|
14.66
|
|
|
$
|
0.07
|
|
Second Quarter
|
20.55
|
|
|
16.00
|
|
|
0.08
|
|
|||
Third Quarter
|
18.70
|
|
|
14.30
|
|
|
0.08
|
|
|||
Fourth Quarter
|
19.89
|
|
|
14.65
|
|
|
0.08
|
|
|||
2017:
|
|
|
|
|
|
||||||
First Quarter
|
$
|
21.70
|
|
|
$
|
18.54
|
|
|
$
|
0.08
|
|
Second Quarter
|
22.60
|
|
|
19.38
|
|
|
0.09
|
|
|||
Third Quarter
|
23.94
|
|
|
20.69
|
|
|
0.09
|
|
|||
Fourth Quarter
|
25.83
|
|
|
23.15
|
|
|
0.09
|
|
|
12/12
|
12/13
|
12/14
|
12/15
|
12/16
|
12/17
|
||||||||||||
CNO Financial Group, Inc.
|
$
|
100.00
|
|
$
|
191.14
|
|
$
|
188.63
|
|
$
|
212.24
|
|
$
|
216.62
|
|
$
|
283.81
|
|
S&P 500 Index
|
100.00
|
|
132.39
|
|
150.51
|
|
152.59
|
|
170.84
|
|
208.14
|
|
||||||
S&P Life & Health Insurance Index
|
100.00
|
|
163.48
|
|
166.66
|
|
156.14
|
|
194.96
|
|
226.98
|
|
||||||
S&P MidCap 400 Index
|
100.00
|
|
133.50
|
|
146.54
|
|
143.35
|
|
173.08
|
|
201.20
|
|
Period (in 2017)
|
|
Total number of shares (or units)
|
|
Average price paid per share (or unit)
|
|
Total number of shares (or units) purchased as part of publicly announced plans or programs
|
|
Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs(a)
|
||||||
|
|
|
|
|
|
|
|
(dollars in millions)
|
||||||
October 1 through October 31
|
|
33,200
|
|
|
$
|
24.10
|
|
|
33,200
|
|
|
$
|
411.8
|
|
November 1 through November 30
|
|
663,003
|
|
|
24.01
|
|
|
662,263
|
|
|
395.9
|
|
||
December 1 through December 31
|
|
411,576
|
|
|
25.00
|
|
|
411,576
|
|
|
385.6
|
|
||
Total
|
|
1,107,779
|
|
|
24.38
|
|
|
1,107,039
|
|
|
385.6
|
|
(a)
|
In May 2011, the Company announced a securities repurchase program of up to
$100.0 million
. In February 2012, June 2012, December 2012, December 2013, November 2014, November 2015 and May 2017, the Company's Board of Directors approved, in aggregate, an additional
$1,900.0 million
to repurchase the Company's outstanding securities.
|
|
|
Number of securities to be issued upon exercise of outstanding options and rights
|
|
Weighted-average exercise price of outstanding options and rights
|
|
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column)
|
||||
Equity compensation plans approved by security holders
|
|
5,120,818
|
|
|
$
|
15.95
|
|
|
7,488,231
|
|
Equity compensation plans not approved by security holders
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Total
|
|
5,120,818
|
|
|
$
|
15.95
|
|
|
7,488,231
|
|
|
|
Years ended December 31,
|
||||||||||||||||||
|
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
|
|
(Amounts in millions, except per share data)
|
||||||||||||||||||
STATEMENT OF OPERATIONS DATA
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Insurance policy income
|
|
$
|
2,647.3
|
|
|
$
|
2,601.1
|
|
|
$
|
2,556.0
|
|
|
$
|
2,629.7
|
|
|
$
|
2,744.7
|
|
Net investment income
|
|
1,551.3
|
|
|
1,325.2
|
|
|
1,233.6
|
|
|
1,427.4
|
|
|
1,664.0
|
|
|||||
Net realized investment gains (losses)
|
|
50.3
|
|
|
8.3
|
|
|
(36.6
|
)
|
|
36.7
|
|
|
33.4
|
|
|||||
Total revenues
|
|
4,297.2
|
|
|
3,985.1
|
|
|
3,811.9
|
|
|
4,144.7
|
|
|
4,476.1
|
|
|||||
Interest expense
|
|
123.7
|
|
|
116.4
|
|
|
94.9
|
|
|
92.8
|
|
|
105.3
|
|
|||||
Total benefits and expenses
|
|
3,816.7
|
|
|
3,631.9
|
|
|
3,444.2
|
|
|
3,969.6
|
|
|
4,171.3
|
|
|||||
Income before income taxes
|
|
480.5
|
|
|
353.2
|
|
|
367.7
|
|
|
175.1
|
|
|
304.8
|
|
|||||
Income tax expense (benefit)
|
|
304.9
|
|
|
(5.0
|
)
|
|
97.0
|
|
|
123.7
|
|
|
(173.2
|
)
|
|||||
Net income
|
|
175.6
|
|
|
358.2
|
|
|
270.7
|
|
|
51.4
|
|
|
478.0
|
|
|||||
PER SHARE DATA
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net income, basic
|
|
$
|
1.03
|
|
|
$
|
2.03
|
|
|
$
|
1.40
|
|
|
$
|
.24
|
|
|
$
|
2.16
|
|
Net income, diluted
|
|
1.02
|
|
|
2.01
|
|
|
1.39
|
|
|
.24
|
|
|
2.06
|
|
|||||
Dividends declared per common share
|
|
.35
|
|
|
.31
|
|
|
.27
|
|
|
.24
|
|
|
.11
|
|
|||||
Book value per common share outstanding
|
|
29.05
|
|
|
25.82
|
|
|
22.49
|
|
|
23.06
|
|
|
22.49
|
|
|||||
Weighted average shares outstanding for basic earnings
|
|
170.0
|
|
|
176.6
|
|
|
193.1
|
|
|
212.9
|
|
|
221.6
|
|
|||||
Weighted average shares outstanding for diluted earnings
|
|
172.1
|
|
|
178.3
|
|
|
195.2
|
|
|
217.7
|
|
|
232.7
|
|
|||||
Shares outstanding at period-end
|
|
166.9
|
|
|
173.8
|
|
|
184.0
|
|
|
203.3
|
|
|
220.3
|
|
|||||
BALANCE SHEET DATA
-
AT PERIOD END
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Total investments
|
|
$
|
27,854.1
|
|
|
$
|
26,237.6
|
|
|
$
|
24,487.1
|
|
|
$
|
24,908.3
|
|
|
$
|
27,151.7
|
|
Total assets
|
|
33,110.3
|
|
|
31,975.2
|
|
|
31,125.1
|
|
|
31,155.9
|
|
|
34,750.2
|
|
|||||
Corporate notes payable
|
|
914.6
|
|
|
912.9
|
|
|
911.1
|
|
|
780.3
|
|
|
838.0
|
|
|||||
Total liabilities
|
|
28,262.8
|
|
|
27,488.3
|
|
|
26,986.6
|
|
|
26,467.7
|
|
|
29,795.0
|
|
|||||
Shareholders' equity
|
|
4,847.5
|
|
|
4,486.9
|
|
|
4,138.5
|
|
|
4,688.2
|
|
|
4,955.2
|
|
|||||
STATUTORY DATA - AT PERIOD END (a)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Statutory capital and surplus
|
|
$
|
1,904.4
|
|
|
$
|
1,956.8
|
|
|
$
|
1,739.2
|
|
|
$
|
1,654.4
|
|
|
$
|
1,711.9
|
|
Asset valuation reserve ("AVR")
|
|
246.8
|
|
|
253.3
|
|
|
196.9
|
|
|
203.1
|
|
|
233.9
|
|
|||||
Total statutory capital and surplus and AVR
|
|
2,151.2
|
|
|
2,210.1
|
|
|
1,936.1
|
|
|
1,857.5
|
|
|
1,945.8
|
|
(a)
|
We have derived the statutory data from statements filed by our insurance subsidiaries with regulatory authorities which are prepared in accordance with statutory accounting principles, which vary in certain respects from GAAP.
|
ITEM 7.
|
MANAGEMENT'S DISCUSSION AND ANALYSIS OF CONSOLIDATED FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
|
•
|
changes in or sustained low interest rates causing reductions in investment income, the margins of our fixed annuity and life insurance businesses, and sales of, and demand for, our products;
|
•
|
expectations of lower future investment earnings may cause us to accelerate amortization, write down the balance of insurance acquisition costs or establish additional liabilities for insurance products;
|
•
|
general economic, market and political conditions and uncertainties, including the performance and fluctuations of the financial markets which may affect the value of our investments as well as our ability to raise capital or refinance existing indebtedness and the cost of doing so;
|
•
|
the ultimate outcome of lawsuits filed against us and other legal and regulatory proceedings to which we are subject;
|
•
|
our ability to make anticipated changes to certain non-guaranteed elements of our life insurance products;
|
•
|
our ability to obtain adequate and timely rate increases on our health products, including our long-term care business;
|
•
|
the receipt of any required regulatory approvals for dividend and surplus debenture interest payments from our insurance subsidiaries;
|
•
|
mortality, morbidity, the increased cost and usage of health care services, persistency, the adequacy of our previous reserve estimates and other factors which may affect the profitability of our insurance products;
|
•
|
changes in our assumptions related to deferred acquisition costs or the present value of future profits;
|
•
|
the recoverability of our deferred tax assets and the effect of potential ownership changes and tax rate changes on their value;
|
•
|
changes to our estimates of the impact of comprehensive federal tax legislation related to the Tax Reform Act;
|
•
|
our assumption that the positions we take on our tax return filings will not be successfully challenged by the IRS;
|
•
|
changes in accounting principles and the interpretation thereof;
|
•
|
our ability to continue to satisfy the financial ratio and balance requirements and other covenants of our debt agreements;
|
•
|
our ability to achieve anticipated expense reductions and levels of operational efficiencies including improvements in claims adjudication and continued automation and rationalization of operating systems;
|
•
|
performance and valuation of our investments, including the impact of realized losses (including other-than-temporary impairment charges);
|
•
|
our ability to identify products and markets in which we can compete effectively against competitors with greater market share, higher ratings, greater financial resources and stronger brand recognition;
|
•
|
our ability to generate sufficient liquidity to meet our debt service obligations and other cash needs;
|
•
|
changes in capital deployment opportunities;
|
•
|
our ability to maintain effective controls over financial reporting;
|
•
|
our ability to continue to recruit and retain productive agents and distribution partners;
|
•
|
customer response to new products, distribution channels and marketing initiatives;
|
•
|
our ability to achieve additional upgrades of the financial strength ratings of CNO and our insurance company subsidiaries as well as the impact of our ratings on our business, our ability to access capital, and the cost of capital;
|
•
|
regulatory changes or actions, including: those relating to regulation of the financial affairs of our insurance companies, such as the calculation of risk-based capital and minimum capital requirements, and payment of dividends and surplus debenture interest to us; regulation of the sale, underwriting and pricing of products; and health care regulation affecting health insurance products;
|
•
|
changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products or affect the value of our deferred tax assets;
|
•
|
availability and effectiveness of reinsurance arrangements, as well as the impact of any defaults or failure of reinsurers to perform;
|
•
|
the amount we may need to pay to a reinsurer and the earnings charge we may incur in connection with a long-term care reinsurance transaction;
|
•
|
the performance of third party service providers and potential difficulties arising from outsourcing arrangements;
|
•
|
the growth rate of sales, collected premiums, annuity deposits and assets;
|
•
|
interruption in telecommunication, information technology or other operational systems or failure to maintain the security, confidentiality or privacy of sensitive data on such systems;
|
•
|
events of terrorism, cyber attacks, natural disasters or other catastrophic events, including losses from a disease pandemic;
|
•
|
ineffectiveness of risk management policies and procedures in identifying, monitoring and managing risks; and
|
•
|
the risk factors or uncertainties listed from time to time in our filings with the SEC.
|
•
|
Bankers Life,
which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices. The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company. Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and PDP products in exchange for a fee.
|
•
|
Washington National,
which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite. These products are marketed through PMA and through independent marketing organizations and insurance agencies including worksite marketing. The products being marketed are underwritten by Washington National. This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.
|
•
|
Colonial Penn
, which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing. The Colonial Penn segment includes primarily the business of Colonial Penn.
|
•
|
Long-term care in run-off
consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and BCLIC.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Adjusted EBIT (a non-GAAP financial measure) (a):
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
418.9
|
|
|
$
|
397.9
|
|
|
$
|
369.6
|
|
Washington National
|
98.3
|
|
|
102.9
|
|
|
111.5
|
|
|||
Colonial Penn
|
22.6
|
|
|
1.7
|
|
|
5.6
|
|
|||
Long-term care in run-off
|
1.7
|
|
|
(3.9
|
)
|
|
—
|
|
|||
Adjusted EBIT from business segments
|
541.5
|
|
|
498.6
|
|
|
486.7
|
|
|||
Corporate Operations, excluding corporate interest expense
|
(40.3
|
)
|
|
(42.5
|
)
|
|
(18.9
|
)
|
|||
Adjusted EBIT
|
501.2
|
|
|
456.1
|
|
|
467.8
|
|
|||
Corporate interest expense
|
(46.5
|
)
|
|
(45.8
|
)
|
|
(45.0
|
)
|
|||
Operating earnings before taxes
|
454.7
|
|
|
410.3
|
|
|
422.8
|
|
|||
Tax expense on operating income
|
153.8
|
|
|
147.8
|
|
|
148.1
|
|
|||
Net operating income
|
300.9
|
|
|
262.5
|
|
|
274.7
|
|
|||
Net realized investment gains (losses) (net of related amortization)
|
49.3
|
|
|
7.6
|
|
|
(36.1
|
)
|
|||
Fair value changes in embedded derivative liabilities (net of related amortization)
|
(2.5
|
)
|
|
9.6
|
|
|
11.9
|
|
|||
Fair value changes and amendment related to agent deferred compensation plan
|
(12.2
|
)
|
|
3.1
|
|
|
15.1
|
|
|||
Loss on reinsurance transaction (b)
|
—
|
|
|
(75.4
|
)
|
|
—
|
|
|||
Loss on extinguishment of debt
|
—
|
|
|
—
|
|
|
(32.8
|
)
|
|||
Other
|
(8.8
|
)
|
|
(2.0
|
)
|
|
(13.2
|
)
|
|||
Non-operating income (loss) before taxes
|
25.8
|
|
|
(57.1
|
)
|
|
(55.1
|
)
|
|||
Income tax expense (benefit):
|
|
|
|
|
|
||||||
On non-operating income (loss)
|
9.0
|
|
|
(20.0
|
)
|
|
(18.6
|
)
|
|||
Valuation allowance for deferred tax assets and other tax items
|
142.1
|
|
|
(132.8
|
)
|
|
(32.5
|
)
|
|||
Net non-operating income (loss)
|
(125.3
|
)
|
|
95.7
|
|
|
(4.0
|
)
|
|||
Net income
|
$
|
175.6
|
|
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
|
|
|
|
|
||||||
Per diluted share:
|
|
|
|
|
|
||||||
Net operating income
|
$
|
1.75
|
|
|
$
|
1.47
|
|
|
$
|
1.41
|
|
Net realized investment gains (losses) (net of related amortization and taxes)
|
.19
|
|
|
.03
|
|
|
(.12
|
)
|
|||
Fair value changes in embedded derivative liabilities (net of related amortization and taxes)
|
(.01
|
)
|
|
.04
|
|
|
.04
|
|
|||
Fair value changes and amendment related to agent deferred compensation plan (net of taxes)
|
(.05
|
)
|
|
.01
|
|
|
.05
|
|
|||
Loss on reinsurance transaction (net of taxes)
|
—
|
|
|
(.27
|
)
|
|
—
|
|
|||
Loss on extinguishment of debt (net of taxes)
|
—
|
|
|
—
|
|
|
(.11
|
)
|
|||
Valuation allowance for deferred tax assets and other tax items
|
(.83
|
)
|
|
.74
|
|
|
.17
|
|
|||
Other
|
(.03
|
)
|
|
(.01
|
)
|
|
(.05
|
)
|
|||
Net income
|
$
|
1.02
|
|
|
$
|
2.01
|
|
|
$
|
1.39
|
|
(a)
|
Management believes that an analysis of net operating income provides a clearer comparison of the operating results of the Company from period to period because it excludes: (i) loss on reinsurance transaction, including impact of taxes; (ii) net realized investment gains or losses, net of related amortization and taxes; (iii) fair value changes due to fluctuations in the interest rates used to discount embedded derivative liabilities related to our fixed index annuities, net of related amortization and taxes; (iv) fair value changes and amendment related to the agent deferred compensation plan, net of taxes; (v) loss on extinguishment of debt, net of taxes; (vi) changes in the valuation allowance for deferred tax assets and other tax items; and (vii)
other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to variable interest entities
. Net realized investment gains or losses include: (i) gains or losses on the sales of investments; (ii) other-than-temporary impairments recognized through net income; and (iii) changes in fair value of certain fixed maturity investments with embedded derivatives. Adjusted EBIT is presented as net operating income excluding corporate interest expense and income tax expense. The table above reconciles the non-GAAP measure to the corresponding GAAP measure.
|
•
|
Maximize our product portfolio to ensure it meets our customers’ needs for integrated products and advice covering a broad range of their financial needs
|
•
|
Position marketing and our distribution channels to respond effectively to evolving customer preferences
|
•
|
Expand and enhance elements of our broker-dealer and registered investment advisor program
|
•
|
Increase the speed-to-market for new products that are a good fit for our customers
|
•
|
Make strategic, measured changes to our business practices to improve our competitive advantage
|
•
|
Continue to invest in technology partnerships that will support our field force and relationships with our customers
|
•
|
Maintain our strong capital position and favorable financial metrics
|
•
|
Work to increase our return on equity
|
•
|
Maintain pricing discipline
|
•
|
Maintain an active enterprise risk management process
|
•
|
Utilize excess cash flow to maximize returns
|
•
|
Maintain a competitive dividend payout ratio
|
•
|
Reduce relative legacy long-term care exposure
|
•
|
Attract, retain and develop the best talent to help us drive sustainable growth, and provide them with development opportunities
|
•
|
Recruit, develop and retain our agent force
|
•
|
Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.
|
•
|
Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include: certain publicly registered and privately placed corporate fixed
|
•
|
Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.
|
Change in assumptions
|
|
Estimated adjustment to income before income taxes based on revisions to certain assumptions
|
||
|
|
(dollars in millions)
|
||
Interest-sensitive life products:
|
|
|
||
5% increase to assumed mortality
|
|
$
|
(29
|
)
|
5% decrease to assumed mortality
|
|
29
|
|
|
15% increase to assumed expenses
|
|
(11
|
)
|
|
15% decrease to assumed expenses
|
|
11
|
|
|
10 basis point decrease to assumed spread
|
|
(9
|
)
|
|
10 basis point increase to assumed spread
|
|
9
|
|
|
20% increase to assumed lapses
|
|
(10
|
)
|
|
20% decrease to assumed lapses
|
|
11
|
|
|
Fixed index and fixed interest annuity products:
|
|
|
||
20% increase to assumed surrenders
|
|
(74
|
)
|
|
20% decrease to assumed surrenders
|
|
91
|
|
|
15% increase to assumed expenses
|
|
(7
|
)
|
|
15% decrease to assumed expenses
|
|
7
|
|
|
10 basis point decrease to assumed spread
|
|
(33
|
)
|
|
10 basis point increase to assumed spread
|
|
33
|
|
|
Other than interest-sensitive life and annuity products (a):
|
|
|
||
5% increase to assumed morbidity
|
|
(11
|
)
|
|
No increase in new money rate assumption after one year
|
|
(2
|
)
|
(a)
|
We have excluded the effect of reasonably likely changes in lapse, surrender and expense assumptions for policies other than interest-sensitive life and annuity products.
|
|
Years ended December 31,
|
|||||||
|
2017
|
|
2016
|
|
2015
|
|||
Bankers Life:
|
|
|
|
|
|
|||
Medicare supplement (1)
|
85.0
|
%
|
|
85.9
|
%
|
|
86.3
|
%
|
Long-term care (1)
|
90.3
|
%
|
|
90.0
|
%
|
|
90.4
|
%
|
Fixed index annuities (2)
|
91.2
|
%
|
|
91.5
|
%
|
|
91.2
|
%
|
Other annuities (2)
|
85.2
|
%
|
|
85.8
|
%
|
|
85.1
|
%
|
Life (1)
|
87.5
|
%
|
|
87.1
|
%
|
|
87.3
|
%
|
Washington National:
|
|
|
|
|
|
|||
Medicare supplement (1)
|
85.3
|
%
|
|
85.8
|
%
|
|
83.7
|
%
|
Supplemental health (1)
|
89.2
|
%
|
|
89.2
|
%
|
|
89.0
|
%
|
Life (1)
|
90.6
|
%
|
|
91.2
|
%
|
|
91.8
|
%
|
Colonial Penn:
|
|
|
|
|
|
|||
Life (1)
|
83.4
|
%
|
|
83.0
|
%
|
|
82.6
|
%
|
(1)
|
Based on number of inforce policies.
|
(2)
|
Based on the percentage of the inforce block persisting.
|
|
|
2017
|
|
2016
|
||||
|
|
(Dollars in millions)
|
||||||
Amounts classified as future policy benefits:
|
|
|
|
|
||||
Active life reserves
|
|
$
|
3,846.0
|
|
|
$
|
3,816.4
|
|
Reserves for the present value of amounts not yet due on claims
|
|
1,366.9
|
|
|
1,338.4
|
|
||
Future loss reserves
|
|
190.0
|
|
|
191.3
|
|
||
Premium deficiency reserves assuming net unrealized gains had been realized
|
|
266.1
|
|
|
—
|
|
||
Amounts classified as liability for policy and contract claims:
|
|
|
|
|
|
|||
Liability for due and unpaid claims, claims in the course of settlement and incurred but not reported claims
|
|
200.1
|
|
|
187.5
|
|
||
Total
|
|
5,869.1
|
|
|
5,533.6
|
|
||
Reinsurance receivables
|
|
221.5
|
|
|
194.3
|
|
||
Long-term care reserves, net of reinsurance receivables
|
|
$
|
5,647.6
|
|
|
$
|
5,339.3
|
|
•
|
We recognize fee income based on either: (i) a fixed fee per contract sold; or (ii) a percentage of premiums collected. This fee income is recognized over the calendar year term of the contract.
|
•
|
We also pay commissions to our agents who sell the plans. These payments are deferred and amortized over the term of the contract.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Fee revenue:
|
|
|
|
|
|
||||||
Medicare Advantage contracts
|
$
|
24.6
|
|
|
$
|
23.2
|
|
|
$
|
23.1
|
|
PDP contracts
|
3.3
|
|
|
3.1
|
|
|
3.2
|
|
|||
Total revenue
|
27.9
|
|
|
26.3
|
|
|
26.3
|
|
|||
Distribution expenses
|
10.9
|
|
|
9.3
|
|
|
9.4
|
|
|||
Fee revenue, net of distribution expenses
|
$
|
17.0
|
|
|
$
|
17.0
|
|
|
$
|
16.9
|
|
Balance, December 31, 2014
|
$
|
246.0
|
|
|
Decrease in 2015
|
(32.5
|
)
|
(a)
|
|
Balance, December 31, 2015
|
213.5
|
|
|
|
Increase in 2016
|
26.7
|
|
(b)
|
|
Balance, December 31, 2016
|
240.2
|
|
|
|
Decrease in 2017
|
(166.8
|
)
|
(c)
|
|
Cumulative effect of accounting change
|
15.7
|
|
(d)
|
|
Balance, December 31, 2017
|
$
|
89.1
|
|
|
(a)
|
The
2015
reduction to the deferred tax valuation allowance primarily resulted from higher actual and projected non-life income.
|
(b)
|
The
2016
increase to the deferred tax valuation allowance primarily resulted from additional non-life NOLs due to the settlement with the IRS.
|
(c)
|
The
2017
decrease to the deferred tax valuation allowance includes: (i) $138.1 million related to a reduction in the federal corporate income tax rate and other changes from the Tax Reform Act; (ii)
$13.4 million
of reductions to the deferred tax valuation allowance primarily related to the recognition of capital gains; and (iii)
$15.3 million
of reductions in the deferred tax valuation allowance reflecting higher current year taxable income than previously reflected in our deferred tax valuation model.
|
(d)
|
Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences. Under the new guidance, any excess tax benefits are recognized as an income tax benefit in the income statement. The new guidance is applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings for all tax benefits that were not previously recognized because the related tax deduction had not reduced taxes payable. The Company had NOL carryforwards of
$15.7 million
related to deductions for stock options and restricted stock on the date of adoption. However, a corresponding valuation allowance of
$15.7 million
was recognized as a result of adopting this guidance. Therefore, there was no impact to our consolidated financial statements related to the initial adoption of this provision of the new guidance.
|
|
|
Net operating loss
|
||
Year of expiration
|
|
carryforwards
|
||
2023
|
|
$
|
1,744.8
|
|
2025
|
|
85.2
|
|
|
2026
|
|
149.9
|
|
|
2027
|
|
10.8
|
|
|
2028
|
|
80.3
|
|
|
2029
|
|
213.2
|
|
|
2030
|
|
.3
|
|
|
2031
|
|
.2
|
|
|
2032
|
|
44.4
|
|
|
2033
|
|
.6
|
|
|
2034
|
|
.9
|
|
|
2035
|
|
.8
|
|
|
Total federal NOLs
|
|
$
|
2,331.4
|
|
|
2016
|
||
|
|
||
Balance at beginning of year
|
$
|
234.2
|
|
Increase based on tax positions taken in prior years
|
3.4
|
|
|
Decrease in unrecognized tax benefits related to settlements with taxing authorities
|
(237.6
|
)
|
|
Balance at end of year
|
$
|
—
|
|
•
|
Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.
|
•
|
Benefit reductions - If there is a premium rate increase on one of our long-term care policies, a policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.
|
•
|
Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Pre-tax operating earnings (a non-GAAP measure) (a):
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
418.9
|
|
|
$
|
397.9
|
|
|
$
|
369.6
|
|
Washington National
|
98.3
|
|
|
102.9
|
|
|
111.5
|
|
|||
Colonial Penn
|
22.6
|
|
|
1.7
|
|
|
5.6
|
|
|||
Long-term care in run-off
|
1.7
|
|
|
(3.9
|
)
|
|
—
|
|
|||
Corporate operations
|
(86.8
|
)
|
|
(88.3
|
)
|
|
(63.9
|
)
|
|||
|
454.7
|
|
|
410.3
|
|
|
422.8
|
|
|||
Loss on reinsurance transaction:
|
|
|
|
|
|
||||||
Corporate operations
|
—
|
|
|
(75.4
|
)
|
|
—
|
|
|||
|
—
|
|
|
(75.4
|
)
|
|
—
|
|
|||
Net realized investment gains (losses), net of related amortization:
|
|
|
|
|
|
||||||
Bankers Life
|
33.6
|
|
|
(3.6
|
)
|
|
(16.7
|
)
|
|||
Washington National
|
11.7
|
|
|
19.4
|
|
|
(9.6
|
)
|
|||
Colonial Penn
|
—
|
|
|
(.2
|
)
|
|
1.2
|
|
|||
Long-term care in run-off
|
7.0
|
|
|
(5.3
|
)
|
|
—
|
|
|||
Corporate operations
|
(3.0
|
)
|
|
(2.7
|
)
|
|
(11.0
|
)
|
|||
|
49.3
|
|
|
7.6
|
|
|
(36.1
|
)
|
|||
Fair value changes in embedded derivative liabilities, net of related amortization:
|
|
|
|
|
|
||||||
Bankers Life
|
(2.7
|
)
|
|
9.4
|
|
|
11.7
|
|
|||
Washington National
|
.2
|
|
|
.2
|
|
|
.2
|
|
|||
|
(2.5
|
)
|
|
9.6
|
|
|
11.9
|
|
|||
Equity in earnings of certain non-strategic investments and earnings attributable to VIEs:
|
|
|
|
|
|
||||||
Corporate operations
|
(8.8
|
)
|
|
(2.0
|
)
|
|
(6.7
|
)
|
|||
Net revenue pursuant to transition and support services agreements, net of taxes:
|
|
|
|
|
|
||||||
Corporate operations
|
—
|
|
|
—
|
|
|
2.5
|
|
|||
Fair value changes and amendment related to agent deferred compensation plan:
|
|
|
|
|
|
||||||
Corporate operations
|
(12.2
|
)
|
|
3.1
|
|
|
15.1
|
|
|||
Transition expenses:
|
|
|
|
|
|
||||||
Corporate operations
|
—
|
|
|
—
|
|
|
(9.0
|
)
|
|||
Loss on extinguishment of debt:
|
|
|
|
|
|
||||||
Corporate operations
|
—
|
|
|
—
|
|
|
(32.8
|
)
|
|||
Income (loss) before income taxes:
|
|
|
|
|
|
||||||
Bankers Life
|
449.8
|
|
|
403.7
|
|
|
364.6
|
|
|||
Washington National
|
110.2
|
|
|
122.5
|
|
|
102.1
|
|
|||
Colonial Penn
|
22.6
|
|
|
1.5
|
|
|
6.8
|
|
|||
Long-term care in run-off
|
8.7
|
|
|
(9.2
|
)
|
|
—
|
|
|||
Corporate operations
|
(110.8
|
)
|
|
(165.3
|
)
|
|
(105.8
|
)
|
|||
Income before income taxes
|
$
|
480.5
|
|
|
$
|
353.2
|
|
|
$
|
367.7
|
|
(a)
|
These non-GAAP measures as presented in the above table and in the following segment financial data and discussions of segment results exclude the loss on reinsurance transaction and transition expenses, net realized investment gains (losses), fair value changes in embedded derivative liabilities, net of related amortization, fair value changes and amendment related to the agent deferred compensation plan, equity in earnings of certain non-strategic investments and earnings attributable to VIEs
, transition expenses,
loss on extinguishment of debt and before income taxes. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Premium collections:
|
|
|
|
|
|
||||||
Annuities
|
$
|
1,030.6
|
|
|
$
|
970.0
|
|
|
$
|
803.0
|
|
Medicare supplement and other supplemental health
|
1,213.4
|
|
|
1,235.3
|
|
|
1,242.3
|
|
|||
Life
|
462.4
|
|
|
461.1
|
|
|
446.0
|
|
|||
Total collections
|
$
|
2,706.4
|
|
|
$
|
2,666.4
|
|
|
$
|
2,491.3
|
|
Average liabilities for insurance products:
|
|
|
|
|
|
|
|||||
Fixed index annuities
|
$
|
5,139.6
|
|
|
$
|
4,527.8
|
|
|
$
|
4,075.5
|
|
Fixed interest annuities
|
2,899.5
|
|
|
3,188.2
|
|
|
3,487.8
|
|
|||
SPIAs and supplemental contracts:
|
|
|
|
|
|
||||||
Mortality based
|
160.5
|
|
|
174.9
|
|
|
189.5
|
|
|||
Deposit based
|
149.0
|
|
|
153.7
|
|
|
153.8
|
|
|||
Health:
|
|
|
|
|
|
||||||
Long-term care
|
4,987.4
|
|
|
4,998.0
|
|
|
4,916.2
|
|
|||
Medicare supplement
|
334.9
|
|
|
336.8
|
|
|
331.0
|
|
|||
Other health
|
55.9
|
|
|
50.3
|
|
|
47.7
|
|
|||
Life:
|
|
|
|
|
|
||||||
Interest sensitive
|
778.2
|
|
|
714.6
|
|
|
643.0
|
|
|||
Non-interest sensitive
|
1,089.9
|
|
|
1,018.0
|
|
|
941.5
|
|
|||
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
15,594.9
|
|
|
$
|
15,162.3
|
|
|
$
|
14,786.0
|
|
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
1,666.6
|
|
|
$
|
1,659.1
|
|
|
$
|
1,648.7
|
|
Net investment income:
|
|
|
|
|
|
||||||
General account invested assets
|
953.8
|
|
|
909.5
|
|
|
918.7
|
|
|||
Fixed index products
|
153.5
|
|
|
27.3
|
|
|
(34.0
|
)
|
|||
Fee revenue and other income
|
44.1
|
|
|
34.4
|
|
|
27.7
|
|
|||
Total revenues
|
2,818.0
|
|
|
2,630.3
|
|
|
2,561.1
|
|
|||
Expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
1,448.5
|
|
|
1,417.4
|
|
|
1,442.5
|
|
|||
Amounts added to policyholder account balances:
|
|
|
|
|
|
||||||
Cost of interest credited to policyholders
|
105.0
|
|
|
110.8
|
|
|
118.5
|
|
|||
Cost of options to fund index credits, net of forfeitures
|
63.7
|
|
|
66.1
|
|
|
60.3
|
|
|||
Market value changes credited to policyholders
|
154.6
|
|
|
26.3
|
|
|
(32.9
|
)
|
|||
Amortization related to operations
|
163.6
|
|
|
176.5
|
|
|
187.1
|
|
|||
Interest expense on investment borrowings
|
19.8
|
|
|
13.2
|
|
|
8.8
|
|
|||
Other operating costs and expenses
|
443.9
|
|
|
422.1
|
|
|
407.2
|
|
|||
Total benefits and expenses
|
2,399.1
|
|
|
2,232.4
|
|
|
2,191.5
|
|
|||
Income before net realized investment gains (losses), net of related amortization, and fair value changes in embedded derivative liabilities, net of related amortization, and income taxes
|
418.9
|
|
|
397.9
|
|
|
369.6
|
|
|||
Net realized investment gains (losses)
|
34.6
|
|
|
(3.2
|
)
|
|
(17.2
|
)
|
|||
Amortization related to net realized investment gains (losses)
|
(1.0
|
)
|
|
(.4
|
)
|
|
.5
|
|
|||
Net realized investment gains (losses), net of related amortization
|
33.6
|
|
|
(3.6
|
)
|
|
(16.7
|
)
|
|||
Insurance policy benefits - fair value changes in embedded derivative liabilities
|
(3.4
|
)
|
|
10.7
|
|
|
14.9
|
|
|||
Amortization related to fair value changes in embedded derivative liabilities
|
.7
|
|
|
(1.3
|
)
|
|
(3.2
|
)
|
|||
Fair value changes in embedded derivative liabilities, net of related amortization
|
(2.7
|
)
|
|
9.4
|
|
|
11.7
|
|
|||
Income before income taxes
|
$
|
449.8
|
|
|
$
|
403.7
|
|
|
$
|
364.6
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Health benefit ratios:
|
|
|
|
|
|
||||||
All health lines:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
1,149.9
|
|
|
$
|
1,192.3
|
|
|
$
|
1,205.1
|
|
Benefit ratio (a)
|
93.4
|
%
|
|
95.8
|
%
|
|
96.3
|
%
|
|||
Medicare supplement:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
550.6
|
|
|
$
|
556.2
|
|
|
$
|
536.1
|
|
Benefit ratio (a)
|
70.8
|
%
|
|
71.9
|
%
|
|
69.6
|
%
|
|||
Long-term care:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
599.3
|
|
|
$
|
636.1
|
|
|
$
|
669.0
|
|
Benefit ratio (a)
|
132.3
|
%
|
|
135.0
|
%
|
|
139.2
|
%
|
|||
Interest-adjusted benefit ratio (b)
|
71.2
|
%
|
|
76.7
|
%
|
|
82.8
|
%
|
(a)
|
We calculate benefit ratios by dividing the related product's insurance policy benefits by insurance policy income.
|
(b)
|
We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Bankers Life's long-term care products by dividing such product's insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Commission expense and agent manager benefits
|
$
|
70.8
|
|
|
$
|
71.6
|
|
|
$
|
64.4
|
|
Other operating expenses
|
373.1
|
|
|
350.5
|
|
|
342.8
|
|
|||
Total
|
$
|
443.9
|
|
|
$
|
422.1
|
|
|
$
|
407.2
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Premium collections:
|
|
|
|
|
|
||||||
Supplemental health and other health
|
$
|
589.1
|
|
|
$
|
567.4
|
|
|
$
|
547.0
|
|
Medicare supplement
|
51.6
|
|
|
61.0
|
|
|
72.6
|
|
|||
Life
|
30.0
|
|
|
29.4
|
|
|
27.7
|
|
|||
Annuity
|
.9
|
|
|
1.5
|
|
|
2.4
|
|
|||
Total collections
|
$
|
671.6
|
|
|
$
|
659.3
|
|
|
$
|
649.7
|
|
Average liabilities for insurance products:
|
|
|
|
|
|
|
|||||
Fixed index annuities
|
$
|
314.2
|
|
|
$
|
350.2
|
|
|
$
|
386.0
|
|
Fixed interest annuities
|
97.9
|
|
|
107.0
|
|
|
119.1
|
|
|||
SPIAs and supplemental contracts:
|
|
|
|
|
|
||||||
Mortality based
|
232.1
|
|
|
248.6
|
|
|
258.4
|
|
|||
Deposit based
|
269.5
|
|
|
267.2
|
|
|
260.5
|
|
|||
Separate Accounts
|
4.7
|
|
|
4.7
|
|
|
5.2
|
|
|||
Health:
|
|
|
|
|
|
||||||
Supplemental health
|
2,732.0
|
|
|
2,604.4
|
|
|
2,494.0
|
|
|||
Medicare supplement
|
24.8
|
|
|
28.3
|
|
|
30.9
|
|
|||
Other health
|
13.5
|
|
|
14.1
|
|
|
15.0
|
|
|||
Life:
|
|
|
|
|
|
||||||
Interest sensitive life
|
149.2
|
|
|
150.3
|
|
|
151.9
|
|
|||
Non-interest sensitive life
|
175.0
|
|
|
179.8
|
|
|
185.9
|
|
|||
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
4,012.9
|
|
|
$
|
3,954.6
|
|
|
$
|
3,906.9
|
|
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
671.4
|
|
|
$
|
655.8
|
|
|
$
|
643.8
|
|
Net investment income (loss):
|
|
|
|
|
|
||||||
General account invested assets
|
257.5
|
|
|
256.2
|
|
|
256.0
|
|
|||
Fixed index products
|
9.0
|
|
|
1.9
|
|
|
(2.2
|
)
|
|||
Trading account income related to policyholder accounts
|
3.7
|
|
|
1.2
|
|
|
(.2
|
)
|
|||
Fee revenue and other income
|
1.0
|
|
|
1.3
|
|
|
1.3
|
|
|||
Total revenues
|
942.6
|
|
|
916.4
|
|
|
898.7
|
|
|||
Expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
550.7
|
|
|
538.2
|
|
|
528.4
|
|
|||
Amounts added to policyholder account balances:
|
|
|
|
|
|
||||||
Cost of interest credited to policyholders
|
12.9
|
|
|
13.8
|
|
|
14.6
|
|
|||
Cost of options to fund index credits, net of forfeitures
|
4.4
|
|
|
5.8
|
|
|
6.3
|
|
|||
Market value changes credited to policyholders
|
13.1
|
|
|
3.9
|
|
|
(2.7
|
)
|
|||
Amortization related to operations
|
58.8
|
|
|
59.1
|
|
|
55.2
|
|
|||
Interest expense on investment borrowings
|
6.3
|
|
|
3.7
|
|
|
2.0
|
|
|||
Other operating costs and expenses
|
198.1
|
|
|
189.0
|
|
|
183.4
|
|
|||
Total benefits and expenses
|
844.3
|
|
|
813.5
|
|
|
787.2
|
|
|||
Income before net realized investment gains (losses) and fair value changes in embedded derivative liabilities, net of related amortization, and income taxes
|
98.3
|
|
|
102.9
|
|
|
111.5
|
|
|||
Net realized investment gains (losses)
|
11.7
|
|
|
19.7
|
|
|
(9.6
|
)
|
|||
Amortization related to net realized investment gains (losses)
|
—
|
|
|
(.3
|
)
|
|
—
|
|
|||
Net realized investment gains (losses), net of related amortization
|
11.7
|
|
|
19.4
|
|
|
(9.6
|
)
|
|||
Insurance policy benefits - fair value changes in embedded derivative liabilities
|
.5
|
|
|
.6
|
|
|
.8
|
|
|||
Amortization related to fair value changes in embedded derivative liabilities
|
(.3
|
)
|
|
(.4
|
)
|
|
(.6
|
)
|
|||
Fair value changes in embedded derivative liabilities, net of related amortization
|
.2
|
|
|
.2
|
|
|
.2
|
|
|||
Income before income taxes
|
$
|
110.2
|
|
|
$
|
122.5
|
|
|
$
|
102.1
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Health benefit ratios:
|
|
|
|
|
|
||||||
Supplemental health:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
489.8
|
|
|
$
|
469.3
|
|
|
$
|
455.3
|
|
Benefit ratio (a)
|
83.2
|
%
|
|
83.0
|
%
|
|
84.0
|
%
|
|||
Interest-adjusted benefit ratio (b)
|
59.1
|
%
|
|
59.0
|
%
|
|
59.6
|
%
|
|||
Medicare supplement:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
37.0
|
|
|
$
|
42.7
|
|
|
$
|
47.9
|
|
Benefit ratio (a)
|
68.1
|
%
|
|
68.4
|
%
|
|
65.0
|
%
|
(a)
|
We calculate benefit ratios by dividing the related product’s insurance policy benefits by insurance policy income.
|
(b)
|
We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Washington National's supplemental health products by dividing such product’s insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Premium collections:
|
|
|
|
|
|
||||||
Life
|
$
|
289.6
|
|
|
$
|
277.8
|
|
|
$
|
259.9
|
|
Medicare supplement and other health
|
2.0
|
|
|
2.4
|
|
|
3.0
|
|
|||
Total collections
|
$
|
291.6
|
|
|
$
|
280.2
|
|
|
$
|
262.9
|
|
Average liabilities for insurance products:
|
|
|
|
|
|
|
|||||
SPIAs - mortality based
|
$
|
73.0
|
|
|
$
|
74.1
|
|
|
$
|
73.1
|
|
Health:
|
|
|
|
|
|
||||||
Medicare supplement
|
5.7
|
|
|
6.5
|
|
|
7.7
|
|
|||
Other health
|
4.1
|
|
|
4.2
|
|
|
4.4
|
|
|||
Life:
|
|
|
|
|
|
||||||
Interest sensitive
|
15.5
|
|
|
16.2
|
|
|
16.5
|
|
|||
Non-interest sensitive
|
717.5
|
|
|
689.4
|
|
|
670.1
|
|
|||
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
815.8
|
|
|
$
|
790.4
|
|
|
$
|
771.8
|
|
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
291.8
|
|
|
$
|
281.4
|
|
|
$
|
263.5
|
|
Net investment income on general account invested assets
|
44.4
|
|
|
44.2
|
|
|
43.0
|
|
|||
Fee revenue and other income
|
1.3
|
|
|
1.1
|
|
|
1.0
|
|
|||
Total revenues
|
337.5
|
|
|
326.7
|
|
|
307.5
|
|
|||
Expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
199.0
|
|
|
201.2
|
|
|
188.3
|
|
|||
Amounts added to annuity and interest-sensitive life product account balances
|
.6
|
|
|
.7
|
|
|
.7
|
|
|||
Amortization related to operations
|
16.3
|
|
|
15.3
|
|
|
14.4
|
|
|||
Interest expense on investment borrowings
|
.9
|
|
|
.6
|
|
|
.1
|
|
|||
Other operating costs and expenses
|
98.1
|
|
|
107.2
|
|
|
98.4
|
|
|||
Total benefits and expenses
|
314.9
|
|
|
325.0
|
|
|
301.9
|
|
|||
Income before net realized investment gains (losses) and income taxes
|
22.6
|
|
|
1.7
|
|
|
5.6
|
|
|||
Net realized investment gains (losses)
|
—
|
|
|
(.2
|
)
|
|
1.2
|
|
|||
Income before income taxes
|
$
|
22.6
|
|
|
$
|
1.5
|
|
|
$
|
6.8
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Adjusted EBIT from In-force Business
|
|
|
|
|
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
241.8
|
|
|
$
|
226.5
|
|
|
$
|
212.0
|
|
Net investment income and other
|
45.7
|
|
|
45.3
|
|
|
44.0
|
|
|||
Total revenues
|
287.5
|
|
|
271.8
|
|
|
256.0
|
|
|||
Benefits and expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
169.2
|
|
|
168.5
|
|
|
159.4
|
|
|||
Amortization
|
15.6
|
|
|
14.5
|
|
|
13.7
|
|
|||
Other expenses
|
33.9
|
|
|
34.4
|
|
|
29.3
|
|
|||
Total benefits and expenses
|
218.7
|
|
|
217.4
|
|
|
202.4
|
|
|||
Adjusted EBIT from In-force Business
|
$
|
68.8
|
|
|
$
|
54.4
|
|
|
$
|
53.6
|
|
|
|
|
|
|
|
||||||
Adjusted EBIT from New Business
|
|
|
|
|
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
50.0
|
|
|
$
|
54.9
|
|
|
$
|
51.5
|
|
Net investment income and other
|
—
|
|
|
—
|
|
|
—
|
|
|||
Total revenues
|
50.0
|
|
|
54.9
|
|
|
51.5
|
|
|||
Benefits and expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
30.4
|
|
|
33.4
|
|
|
29.6
|
|
|||
Amortization
|
.7
|
|
|
.8
|
|
|
.7
|
|
|||
Other expenses
|
65.1
|
|
|
73.4
|
|
|
69.2
|
|
|||
Total benefits and expenses
|
96.2
|
|
|
107.6
|
|
|
99.5
|
|
|||
Adjusted EBIT from New Business
|
$
|
(46.2
|
)
|
|
$
|
(52.7
|
)
|
|
$
|
(48.0
|
)
|
|
|
|
|
|
|
||||||
Adjusted EBIT from In-force and New Business
|
|
|
|
|
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
291.8
|
|
|
$
|
281.4
|
|
|
$
|
263.5
|
|
Net investment income and other
|
45.7
|
|
|
45.3
|
|
|
44.0
|
|
|||
Total revenues
|
337.5
|
|
|
326.7
|
|
|
307.5
|
|
|||
Benefits and expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
199.6
|
|
|
201.9
|
|
|
189.0
|
|
|||
Amortization
|
16.3
|
|
|
15.3
|
|
|
14.4
|
|
|||
Other expenses
|
99.0
|
|
|
107.8
|
|
|
98.5
|
|
|||
Total benefits and expenses
|
314.9
|
|
|
325.0
|
|
|
301.9
|
|
|||
Adjusted EBIT from In-force and New Business
|
$
|
22.6
|
|
|
$
|
1.7
|
|
|
$
|
5.6
|
|
|
2017
|
|
2016
|
||||
Premium collections:
|
|
|
|
||||
Long-term care (all renewal)
|
$
|
16.9
|
|
|
$
|
4.7
|
|
|
|
|
|
||||
Average liabilities for insurance products:
|
|
|
|
||||
Average liabilities for long-term care products, net of reinsurance ceded
|
$
|
572.4
|
|
|
$
|
138.4
|
|
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
17.5
|
|
|
$
|
4.8
|
|
Net investment income on general account invested assets
|
34.6
|
|
|
9.4
|
|
||
Total revenues
|
52.1
|
|
|
14.2
|
|
||
Expenses:
|
|
|
|
||||
Insurance policy benefits
|
47.3
|
|
|
17.6
|
|
||
Other operating costs and expenses
|
3.1
|
|
|
.5
|
|
||
Total benefits and expenses
|
50.4
|
|
|
18.1
|
|
||
Income (loss) before net realized investment gains (losses) and income taxes
|
1.7
|
|
|
(3.9
|
)
|
||
Net realized investment gains (losses)
|
7.0
|
|
|
(5.3
|
)
|
||
Income (loss) before income taxes
|
$
|
8.7
|
|
|
$
|
(9.2
|
)
|
|
2017
|
|
2016
|
||||
Health benefit ratios:
|
|
|
|
||||
Long-term care:
|
|
|
|
||||
Insurance policy benefits
|
$
|
47.3
|
|
|
$
|
17.6
|
|
Benefit ratio (a)
|
270.5
|
%
|
|
365.8
|
%
|
||
Interest-adjusted benefit ratio (b)
|
104.1
|
%
|
|
213.5
|
%
|
(a)
|
We calculate benefit ratios by dividing the related product's insurance policy benefits by insurance policy income.
|
(b)
|
We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for long-term care products in this segment by dividing such product's insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Corporate operations:
|
|
|
|
|
|
||||||
Interest expense on corporate debt
|
$
|
(46.5
|
)
|
|
$
|
(45.8
|
)
|
|
$
|
(45.0
|
)
|
Net investment income (loss):
|
|
|
|
|
|
||||||
General investment portfolio
|
5.6
|
|
|
4.8
|
|
|
6.9
|
|
|||
Other special-purpose portfolios:
|
|
|
|
|
|
||||||
COLI
|
17.4
|
|
|
(.3
|
)
|
|
(6.4
|
)
|
|||
Investments held in a rabbi trust
|
3.4
|
|
|
1.1
|
|
|
(.1
|
)
|
|||
Other trading account activities
|
9.1
|
|
|
11.0
|
|
|
10.9
|
|
|||
Fee revenue and other income
|
8.5
|
|
|
10.0
|
|
|
8.6
|
|
|||
Interest expense on investment borrowings
|
—
|
|
|
—
|
|
|
(.2
|
)
|
|||
Other operating costs and expenses
|
(84.3
|
)
|
|
(69.1
|
)
|
|
(38.6
|
)
|
|||
Loss before net realized investment losses, equity in earnings of certain non-strategic investments and earnings attributable to non-controlling interests, fair value changes and amendment related to agent deferred compensation plan, loss on reinsurance transaction, transition expenses, loss on extinguishment of debt and income taxes
|
(86.8
|
)
|
|
(88.3
|
)
|
|
(63.9
|
)
|
|||
Net realized investment losses
|
(3.0
|
)
|
|
(2.7
|
)
|
|
(11.0
|
)
|
|||
Equity in earnings of certain non-strategic investments and earnings attributable to VIEs
|
(8.8
|
)
|
|
(2.0
|
)
|
|
(6.7
|
)
|
|||
Fair value changes and amendment related to agent deferred compensation plan
|
(12.2
|
)
|
|
3.1
|
|
|
15.1
|
|
|||
Loss on reinsurance transaction and transition expenses
|
—
|
|
|
(75.4
|
)
|
|
—
|
|
|||
Net revenue pursuant to transition and support services agreements
|
—
|
|
|
—
|
|
|
2.5
|
|
|||
Transition expenses
|
—
|
|
|
—
|
|
|
(9.0
|
)
|
|||
Loss on extinguishment of debt
|
—
|
|
|
—
|
|
|
(32.8
|
)
|
|||
Loss before income taxes
|
$
|
(110.8
|
)
|
|
$
|
(165.3
|
)
|
|
$
|
(105.8
|
)
|
|
2017
|
|
2016
|
|
2015
|
||||||
First year:
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
1,245.6
|
|
|
$
|
1,211.8
|
|
|
$
|
1,065.7
|
|
Washington National
|
78.4
|
|
|
78.2
|
|
|
80.2
|
|
|||
Colonial Penn
|
50.1
|
|
|
54.8
|
|
|
51.5
|
|
|||
Total first year
|
1,374.1
|
|
|
1,344.8
|
|
|
1,197.4
|
|
|||
|
|
|
|
|
|
||||||
Renewal:
|
|
|
|
|
|
||||||
Bankers Life
|
1,460.8
|
|
|
1,454.6
|
|
|
1,425.6
|
|
|||
Washington National
|
595.0
|
|
|
581.1
|
|
|
569.5
|
|
|||
Colonial Penn
|
241.5
|
|
|
225.4
|
|
|
211.4
|
|
|||
Long-term care in run-off
|
16.9
|
|
|
4.7
|
|
|
—
|
|
|||
Total renewal
|
2,314.2
|
|
|
2,265.8
|
|
|
2,206.5
|
|
|||
Total premiums collected
|
$
|
3,688.3
|
|
|
$
|
3,610.6
|
|
|
$
|
3,403.9
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Premiums collected by product:
|
|
|
|
|
|
||||||
Annuities:
|
|
|
|
|
|
||||||
Fixed index (first-year)
|
$
|
964.7
|
|
|
$
|
868.1
|
|
|
$
|
706.6
|
|
Other fixed interest (first-year)
|
59.8
|
|
|
95.7
|
|
|
89.6
|
|
|||
Other fixed interest (renewal)
|
6.1
|
|
|
6.2
|
|
|
6.8
|
|
|||
Subtotal - other fixed interest annuities
|
65.9
|
|
|
101.9
|
|
|
96.4
|
|
|||
Total annuities
|
1,030.6
|
|
|
970.0
|
|
|
803.0
|
|
|||
Health:
|
|
|
|
|
|
||||||
Medicare supplement (first-year)
|
69.3
|
|
|
75.6
|
|
|
80.3
|
|
|||
Medicare supplement (renewal)
|
670.1
|
|
|
663.7
|
|
|
659.1
|
|
|||
Subtotal - Medicare supplement
|
739.4
|
|
|
739.3
|
|
|
739.4
|
|
|||
Long-term care (first-year)
|
16.0
|
|
|
17.4
|
|
|
16.7
|
|
|||
Long-term care (renewal)
|
429.3
|
|
|
451.2
|
|
|
459.9
|
|
|||
Subtotal - long-term care
|
445.3
|
|
|
468.6
|
|
|
476.6
|
|
|||
Supplemental health (first-year)
|
5.0
|
|
|
5.5
|
|
|
6.1
|
|
|||
Supplemental health (renewal)
|
17.6
|
|
|
15.7
|
|
|
13.1
|
|
|||
Subtotal – supplemental health
|
22.6
|
|
|
21.2
|
|
|
19.2
|
|
|||
Other health (first-year)
|
.8
|
|
|
.1
|
|
|
.1
|
|
|||
Other health (renewal)
|
5.3
|
|
|
6.1
|
|
|
7.0
|
|
|||
Subtotal - other health
|
6.1
|
|
|
6.2
|
|
|
7.1
|
|
|||
Total health
|
1,213.4
|
|
|
1,235.3
|
|
|
1,242.3
|
|
|||
Life insurance:
|
|
|
|
|
|
||||||
Traditional (first-year)
|
82.6
|
|
|
78.8
|
|
|
83.0
|
|
|||
Traditional (renewal)
|
217.3
|
|
|
207.3
|
|
|
193.9
|
|
|||
Subtotal - traditional
|
299.9
|
|
|
286.1
|
|
|
276.9
|
|
|||
Interest-sensitive (first-year)
|
47.4
|
|
|
70.6
|
|
|
83.3
|
|
|||
Interest-sensitive (renewal)
|
115.1
|
|
|
104.4
|
|
|
85.8
|
|
|||
Subtotal - interest-sensitive
|
162.5
|
|
|
175.0
|
|
|
169.1
|
|
|||
Total life insurance
|
462.4
|
|
|
461.1
|
|
|
446.0
|
|
|||
Collections on insurance products:
|
|
|
|
|
|
||||||
Total first-year premium collections on insurance products
|
1,245.6
|
|
|
1,211.8
|
|
|
1,065.7
|
|
|||
Total renewal premium collections on insurance products
|
1,460.8
|
|
|
1,454.6
|
|
|
1,425.6
|
|
|||
Total collections on insurance products
|
$
|
2,706.4
|
|
|
$
|
2,666.4
|
|
|
$
|
2,491.3
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Premiums collected by product:
|
|
|
|
|
|
||||||
Health:
|
|
|
|
|
|
||||||
Medicare supplement (renewal)
|
$
|
51.6
|
|
|
$
|
61.0
|
|
|
$
|
72.6
|
|
Supplemental health (first-year)
|
73.2
|
|
|
72.2
|
|
|
74.9
|
|
|||
Supplemental health (renewal)
|
515.9
|
|
|
493.3
|
|
|
469.9
|
|
|||
Subtotal – supplemental health
|
589.1
|
|
|
565.5
|
|
|
544.8
|
|
|||
Other health (first-year)
|
.3
|
|
|
.2
|
|
|
.2
|
|
|||
Other health (renewal)
|
1.5
|
|
|
1.7
|
|
|
2.0
|
|
|||
Subtotal – other health
|
1.8
|
|
|
1.9
|
|
|
2.2
|
|
|||
Total health
|
642.5
|
|
|
628.4
|
|
|
619.6
|
|
|||
Life insurance:
|
|
|
|
|
|
||||||
Traditional (first-year)
|
.7
|
|
|
.9
|
|
|
.7
|
|
|||
Traditional (renewal)
|
10.2
|
|
|
10.5
|
|
|
11.4
|
|
|||
Subtotal - traditional
|
10.9
|
|
|
11.4
|
|
|
12.1
|
|
|||
Interest-sensitive (first-year)
|
4.2
|
|
|
4.7
|
|
|
4.3
|
|
|||
Interest-sensitive (renewal)
|
14.9
|
|
|
13.3
|
|
|
11.3
|
|
|||
Subtotal - interest-sensitive
|
19.1
|
|
|
18.0
|
|
|
15.6
|
|
|||
Total life insurance
|
30.0
|
|
|
29.4
|
|
|
27.7
|
|
|||
Annuities:
|
|
|
|
|
|
||||||
Fixed index (first-year)
|
—
|
|
|
.2
|
|
|
.1
|
|
|||
Fixed index (renewal)
|
.6
|
|
|
1.0
|
|
|
1.8
|
|
|||
Subtotal - fixed index annuities
|
.6
|
|
|
1.2
|
|
|
1.9
|
|
|||
Other fixed interest (renewal)
|
.3
|
|
|
.3
|
|
|
.5
|
|
|||
Total annuities
|
.9
|
|
|
1.5
|
|
|
2.4
|
|
|||
Collections on insurance products:
|
|
|
|
|
|
||||||
Total first-year premium collections on insurance products
|
78.4
|
|
|
78.2
|
|
|
80.2
|
|
|||
Total renewal premium collections on insurance products
|
595.0
|
|
|
581.1
|
|
|
569.5
|
|
|||
Total collections on insurance products
|
$
|
673.4
|
|
|
$
|
659.3
|
|
|
$
|
649.7
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Premiums collected by product:
|
|
|
|
|
|
||||||
Life insurance:
|
|
|
|
|
|
||||||
Traditional (first-year)
|
$
|
50.1
|
|
|
$
|
54.8
|
|
|
$
|
51.5
|
|
Traditional (renewal)
|
239.3
|
|
|
222.7
|
|
|
208.2
|
|
|||
Subtotal - traditional
|
289.4
|
|
|
277.5
|
|
|
259.7
|
|
|||
Interest-sensitive (all renewal)
|
.2
|
|
|
.3
|
|
|
.2
|
|
|||
Total life insurance
|
289.6
|
|
|
277.8
|
|
|
259.9
|
|
|||
Health (all renewal):
|
|
|
|
|
|
||||||
Medicare supplement
|
1.9
|
|
|
2.3
|
|
|
2.7
|
|
|||
Other health
|
.1
|
|
|
.1
|
|
|
.3
|
|
|||
Total health
|
2.0
|
|
|
2.4
|
|
|
3.0
|
|
|||
Collections on insurance products:
|
|
|
|
|
|
||||||
Total first-year premium collections on insurance products
|
50.1
|
|
|
54.8
|
|
|
51.5
|
|
|||
Total renewal premium collections on insurance products
|
241.5
|
|
|
225.4
|
|
|
211.4
|
|
|||
Total collections on insurance products
|
$
|
291.6
|
|
|
$
|
280.2
|
|
|
$
|
262.9
|
|
|
2017
|
|
2016
|
||||
Premiums collected by product:
|
|
|
|
||||
Health:
|
|
|
|
||||
Long-term care (renewal)
|
$
|
16.9
|
|
|
$
|
4.7
|
|
|
Carrying value
|
|
Percent of total investments
|
|||
Fixed maturities, available for sale
|
$
|
22,910.9
|
|
|
82
|
%
|
Equity securities
|
511.7
|
|
|
2
|
|
|
Mortgage loans
|
1,650.6
|
|
|
6
|
|
|
Policy loans
|
116.0
|
|
|
—
|
|
|
Trading securities
|
284.6
|
|
|
1
|
|
|
Investments held by variable interest entities
|
1,526.9
|
|
|
6
|
|
|
Company-owned life insurance
|
182.3
|
|
|
1
|
|
|
Other invested assets
|
671.1
|
|
|
2
|
|
|
Total investments
|
$
|
27,854.1
|
|
|
100
|
%
|
|
Carrying value
|
|
Percent of fixed maturities
|
|
Gross unrealized losses
|
|
Percent of gross unrealized losses
|
||||||
Asset-backed securities
|
$
|
3,254.4
|
|
|
14.2
|
%
|
|
$
|
4.1
|
|
|
9.8
|
%
|
States and political subdivisions
|
2,056.3
|
|
|
9.0
|
|
|
.4
|
|
|
1.0
|
|
||
Insurance
|
1,831.8
|
|
|
8.0
|
|
|
.4
|
|
|
1.0
|
|
||
Utilities
|
1,694.2
|
|
|
7.4
|
|
|
.1
|
|
|
.2
|
|
||
Energy
|
1,488.4
|
|
|
6.5
|
|
|
6.4
|
|
|
15.0
|
|
||
Commercial mortgage-backed securities
|
1,377.5
|
|
|
6.0
|
|
|
10.3
|
|
|
24.0
|
|
||
Healthcare/pharmaceuticals
|
1,320.5
|
|
|
5.8
|
|
|
.8
|
|
|
1.8
|
|
||
Banks
|
1,268.5
|
|
|
5.5
|
|
|
.4
|
|
|
1.0
|
|
||
Food/beverage
|
1,024.3
|
|
|
4.5
|
|
|
.1
|
|
|
.3
|
|
||
Collateralized mortgage obligations
|
742.1
|
|
|
3.3
|
|
|
.3
|
|
|
.7
|
|
||
Cable/media
|
649.2
|
|
|
2.8
|
|
|
5.8
|
|
|
13.6
|
|
||
Capital goods
|
596.0
|
|
|
2.6
|
|
|
.1
|
|
|
.3
|
|
||
Chemicals
|
573.7
|
|
|
2.5
|
|
|
1.7
|
|
|
3.9
|
|
||
Transportation
|
573.1
|
|
|
2.5
|
|
|
.7
|
|
|
1.6
|
|
||
Real estate/REITs
|
530.2
|
|
|
2.3
|
|
|
.1
|
|
|
.3
|
|
||
Telecom
|
486.6
|
|
|
2.1
|
|
|
.4
|
|
|
1.0
|
|
||
Technology
|
426.4
|
|
|
1.9
|
|
|
1.5
|
|
|
3.6
|
|
||
Brokerage
|
352.3
|
|
|
1.5
|
|
|
1.3
|
|
|
3.0
|
|
||
Building materials
|
296.8
|
|
|
1.3
|
|
|
1.0
|
|
|
2.5
|
|
||
Autos
|
296.5
|
|
|
1.3
|
|
|
.3
|
|
|
.6
|
|
||
Aerospace/defense
|
283.1
|
|
|
1.2
|
|
|
—
|
|
|
—
|
|
||
Collateralized debt obligations
|
259.4
|
|
|
1.1
|
|
|
—
|
|
|
—
|
|
||
Retail
|
226.3
|
|
|
1.0
|
|
|
.7
|
|
|
1.6
|
|
||
Business services
|
191.9
|
|
|
.8
|
|
|
1.8
|
|
|
4.3
|
|
||
Other
|
1,111.4
|
|
|
4.9
|
|
|
3.8
|
|
|
8.9
|
|
||
Total fixed maturities, available for sale
|
$
|
22,910.9
|
|
|
100.0
|
%
|
|
$
|
42.5
|
|
|
100.0
|
%
|
|
Investment grade
|
|
Below-investment grade
|
|
|
||||||||||||||
|
AAA/AA/A
|
|
BBB
|
|
BB
|
|
B+ and
below
|
|
Total gross
unrealized
losses |
||||||||||
Commercial mortgage-backed securities
|
$
|
8.8
|
|
|
$
|
.3
|
|
|
$
|
1.2
|
|
|
$
|
—
|
|
|
$
|
10.3
|
|
Energy
|
—
|
|
|
3.1
|
|
|
—
|
|
|
3.3
|
|
|
6.4
|
|
|||||
Cable/media
|
.1
|
|
|
5.4
|
|
|
.3
|
|
|
—
|
|
|
5.8
|
|
|||||
Asset-backed securities
|
2.5
|
|
|
.7
|
|
|
.3
|
|
|
.6
|
|
|
4.1
|
|
|||||
Entertainment/hotels
|
—
|
|
|
.5
|
|
|
1.9
|
|
|
.1
|
|
|
2.5
|
|
|||||
Business services
|
—
|
|
|
—
|
|
|
1.8
|
|
|
—
|
|
|
1.8
|
|
|||||
Chemicals
|
—
|
|
|
—
|
|
|
1.7
|
|
|
—
|
|
|
1.7
|
|
|||||
Technology
|
—
|
|
|
1.5
|
|
|
—
|
|
|
—
|
|
|
1.5
|
|
|||||
Brokerage
|
—
|
|
|
.7
|
|
|
—
|
|
|
.6
|
|
|
1.3
|
|
|||||
Building materials
|
—
|
|
|
.4
|
|
|
.6
|
|
|
—
|
|
|
1.0
|
|
|||||
Healthcare/pharmaceuticals
|
—
|
|
|
.1
|
|
|
—
|
|
|
.7
|
|
|
.8
|
|
|||||
Transportation
|
—
|
|
|
.2
|
|
|
.5
|
|
|
|
|
.7
|
|
||||||
Retail
|
—
|
|
|
.3
|
|
|
—
|
|
|
.4
|
|
|
.7
|
|
|||||
Insurance
|
—
|
|
|
.4
|
|
|
—
|
|
|
—
|
|
|
.4
|
|
|||||
States and political subdivisions
|
.1
|
|
|
.3
|
|
|
—
|
|
|
—
|
|
|
.4
|
|
|||||
Telecom
|
—
|
|
|
.4
|
|
|
—
|
|
|
—
|
|
|
.4
|
|
|||||
Banks
|
.2
|
|
|
.2
|
|
|
—
|
|
|
—
|
|
|
.4
|
|
|||||
Collateralized mortgage obligations
|
.2
|
|
|
—
|
|
|
—
|
|
|
.1
|
|
|
.3
|
|
|||||
Autos
|
—
|
|
|
—
|
|
|
.3
|
|
|
—
|
|
|
.3
|
|
|||||
United States Treasury securities and obligations of United States government corporations and agencies
|
.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
.2
|
|
|||||
Debt securities issued by foreign governments
|
.1
|
|
|
.1
|
|
|
—
|
|
|
—
|
|
|
.2
|
|
|||||
Food/beverage
|
—
|
|
|
—
|
|
|
—
|
|
|
.1
|
|
|
.1
|
|
|||||
Real estate/REITs
|
—
|
|
|
.1
|
|
|
—
|
|
|
—
|
|
|
.1
|
|
|||||
Capital goods
|
.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
.1
|
|
|||||
Consumer products
|
—
|
|
|
—
|
|
|
—
|
|
|
.1
|
|
|
.1
|
|
|||||
Utilities
|
.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
.1
|
|
|||||
Other
|
.6
|
|
|
.2
|
|
|
—
|
|
|
—
|
|
|
.8
|
|
|||||
Total fixed maturities, available for sale
|
$
|
13.0
|
|
|
$
|
14.9
|
|
|
$
|
8.6
|
|
|
$
|
6.0
|
|
|
$
|
42.5
|
|
•
|
Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.
|
•
|
Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include: certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.
|
•
|
Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.
|
•
|
Investments held by VIEs
|
•
|
Other invested assets - derivatives
|
|
Quoted prices in active markets
for identical assets or liabilities (Level 1) |
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
$
|
—
|
|
|
$
|
14,728.0
|
|
|
$
|
230.4
|
|
|
$
|
14,958.4
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
177.7
|
|
|
—
|
|
|
177.7
|
|
||||
States and political subdivisions
|
—
|
|
|
2,056.3
|
|
|
—
|
|
|
2,056.3
|
|
||||
Debt securities issued by foreign governments
|
—
|
|
|
79.2
|
|
|
3.9
|
|
|
83.1
|
|
||||
Asset-backed securities
|
—
|
|
|
3,230.2
|
|
|
24.2
|
|
|
3,254.4
|
|
||||
Collateralized debt obligations
|
—
|
|
|
259.4
|
|
|
—
|
|
|
259.4
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
1,377.5
|
|
|
—
|
|
|
1,377.5
|
|
||||
Mortgage pass-through securities
|
—
|
|
|
2.0
|
|
|
—
|
|
|
2.0
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
742.1
|
|
|
—
|
|
|
742.1
|
|
||||
Total fixed maturities, available for sale
|
—
|
|
|
22,652.4
|
|
|
258.5
|
|
|
22,910.9
|
|
||||
Equity securities - corporate securities
|
287.8
|
|
|
202.7
|
|
|
21.2
|
|
|
511.7
|
|
||||
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate securities
|
—
|
|
|
21.6
|
|
|
—
|
|
|
21.6
|
|
||||
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
.5
|
|
|
—
|
|
|
.5
|
|
||||
Asset-backed securities
|
—
|
|
|
95.8
|
|
|
—
|
|
|
95.8
|
|
||||
Collateralized debt obligations
|
—
|
|
|
2.7
|
|
|
—
|
|
|
2.7
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
92.5
|
|
|
—
|
|
|
92.5
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
68.7
|
|
|
—
|
|
|
68.7
|
|
||||
Equity securities
|
2.8
|
|
|
—
|
|
|
—
|
|
|
2.8
|
|
||||
Total trading securities
|
2.8
|
|
|
281.8
|
|
|
—
|
|
|
284.6
|
|
||||
Investments held by variable interest entities - corporate securities
|
—
|
|
|
1,522.0
|
|
|
4.9
|
|
|
1,526.9
|
|
||||
Other invested assets - derivatives
|
—
|
|
|
170.2
|
|
|
—
|
|
|
170.2
|
|
||||
Assets held in separate accounts
|
—
|
|
|
5.0
|
|
|
—
|
|
|
5.0
|
|
||||
Total assets carried at fair value by category
|
$
|
290.6
|
|
|
$
|
24,834.1
|
|
|
$
|
284.6
|
|
|
$
|
25,409.3
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,334.8
|
|
|
$
|
1,334.8
|
|
|
|
December 31, 2017
|
|
|
||||||||||||||||||||||||||||
|
|
Beginning balance as of December 31, 2016
|
|
Purchases, sales, issuances and settlements, net (b)
|
|
Total realized and unrealized gains (losses) included in net income
|
|
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)
|
|
Transfers into Level 3 (a)
|
|
Transfers out of Level 3 (a)
|
|
Ending balance as of December 31, 2017
|
|
Amount of total gains (losses) for the year ended December 31, 2017 included in our net income relating to assets and liabilities still held as of the reporting date
|
||||||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate securities
|
|
$
|
258.5
|
|
|
$
|
(70.4
|
)
|
|
$
|
5.8
|
|
|
$
|
5.3
|
|
|
$
|
31.2
|
|
|
$
|
—
|
|
|
$
|
230.4
|
|
|
$
|
(8.0
|
)
|
Debt securities issued by foreign governments
|
|
3.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.9
|
|
|
—
|
|
||||||||
Asset-backed securities
|
|
60.4
|
|
|
(4.3
|
)
|
|
—
|
|
|
.7
|
|
|
—
|
|
|
(32.6
|
)
|
|
24.2
|
|
|
—
|
|
||||||||
Collateralized debt obligations
|
|
5.4
|
|
|
(2.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2.9
|
)
|
|
—
|
|
|
—
|
|
||||||||
Commercial mortgage-backed securities
|
|
32.0
|
|
|
(1.2
|
)
|
|
.1
|
|
|
(.1
|
)
|
|
—
|
|
|
(30.8
|
)
|
|
—
|
|
|
—
|
|
||||||||
Total fixed maturities, available for sale
|
|
360.2
|
|
|
(78.4
|
)
|
|
5.9
|
|
|
5.9
|
|
|
31.2
|
|
|
(66.3
|
)
|
|
258.5
|
|
|
(8.0
|
)
|
||||||||
Equity securities - corporate securities
|
|
25.2
|
|
|
(8.5
|
)
|
|
6.3
|
|
|
(1.8
|
)
|
|
—
|
|
|
—
|
|
|
21.2
|
|
|
—
|
|
||||||||
Investments held by variable interest entities - corporate securities
|
|
—
|
|
|
4.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.9
|
|
|
—
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
|
(1,092.3
|
)
|
|
(267.5
|
)
|
|
25.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,334.8
|
)
|
|
25.0
|
|
(a)
|
Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.
|
(b)
|
Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the year ended
December 31, 2017
(dollars in millions):
|
|
Purchases
|
|
Sales
|
|
Issuances
|
|
Settlements
|
|
Purchases, sales, issuances and settlements, net
|
||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
||||||||||
Corporate securities
|
$
|
76.6
|
|
|
$
|
(147.0
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(70.4
|
)
|
Asset-backed securities
|
—
|
|
|
(4.3
|
)
|
|
—
|
|
|
—
|
|
|
(4.3
|
)
|
|||||
Collateralized debt obligations
|
—
|
|
|
(2.5
|
)
|
|
—
|
|
|
—
|
|
|
(2.5
|
)
|
|||||
Commercial mortgage-backed securities
|
—
|
|
|
(1.2
|
)
|
|
—
|
|
|
—
|
|
|
(1.2
|
)
|
|||||
Total fixed maturities, available for sale
|
76.6
|
|
|
(155.0
|
)
|
|
—
|
|
|
—
|
|
|
(78.4
|
)
|
|||||
Equity securities - corporate securities
|
—
|
|
|
(8.5
|
)
|
|
—
|
|
|
—
|
|
|
(8.5
|
)
|
|||||
Investments held by variable interest entities - corporate securities
|
8.9
|
|
|
(4.0
|
)
|
|
—
|
|
|
—
|
|
|
4.9
|
|
|||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
(178.9
|
)
|
|
5.4
|
|
|
(159.3
|
)
|
|
65.3
|
|
|
(267.5
|
)
|
|
|
|
Estimated fair value
|
|||||||
Investment rating
|
Amortized cost
|
|
Amount
|
|
Percent of fixed maturities
|
|||||
AAA
|
$
|
1,521.2
|
|
|
$
|
1,552.6
|
|
|
7
|
%
|
AA
|
1,588.4
|
|
|
1,770.8
|
|
|
7
|
|
||
A
|
4,967.3
|
|
|
5,678.2
|
|
|
25
|
|
||
BBB+
|
2,910.5
|
|
|
3,354.0
|
|
|
15
|
|
||
BBB
|
3,870.5
|
|
|
4,291.6
|
|
|
19
|
|
||
BBB-
|
3,194.8
|
|
|
3,410.2
|
|
|
15
|
|
||
Investment grade
|
18,052.7
|
|
|
20,057.4
|
|
|
88
|
|
||
BB+
|
244.3
|
|
|
254.5
|
|
|
1
|
|
||
BB
|
266.7
|
|
|
272.4
|
|
|
1
|
|
||
BB-
|
290.0
|
|
|
293.6
|
|
|
1
|
|
||
B+ and below
|
1,848.4
|
|
|
2,033.0
|
|
|
9
|
|
||
Below-investment grade
|
2,649.4
|
|
|
2,853.5
|
|
|
12
|
|
||
Total fixed maturity securities
|
$
|
20,702.1
|
|
|
$
|
22,910.9
|
|
|
100
|
%
|
|
2017
|
|
2016
|
|
2015
|
||||||
Weighted average general account invested assets at amortized cost
|
$
|
23,819.5
|
|
|
$
|
22,539.5
|
|
|
$
|
21,624.6
|
|
Net investment income on general account invested assets
|
1,290.3
|
|
|
1,219.3
|
|
|
1,217.7
|
|
|||
Yield earned
|
5.42
|
%
|
|
5.41
|
%
|
|
5.63
|
%
|
|
Par
value
|
|
Amortized
cost
|
|
Estimated
fair value
|
||||||
Below 4 percent
|
$
|
2,101.7
|
|
|
$
|
1,944.8
|
|
|
$
|
2,014.9
|
|
4 percent – 5 percent
|
1,656.3
|
|
|
1,516.0
|
|
|
1,596.5
|
|
|||
5 percent – 6 percent
|
1,407.1
|
|
|
1,271.8
|
|
|
1,362.6
|
|
|||
6 percent – 7 percent
|
286.6
|
|
|
260.6
|
|
|
276.8
|
|
|||
7 percent – 8 percent
|
83.0
|
|
|
83.7
|
|
|
92.5
|
|
|||
8 percent and above
|
291.3
|
|
|
291.1
|
|
|
292.1
|
|
|||
Total structured securities
|
$
|
5,826.0
|
|
|
$
|
5,368.0
|
|
|
$
|
5,635.4
|
|
|
|
|
Estimated fair value
|
|||||||
Type
|
Amortized
cost
|
|
Amount
|
|
Percent
of fixed
maturities
|
|||||
Pass-throughs, sequential and equivalent securities
|
$
|
557.7
|
|
|
$
|
617.2
|
|
|
2.7
|
%
|
Planned amortization classes, target amortization classes and accretion-directed bonds
|
95.3
|
|
|
108.5
|
|
|
.5
|
|
||
Commercial mortgage-backed securities
|
1,354.0
|
|
|
1,377.5
|
|
|
6.0
|
|
||
Asset-backed securities
|
3,085.9
|
|
|
3,254.4
|
|
|
14.2
|
|
||
Collateralized debt obligations
|
257.1
|
|
|
259.4
|
|
|
1.1
|
|
||
Other
|
18.0
|
|
|
18.4
|
|
|
.1
|
|
||
Total structured securities
|
$
|
5,368.0
|
|
|
$
|
5,635.4
|
|
|
24.6
|
%
|
|
Number of loans
|
|
Carrying value
|
|||
Retail
|
98
|
|
|
$
|
376.6
|
|
Multi-family
|
34
|
|
|
483.9
|
|
|
Industrial
|
33
|
|
|
278.6
|
|
|
Office building
|
29
|
|
|
290.5
|
|
|
Other
|
21
|
|
|
183.9
|
|
|
Total commercial mortgage loans
|
215
|
|
|
$
|
1,613.5
|
|
|
Number of loans
|
|
Carrying value
|
|||
Under $5 million
|
92
|
|
|
$
|
158.2
|
|
$5 million but less than $10 million
|
62
|
|
|
434.3
|
|
|
$10 million but less than $20 million
|
42
|
|
|
574.3
|
|
|
Over $20 million
|
19
|
|
|
446.7
|
|
|
Total commercial mortgage loans
|
215
|
|
|
$
|
1,613.5
|
|
|
Number of loans
|
|
Carrying value
|
|||
2018
|
21
|
|
|
$
|
96.5
|
|
2019
|
19
|
|
|
32.6
|
|
|
2020
|
8
|
|
|
30.7
|
|
|
2021
|
10
|
|
|
59.5
|
|
|
2022
|
15
|
|
|
105.4
|
|
|
after 2022
|
142
|
|
|
1,288.8
|
|
|
Total commercial mortgage loans
|
215
|
|
|
$
|
1,613.5
|
|
|
|
|
Estimated fair
value
|
||||||||
Loan-to-value ratio (a)
|
Carrying value
|
|
Mortgage loans
|
|
Collateral
|
||||||
Less than 60%
|
$
|
944.7
|
|
|
$
|
960.8
|
|
|
$
|
2,330.6
|
|
60% to 70%
|
439.5
|
|
|
440.2
|
|
|
671.3
|
|
|||
Greater than 70% to 80%
|
138.4
|
|
|
145.9
|
|
|
188.4
|
|
|||
Greater than 80% to 90%
|
52.3
|
|
|
52.9
|
|
|
60.1
|
|
|||
Greater than 90%
|
38.6
|
|
|
40.2
|
|
|
41.7
|
|
|||
Total
|
$
|
1,613.5
|
|
|
$
|
1,640.0
|
|
|
$
|
3,292.1
|
|
(a)
|
Loan-to-value ratios are calculated as the ratio of: (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral.
|
|
December 31,
2017 |
|
December 31, 2016
|
||||
Total capital:
|
|
|
|
||||
Corporate notes payable
|
$
|
914.6
|
|
|
$
|
912.9
|
|
Shareholders’ equity:
|
|
|
|
|
|||
Common stock
|
1.7
|
|
|
1.7
|
|
||
Additional paid-in capital
|
3,073.3
|
|
|
3,212.1
|
|
||
Accumulated other comprehensive income
|
1,212.1
|
|
|
622.4
|
|
||
Retained earnings
|
560.4
|
|
|
650.7
|
|
||
Total shareholders’ equity
|
4,847.5
|
|
|
4,486.9
|
|
||
Total capital
|
$
|
5,762.1
|
|
|
$
|
5,399.8
|
|
|
December 31,
2017 |
|
December 31, 2016
|
||||
Book value per common share
|
$
|
29.05
|
|
|
$
|
25.82
|
|
Book value per common share, excluding accumulated other comprehensive income (a)
|
21.79
|
|
|
22.24
|
|
||
Ratio of earnings to fixed charges
|
2.94X
|
|
|
2.43X
|
|
||
Debt to total capital ratios:
|
|
|
|
||||
Corporate debt to total capital
|
15.9
|
%
|
|
16.9
|
%
|
||
Corporate debt to total capital, excluding accumulated other comprehensive income (a)
|
20.1
|
%
|
|
19.1
|
%
|
(a)
|
This non-GAAP measure differs from the corresponding GAAP measure presented immediately above, because accumulated other comprehensive income has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income. Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. However, this measure does not replace the corresponding GAAP measure.
|
|
|
|
|
|
|
Investments not included in scope of audit
|
|
|
||||||||
|
|
Investments included in initial scope of audit
|
|
Investments included in additional scope of audit
|
|
Cash, fixed maturities and other invested assets
|
|
Total investments
|
||||||||
September 30, 2016 values
|
|
$
|
62.2
|
|
|
$
|
62.6
|
|
|
$
|
379.8
|
|
|
$
|
504.6
|
|
Net cash flows (1)
|
|
(13.5
|
)
|
|
(11.6
|
)
|
|
(359.5
|
)
|
|
(384.6
|
)
|
||||
Realized gains (losses) and impairments (2)
|
|
.4
|
|
|
(1.7
|
)
|
|
(4.0
|
)
|
|
(5.3
|
)
|
||||
Other activity (7)
|
|
3.9
|
|
|
1.9
|
|
|
.6
|
|
|
6.4
|
|
||||
December 31, 2016 values
|
|
53.0
|
|
|
51.2
|
|
|
16.9
|
|
|
121.1
|
|
||||
Net cash flows (1)
|
|
(16.7
|
)
|
|
(5.5
|
)
|
|
(8.7
|
)
|
|
(30.9
|
)
|
||||
Realized gains (losses) and impairments (3)
|
|
3.2
|
|
|
(4.5
|
)
|
|
1.0
|
|
|
(.3
|
)
|
||||
Other activity (7)
|
|
(1.8
|
)
|
|
1.3
|
|
|
(1.4
|
)
|
|
(1.9
|
)
|
||||
March 31, 2017 values
|
|
37.7
|
|
|
42.5
|
|
|
7.8
|
|
|
88.0
|
|
||||
Net cash flows (1)
|
|
.5
|
|
|
(14.4
|
)
|
|
—
|
|
|
(13.9
|
)
|
||||
Realized gains (losses) and impairments (4)
|
|
(3.1
|
)
|
|
4.5
|
|
|
—
|
|
|
1.4
|
|
||||
Other activity (7)
|
|
(.6
|
)
|
|
(.4
|
)
|
|
.3
|
|
|
(.7
|
)
|
||||
June 30, 2017 values
|
|
34.5
|
|
|
32.2
|
|
|
8.1
|
|
|
74.8
|
|
||||
Net cash flows (1)
|
|
(33.5
|
)
|
|
(9.1
|
)
|
|
(1.3
|
)
|
|
(43.9
|
)
|
||||
Realized gains (losses) and impairments (5)
|
|
7.0
|
|
|
(.6
|
)
|
|
.3
|
|
|
6.7
|
|
||||
Other activity (7)
|
|
(.9
|
)
|
|
(.3
|
)
|
|
(3.0
|
)
|
|
(4.2
|
)
|
||||
September 30, 2017 values
|
|
7.1
|
|
|
22.2
|
|
|
4.1
|
|
|
33.4
|
|
||||
Net cash flows (1)
|
|
—
|
|
|
(8.4
|
)
|
|
(3.6
|
)
|
|
(12.0
|
)
|
||||
Realized gains (losses) and impairments (6)
|
|
(1.0
|
)
|
|
(1.5
|
)
|
|
.1
|
|
|
(2.4
|
)
|
||||
Other activity (7)
|
|
1.4
|
|
|
—
|
|
|
(.3
|
)
|
|
1.1
|
|
||||
December 31, 2017 values
|
|
$
|
7.5
|
|
|
$
|
12.3
|
|
|
$
|
.3
|
|
|
$
|
20.1
|
|
|
|
Investments included in initial scope of audit
|
|
Investments included in additional scope of audit
|
|
Total investments included in the scope of audit
|
||||||
Lease related investments
|
$
|
—
|
|
|
$
|
1.7
|
|
|
$
|
1.7
|
|
|
Mortgage loans secured by real estate
|
—
|
|
|
10.6
|
|
|
10.6
|
|
||||
Senior secured loans to companies in the energy sector (8)
|
2.4
|
|
|
—
|
|
|
2.4
|
|
||||
Secured term loan issued by Platinum Partners Credit Opportunity Master Fund L.P.
|
5.1
|
|
|
—
|
|
|
5.1
|
|
||||
Total investments
|
$
|
7.5
|
|
|
$
|
12.3
|
|
|
$
|
19.8
|
|
(1)
|
Net cash inflows from sales and redemptions of investments during the period.
|
(2)
|
Includes $4.6 million of impairment charges and $.7 million of net realized losses recognized on the sale of transferred investments.
|
(3)
|
Includes $8.4 million of impairment charges and $8.1 million of net realized gains recognized on the sale of transferred investments.
|
(4)
|
Includes $3.7 million of impairment charges and $5.1 million of net realized gains recognized on the sale of transferred investments.
|
(5)
|
Includes $4.7 million of impairment charges and $11.4 million of net realized gains recognized on the sale of transferred investments.
|
(6)
|
Includes $1.5 million of impairment charges and $.9 million of net realized losses recognized on the sale of transferred investments.
|
(7)
|
Includes amortization of discount and premium and changes in estimated fair values of investment during the period.
|
(8)
|
Represents $2.4 million of loans issued by Golden Gate Oil, LLC with a par value of $11.7 million. The issuer of this debt has been referred to in articles regarding Platinum.
|
Market value of investments
|
$
|
504.7
|
|
Insurance liabilities
|
(552.2
|
)
|
|
Write-off of reinsurance receivables
|
(17.9
|
)
|
|
Estimated transaction expenses
|
(10.0
|
)
|
|
Pre-tax loss
|
$
|
(75.4
|
)
|
Impact on surplus:
|
|
||
Market value of investments
|
$
|
504.7
|
|
Write-off of estimated receivable due from BRe
|
(17.9
|
)
|
|
Insurance liabilities
|
(587.2
|
)
|
|
Expenses incurred
|
(10.0
|
)
|
|
Statutory earnings impact
|
(110.4
|
)
|
|
Impact on admitted investments
|
(11.0
|
)
|
|
Impact on admitted deferred tax assets
|
(14.5
|
)
|
|
Statutory surplus impact
|
$
|
(135.9
|
)
|
|
|
|
Payment due in
|
||||||||||||||||
|
Total
|
|
2018
|
|
2019-2020
|
|
2021-2022
|
|
Thereafter
|
||||||||||
Insurance liabilities (a)
|
$
|
59,106.0
|
|
|
$
|
3,619.7
|
|
|
$
|
7,517.6
|
|
|
$
|
7,156.9
|
|
|
$
|
40,811.8
|
|
Notes payable (b)
|
1,165.6
|
|
|
44.5
|
|
|
502.8
|
|
|
52.6
|
|
|
565.7
|
|
|||||
Investment borrowings (c)
|
1,799.1
|
|
|
41.6
|
|
|
789.7
|
|
|
926.8
|
|
|
41.0
|
|
|||||
Borrowings related to variable interest
entities (d)
|
1,983.3
|
|
|
50.5
|
|
|
100.6
|
|
|
95.8
|
|
|
1,736.4
|
|
|||||
Postretirement plans (e)
|
267.6
|
|
|
7.4
|
|
|
15.5
|
|
|
16.3
|
|
|
228.4
|
|
|||||
Operating leases and certain other contractual commitments (f)
|
263.4
|
|
|
121.9
|
|
|
109.1
|
|
|
26.0
|
|
|
6.4
|
|
|||||
Total
|
$
|
64,585.0
|
|
|
$
|
3,885.6
|
|
|
$
|
9,035.3
|
|
|
$
|
8,274.4
|
|
|
$
|
43,389.7
|
|
(a)
|
These cash flows represent our estimates of the payments we expect to make to our policyholders, without consideration of future premiums or reinsurance recoveries. These estimates are based on numerous assumptions (depending on the product type) related to mortality, morbidity, lapses, withdrawals, future premiums, future deposits, interest rates on investments, credited rates, expenses and other factors which affect our future payments. The cash flows presented are undiscounted for interest. As a result, total outflows for all years exceed the corresponding liabilities of
$23.5 billion
included in our consolidated balance sheet as of
December 31, 2017
. As such payments are based on numerous assumptions, the actual payments may vary significantly from the amounts shown.
|
•
|
For products such as immediate annuities and structured settlement annuities without life contingencies, the payment obligation is fixed and determinable based on the terms of the policy.
|
•
|
For products such as universal life, ordinary life, long-term care, supplemental health and fixed rate annuities, the future payments are not due until the occurrence of an insurable event (such as death or disability) or a triggering event (such as a surrender or partial withdrawal). We estimated these payments using actuarial models based on historical experience and our expectation of the future payment patterns.
|
•
|
For short-term insurance products such as Medicare supplement insurance, the future payments relate only to amounts necessary to settle all outstanding claims, including those that have been incurred but not reported as of the balance sheet date. We estimated these payments based on our historical experience and our expectation of future payment patterns.
|
•
|
The average interest rate we assumed would be credited to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or fixed index products) over the term of the contracts was 4.6 percent.
|
(b)
|
Includes projected interest payments based on interest rates, as applicable, as of
December 31, 2017
. Refer to the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations" for additional information on notes payable.
|
(c)
|
These borrowings primarily represent collateralized borrowings from the FHLB.
|
(d)
|
These borrowings represent the securities issued by VIEs and include projected interest payments based on interest rates, as applicable, as of
December 31, 2017
.
|
(e)
|
Includes benefits expected to be paid pursuant to our deferred compensation plan and postretirement plans based on numerous actuarial assumptions and interest credited at
3.75 percent
.
|
(f)
|
Includes amounts related to noncancellable operating leases, sponsorship agreements and commitments to purchase investments. Also included are obligations with third parties for information technology services, software maintenance and license agreements and consulting services.
|
•
|
An adverse decision in pending or future litigation.
|
•
|
An inability to obtain rate increases on certain of our insurance products.
|
•
|
Worse than anticipated claims experience.
|
•
|
Lower than expected dividends and/or surplus debenture interest payments from our insurance subsidiaries (resulting from inadequate earnings or capital or regulatory requirements).
|
•
|
An inability to meet and/or maintain the covenants in our Revolving Credit Agreement.
|
•
|
A significant increase in policy surrender levels.
|
•
|
A significant increase in investment defaults.
|
•
|
An inability of our reinsurers to meet their financial obligations.
|
•
|
The amount we may need to pay to a reinsurer in connection with a long-term care reinsurance transaction.
|
Amount
|
|
Maturity
|
|
Interest rate at
|
||
borrowed
|
|
date
|
|
December 31, 2017
|
||
$
|
50.0
|
|
|
January 2019
|
|
Variable rate – 1.779%
|
50.0
|
|
|
February 2019
|
|
Variable rate – 1.509%
|
|
100.0
|
|
|
March 2019
|
|
Variable rate – 1.971%
|
|
21.8
|
|
|
July 2019
|
|
Variable rate – 2.001%
|
|
15.0
|
|
|
October 2019
|
|
Variable rate – 1.887%
|
|
50.0
|
|
|
May 2020
|
|
Variable rate – 1.997%
|
|
21.8
|
|
|
June 2020
|
|
Fixed rate – 1.960%
|
|
25.0
|
|
|
September 2020
|
|
Variable rate – 2.300%
|
|
100.0
|
|
|
September 2020
|
|
Variable rate – 2.212%
|
|
50.0
|
|
|
September 2020
|
|
Variable rate – 2.224%
|
|
75.0
|
|
|
September 2020
|
|
Variable rate – 1.813%
|
|
100.0
|
|
|
October 2020
|
|
Variable rate – 1.453%
|
|
50.0
|
|
|
December 2020
|
|
Variable rate – 2.072%
|
|
100.0
|
|
|
July 2021
|
|
Variable rate – 1.909%
|
|
100.0
|
|
|
July 2021
|
|
Variable rate – 1.879%
|
|
57.7
|
|
|
August 2021
|
|
Variable rate – 1.921%
|
|
28.2
|
|
|
August 2021
|
|
Fixed rate – 2.550%
|
|
125.0
|
|
|
August 2021
|
|
Variable rate – 2.032%
|
|
50.0
|
|
|
September 2021
|
|
Variable rate – 2.002%
|
|
22.0
|
|
|
May 2022
|
|
Variable rate – 1.829%
|
|
100.0
|
|
|
May 2022
|
|
Variable rate – 1.780%
|
|
10.0
|
|
|
June 2022
|
|
Variable rate – 2.150%
|
|
50.0
|
|
|
July 2022
|
|
Variable rate – 1.726%
|
|
50.0
|
|
|
July 2022
|
|
Variable rate – 1.745%
|
|
50.0
|
|
|
July 2022
|
|
Variable rate – 1.758%
|
|
50.0
|
|
|
August 2022
|
|
Variable rate – 1.782%
|
|
50.0
|
|
|
December 2022
|
|
Variable rate – 1.795%
|
|
50.0
|
|
|
December 2022
|
|
Variable rate – 1.795%
|
|
24.7
|
|
|
March 2023
|
|
Fixed rate – 2.160%
|
|
20.5
|
|
|
June 2025
|
|
Fixed rate – 2.940%
|
|
$
|
1,646.7
|
|
|
|
|
|
|
Years ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Dividends from insurance subsidiaries, net of contributions
|
$
|
357.7
|
|
|
$
|
74.3
|
|
|
$
|
265.7
|
|
Surplus debenture interest
|
56.8
|
|
|
56.0
|
|
|
60.6
|
|
|||
Fees for services provided pursuant to service agreements
|
108.1
|
|
|
78.6
|
|
|
70.1
|
|
|||
Total dividends and other distributions paid by insurance subsidiaries
|
$
|
522.6
|
|
|
$
|
208.9
|
|
|
$
|
396.4
|
|
Subsidiary of CLTX
|
|
Earned surplus (deficit)
|
|
Additional information
|
||
Bankers Life
|
|
$
|
578.2
|
|
|
(a)
|
Colonial Penn
|
|
(304.5
|
)
|
|
(b)
|
(a)
|
Bankers Life paid dividends of $159.0 million to CLTX in
2017
.
|
(b)
|
The deficit is primarily due to transactions which occurred several years ago, including a tax planning transaction and the fee paid to recapture a block of business previously ceded to an unaffiliated insurer.
|
|
Principal
|
|
Interest (a)
|
||||
2018
|
$
|
—
|
|
|
$
|
44.5
|
|
2019
|
100.0
|
|
(b)
|
44.2
|
|
||
2020
|
325.0
|
|
|
33.6
|
|
||
2021
|
—
|
|
|
26.3
|
|
||
2022
|
—
|
|
|
26.3
|
|
||
2023 and thereafter
|
500.0
|
|
|
65.7
|
|
||
|
$
|
925.0
|
|
|
$
|
240.6
|
|
(a)
|
Based on interest rates as of
December 31, 2017
.
|
(b)
|
The maturity date of the Revolving Credit Agreement is the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the Company’s 4.50% senior notes due 2020, which is November 30, 2019.
|
Index to Consolidated Financial Statements
|
|
|
Page
|
|
2017
|
|
2016
|
||||
|
|
|
|
||||
Investments:
|
|
|
|
||||
Fixed maturities, available for sale, at fair value (amortized cost: 2017 - $20,702.1; 2016 - $19,803.1)
|
$
|
22,910.9
|
|
|
$
|
21,096.2
|
|
Equity securities at fair value (cost: 2017 - $491.1; 2016 - $580.7)
|
511.7
|
|
|
584.2
|
|
||
Mortgage loans
|
1,650.6
|
|
|
1,768.0
|
|
||
Policy loans
|
116.0
|
|
|
112.0
|
|
||
Trading securities
|
284.6
|
|
|
363.4
|
|
||
Investments held by variable interest entities
|
1,526.9
|
|
|
1,724.3
|
|
||
Other invested assets
|
853.4
|
|
|
589.5
|
|
||
Total investments
|
27,854.1
|
|
|
26,237.6
|
|
||
Cash and cash equivalents - unrestricted
|
578.4
|
|
|
478.9
|
|
||
Cash and cash equivalents held by variable interest entities
|
178.9
|
|
|
189.3
|
|
||
Accrued investment income
|
245.9
|
|
|
239.6
|
|
||
Present value of future profits
|
359.6
|
|
|
401.8
|
|
||
Deferred acquisition costs
|
1,026.8
|
|
|
1,044.7
|
|
||
Reinsurance receivables
|
2,175.2
|
|
|
2,260.4
|
|
||
Income tax assets, net
|
366.9
|
|
|
789.7
|
|
||
Assets held in separate accounts
|
5.0
|
|
|
4.7
|
|
||
Other assets
|
319.5
|
|
|
328.5
|
|
||
Total assets
|
$
|
33,110.3
|
|
|
$
|
31,975.2
|
|
|
2017
|
|
2016
|
||||
|
|
|
|
||||
Liabilities:
|
|
|
|
||||
Liabilities for insurance products:
|
|
|
|
||||
Policyholder account balances
|
$
|
11,220.7
|
|
|
$
|
10,912.7
|
|
Future policy benefits
|
11,521.3
|
|
|
10,953.3
|
|
||
Liability for policy and contract claims
|
530.3
|
|
|
500.6
|
|
||
Unearned and advanced premiums
|
261.7
|
|
|
282.5
|
|
||
Liabilities related to separate accounts
|
5.0
|
|
|
4.7
|
|
||
Other liabilities
|
751.8
|
|
|
611.4
|
|
||
Investment borrowings
|
1,646.7
|
|
|
1,647.4
|
|
||
Borrowings related to variable interest entities
|
1,410.7
|
|
|
1,662.8
|
|
||
Notes payable – direct corporate obligations
|
914.6
|
|
|
912.9
|
|
||
Total liabilities
|
28,262.8
|
|
|
27,488.3
|
|
||
Commitments and Contingencies
|
|
|
|
|
|
||
Shareholders' equity:
|
|
|
|
|
|
||
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2017 - 166,857,931; 2016 - 173,753,614)
|
1.7
|
|
|
1.7
|
|
||
Additional paid-in capital
|
3,073.3
|
|
|
3,212.1
|
|
||
Accumulated other comprehensive income
|
1,212.1
|
|
|
622.4
|
|
||
Retained earnings
|
560.4
|
|
|
650.7
|
|
||
Total shareholders' equity
|
4,847.5
|
|
|
4,486.9
|
|
||
Total liabilities and shareholders' equity
|
$
|
33,110.3
|
|
|
$
|
31,975.2
|
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Revenues:
|
|
|
|
|
|
|
||||||
Insurance policy income
|
|
$
|
2,647.3
|
|
|
$
|
2,601.1
|
|
|
$
|
2,556.0
|
|
Net investment income:
|
|
|
|
|
|
|
|
|
|
|||
General account assets
|
|
1,285.4
|
|
|
1,204.1
|
|
|
1,203.6
|
|
|||
Policyholder and other special-purpose portfolios
|
|
265.9
|
|
|
121.1
|
|
|
30.0
|
|
|||
Realized investment gains (losses):
|
|
|
|
|
|
|
|
|
|
|||
Net realized investment gains (losses), excluding impairment losses
|
|
77.4
|
|
|
47.9
|
|
|
(8.0
|
)
|
|||
Other-than-temporary impairments:
|
|
|
|
|
|
|
|
|
|
|||
Total other-than-temporary impairment losses
|
|
(21.9
|
)
|
|
(35.9
|
)
|
|
(42.9
|
)
|
|||
Portion of other-than-temporary impairment losses recognized in accumulated other comprehensive income
|
|
(.9
|
)
|
|
3.6
|
|
|
3.0
|
|
|||
Net impairment losses recognized
|
|
(22.8
|
)
|
|
(32.3
|
)
|
|
(39.9
|
)
|
|||
Gain (loss) on dissolution of variable interest entities
|
|
(4.3
|
)
|
|
(7.3
|
)
|
|
11.3
|
|
|||
Total realized gains (losses)
|
|
50.3
|
|
|
8.3
|
|
|
(36.6
|
)
|
|||
Fee revenue and other income
|
|
48.3
|
|
|
50.5
|
|
|
58.9
|
|
|||
Total revenues
|
|
4,297.2
|
|
|
3,985.1
|
|
|
3,811.9
|
|
|||
Benefits and expenses:
|
|
|
|
|
|
|
||||||
Insurance policy benefits
|
|
2,602.7
|
|
|
2,390.5
|
|
|
2,308.3
|
|
|||
Loss on reinsurance transaction and transition expenses
|
|
—
|
|
|
75.4
|
|
|
9.0
|
|
|||
Interest expense
|
|
123.7
|
|
|
116.4
|
|
|
94.9
|
|
|||
Amortization
|
|
239.3
|
|
|
253.3
|
|
|
260.0
|
|
|||
Loss on extinguishment of debt
|
|
—
|
|
|
—
|
|
|
32.8
|
|
|||
Loss on extinguishment of borrowings related to variable interest entities
|
|
9.5
|
|
|
—
|
|
|
—
|
|
|||
Other operating costs and expenses
|
|
841.5
|
|
|
796.3
|
|
|
739.2
|
|
|||
Total benefits and expenses
|
|
3,816.7
|
|
|
3,631.9
|
|
|
3,444.2
|
|
|||
Income before income taxes
|
|
480.5
|
|
|
353.2
|
|
|
367.7
|
|
|||
Income tax expense (benefit):
|
|
|
|
|
|
|
||||||
Tax expense on period income
|
|
162.8
|
|
|
127.8
|
|
|
129.5
|
|
|||
Valuation allowance for deferred tax assets and other tax items
|
|
142.1
|
|
|
(132.8
|
)
|
|
(32.5
|
)
|
|||
Net income
|
|
$
|
175.6
|
|
|
$
|
358.2
|
|
|
$
|
270.7
|
|
Earnings per common share:
|
|
|
|
|
|
|
||||||
Basic:
|
|
|
|
|
|
|
||||||
Weighted average shares outstanding
|
|
170,025,000
|
|
|
176,638,000
|
|
|
193,054,000
|
|
|||
Net income
|
|
$
|
1.03
|
|
|
$
|
2.03
|
|
|
$
|
1.40
|
|
Diluted:
|
|
|
|
|
|
|
||||||
Weighted average shares outstanding
|
|
172,144,000
|
|
|
178,323,000
|
|
|
195,166,000
|
|
|||
Net income
|
|
$
|
1.02
|
|
|
$
|
2.01
|
|
|
$
|
1.39
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net income
|
$
|
175.6
|
|
|
$
|
358.2
|
|
|
$
|
270.7
|
|
Other comprehensive income, before tax:
|
|
|
|
|
|
||||||
Unrealized gains (losses) for the period
|
959.3
|
|
|
424.4
|
|
|
(1,337.6
|
)
|
|||
Amortization of present value of future profits and deferred acquisition costs
|
(29.7
|
)
|
|
(27.9
|
)
|
|
157.9
|
|
|||
Amount related to premium deficiencies assuming the net unrealized gains (losses) had been realized
|
(310.5
|
)
|
|
(46.9
|
)
|
|
495.3
|
|
|||
Reclassification adjustments:
|
|
|
|
|
|
||||||
For net realized investment (gains) losses included in net income
|
(40.2
|
)
|
|
(18.6
|
)
|
|
29.6
|
|
|||
For amortization of the present value of future profits and deferred acquisition costs related to net realized investment gains (losses) included in net income
|
1.0
|
|
|
.7
|
|
|
(.5
|
)
|
|||
Unrealized gains (losses) on investments
|
579.9
|
|
|
331.7
|
|
|
(655.3
|
)
|
|||
Change related to deferred compensation plan
|
—
|
|
|
8.6
|
|
|
(.1
|
)
|
|||
Other comprehensive income (loss) before tax
|
579.9
|
|
|
340.3
|
|
|
(655.4
|
)
|
|||
Income tax (expense) benefit related to items of accumulated other comprehensive income
|
(195.6
|
)
|
|
(120.7
|
)
|
|
232.9
|
|
|||
Other comprehensive income (loss), net of tax
|
384.3
|
|
|
219.6
|
|
|
(422.5
|
)
|
|||
Comprehensive income (loss)
|
$
|
559.9
|
|
|
$
|
577.8
|
|
|
$
|
(151.8
|
)
|
|
Common stock and
additional
paid-in capital
|
|
Accumulated other
comprehensive income
|
|
Retained earnings
|
|
Total
|
||||||||
Balance, December 31, 2014
|
$
|
3,734.4
|
|
|
$
|
825.3
|
|
|
$
|
128.5
|
|
|
$
|
4,688.2
|
|
Net income
|
—
|
|
|
—
|
|
|
270.7
|
|
|
270.7
|
|
||||
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax benefit of $231.7)
|
—
|
|
|
(420.4
|
)
|
|
—
|
|
|
(420.4
|
)
|
||||
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax benefit of $1.2)
|
—
|
|
|
(2.1
|
)
|
|
—
|
|
|
(2.1
|
)
|
||||
Cost of common stock repurchased
|
(365.2
|
)
|
|
—
|
|
|
—
|
|
|
(365.2
|
)
|
||||
Dividends on common stock
|
—
|
|
|
—
|
|
|
(52.1
|
)
|
|
(52.1
|
)
|
||||
Stock options, restricted stock and performance units
|
19.4
|
|
|
—
|
|
|
—
|
|
|
19.4
|
|
||||
Balance, December 31, 2015
|
3,388.6
|
|
|
402.8
|
|
|
347.1
|
|
|
4,138.5
|
|
||||
Net income
|
—
|
|
|
—
|
|
|
358.2
|
|
|
358.2
|
|
||||
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense of $121.5)
|
—
|
|
|
221.1
|
|
|
—
|
|
|
221.1
|
|
||||
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax benefit of $.8)
|
—
|
|
|
(1.5
|
)
|
|
—
|
|
|
(1.5
|
)
|
||||
Cost of common stock repurchased
|
(203.0
|
)
|
|
—
|
|
|
—
|
|
|
(203.0
|
)
|
||||
Dividends on common stock
|
—
|
|
|
—
|
|
|
(54.6
|
)
|
|
(54.6
|
)
|
||||
Stock options, restricted stock and performance units
|
28.2
|
|
|
—
|
|
|
—
|
|
|
28.2
|
|
||||
Balance, December 31, 2016
|
3,213.8
|
|
|
622.4
|
|
|
650.7
|
|
|
4,486.9
|
|
||||
Cumulative effect of accounting change
|
.9
|
|
|
—
|
|
|
(.6
|
)
|
|
.3
|
|
||||
Net income
|
—
|
|
|
—
|
|
|
175.6
|
|
|
175.6
|
|
||||
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense of $194.4)
|
—
|
|
|
382.1
|
|
|
—
|
|
|
382.1
|
|
||||
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense of $1.2)
|
—
|
|
|
2.2
|
|
|
—
|
|
|
2.2
|
|
||||
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act
|
—
|
|
|
205.4
|
|
|
(205.4
|
)
|
|
—
|
|
||||
Cost of common stock repurchased
|
(167.1
|
)
|
|
—
|
|
|
—
|
|
|
(167.1
|
)
|
||||
Dividends on common stock
|
—
|
|
|
—
|
|
|
(59.9
|
)
|
|
(59.9
|
)
|
||||
Stock options, restricted stock and performance units
|
27.4
|
|
|
—
|
|
|
—
|
|
|
27.4
|
|
||||
Balance, December 31, 2017
|
$
|
3,075.0
|
|
|
$
|
1,212.1
|
|
|
$
|
560.4
|
|
|
$
|
4,847.5
|
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Cash flows from operating activities:
|
|
|
|
|
|
|
||||||
Insurance policy income
|
|
$
|
2,483.2
|
|
|
$
|
2,457.0
|
|
|
$
|
2,423.4
|
|
Net investment income
|
|
1,229.6
|
|
|
1,201.0
|
|
|
1,205.9
|
|
|||
Fee revenue and other income
|
|
48.3
|
|
|
50.5
|
|
|
58.9
|
|
|||
Cash and cash equivalents received upon recapture of reinsurance
|
|
—
|
|
|
73.6
|
|
|
—
|
|
|||
Insurance policy benefits
|
|
(1,973.1
|
)
|
|
(1,916.0
|
)
|
|
(1,879.4
|
)
|
|||
Interest expense
|
|
(120.5
|
)
|
|
(106.0
|
)
|
|
(90.0
|
)
|
|||
Deferrable policy acquisition costs
|
|
(236.1
|
)
|
|
(242.7
|
)
|
|
(246.4
|
)
|
|||
Other operating costs
|
|
(740.9
|
)
|
|
(747.9
|
)
|
|
(720.5
|
)
|
|||
Income taxes
|
|
(77.4
|
)
|
|
(6.7
|
)
|
|
(4.1
|
)
|
|||
Net cash from operating activities
|
|
613.1
|
|
|
762.8
|
|
|
747.8
|
|
|||
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
||||
Sales of investments
|
|
2,487.4
|
|
|
2,841.8
|
|
|
2,177.6
|
|
|||
Maturities and redemptions of investments
|
|
3,324.6
|
|
|
2,507.2
|
|
|
1,853.4
|
|
|||
Purchases of investments
|
|
(6,141.0
|
)
|
|
(6,159.8
|
)
|
|
(4,767.2
|
)
|
|||
Net sales (purchases) of trading securities
|
|
108.9
|
|
|
(84.2
|
)
|
|
(12.3
|
)
|
|||
Change in cash and cash equivalents held by variable interest entities
|
|
10.4
|
|
|
175.1
|
|
|
(296.1
|
)
|
|||
Other
|
|
(29.9
|
)
|
|
(22.5
|
)
|
|
(25.0
|
)
|
|||
Net cash provided (used) by investing activities
|
|
(239.6
|
)
|
|
(742.4
|
)
|
|
(1,069.6
|
)
|
|||
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
||||
Issuance of notes payable, net
|
|
—
|
|
|
—
|
|
|
910.0
|
|
|||
Payments on notes payable
|
|
—
|
|
|
—
|
|
|
(797.1
|
)
|
|||
Expenses related to extinguishment of debt
|
|
—
|
|
|
—
|
|
|
(17.8
|
)
|
|||
Issuance of common stock
|
|
8.3
|
|
|
8.4
|
|
|
6.3
|
|
|||
Payments to repurchase common stock
|
|
(168.3
|
)
|
|
(210.0
|
)
|
|
(365.4
|
)
|
|||
Common stock dividends paid
|
|
(59.6
|
)
|
|
(54.8
|
)
|
|
(52.0
|
)
|
|||
Amounts received for deposit products
|
|
1,445.9
|
|
|
1,386.7
|
|
|
1,241.9
|
|
|||
Withdrawals from deposit products
|
|
(1,232.6
|
)
|
|
(1,181.6
|
)
|
|
(1,225.0
|
)
|
|||
Issuance of investment borrowings:
|
|
|
|
|
|
|
||||||
Federal Home Loan Bank
|
|
432.0
|
|
|
432.7
|
|
|
475.0
|
|
|||
Related to variable interest entities
|
|
981.6
|
|
|
493.2
|
|
|
544.7
|
|
|||
Payments on investment borrowings:
|
|
|
|
|
|
|
||||||
Federal Home Loan Bank
|
|
(432.7
|
)
|
|
(333.5
|
)
|
|
(425.7
|
)
|
|||
Related to variable interest entities and other
|
|
(1,248.6
|
)
|
|
(514.9
|
)
|
|
(132.0
|
)
|
|||
Investment borrowings - repurchase agreements, net
|
|
—
|
|
|
—
|
|
|
(20.4
|
)
|
|||
Net cash provided (used) by financing activities
|
|
(274.0
|
)
|
|
26.2
|
|
|
142.5
|
|
|||
Net increase (decrease) in cash and cash equivalents
|
|
99.5
|
|
|
46.6
|
|
|
(179.3
|
)
|
|||
Cash and cash equivalents, beginning of year
|
|
478.9
|
|
|
432.3
|
|
|
611.6
|
|
|||
Cash and cash equivalents, end of year
|
|
$
|
578.4
|
|
|
$
|
478.9
|
|
|
$
|
432.3
|
|
•
|
Bankers Life,
which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices. The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company ("Bankers Life"). Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plan products in exchange for a fee.
|
•
|
Washington National,
which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite. These products are marketed through Performance Matters Associates, Inc. and through independent marketing organizations and insurance agencies including worksite marketing. The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.
|
•
|
Colonial Penn
, which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing. The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn").
|
•
|
Long-term care in run-off
consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC").
|
•
|
Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.
|
•
|
Benefit reductions - A policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.
|
•
|
Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.
|
•
|
We recognize distribution income based on either: (i) a fixed fee per contract sold; or (ii) a percentage of premiums collected. This fee income is recognized over the calendar year term of the contract.
|
•
|
We also pay commissions to our agents who sell the plans. These payments are deferred and amortized over the term of the contract.
|
Market value of investments
|
$
|
504.7
|
|
Insurance liabilities
|
(552.2
|
)
|
|
Write-off of reinsurance receivables
|
(17.9
|
)
|
|
Estimated transaction expenses
|
(10.0
|
)
|
|
Pre-tax loss
|
(75.4
|
)
|
|
Tax benefit
|
26.4
|
|
|
Increase in valuation allowance for deferred tax assets
|
(4.1
|
)
|
|
After-tax loss
|
$
|
(53.1
|
)
|
Amount
|
|
Maturity
|
|
Interest rate at
|
||
borrowed
|
|
date
|
|
December 31, 2017
|
||
$
|
50.0
|
|
|
January 2019
|
|
Variable rate – 1.779%
|
50.0
|
|
|
February 2019
|
|
Variable rate – 1.509%
|
|
100.0
|
|
|
March 2019
|
|
Variable rate – 1.971%
|
|
21.8
|
|
|
July 2019
|
|
Variable rate – 2.001%
|
|
15.0
|
|
|
October 2019
|
|
Variable rate – 1.887%
|
|
50.0
|
|
|
May 2020
|
|
Variable rate – 1.997%
|
|
21.8
|
|
|
June 2020
|
|
Fixed rate – 1.960%
|
|
25.0
|
|
|
September 2020
|
|
Variable rate – 2.300%
|
|
100.0
|
|
|
September 2020
|
|
Variable rate – 2.212%
|
|
50.0
|
|
|
September 2020
|
|
Variable rate – 2.224%
|
|
75.0
|
|
|
September 2020
|
|
Variable rate – 1.813%
|
|
100.0
|
|
|
October 2020
|
|
Variable rate – 1.453%
|
|
50.0
|
|
|
December 2020
|
|
Variable rate – 2.072%
|
|
100.0
|
|
|
July 2021
|
|
Variable rate – 1.909%
|
|
100.0
|
|
|
July 2021
|
|
Variable rate – 1.879%
|
|
57.7
|
|
|
August 2021
|
|
Variable rate – 1.921%
|
|
28.2
|
|
|
August 2021
|
|
Fixed rate – 2.550%
|
|
125.0
|
|
|
August 2021
|
|
Variable rate – 2.032%
|
|
50.0
|
|
|
September 2021
|
|
Variable rate – 2.002%
|
|
22.0
|
|
|
May 2022
|
|
Variable rate – 1.829%
|
|
100.0
|
|
|
May 2022
|
|
Variable rate – 1.780%
|
|
10.0
|
|
|
June 2022
|
|
Variable rate – 2.150%
|
|
50.0
|
|
|
July 2022
|
|
Variable rate – 1.726%
|
|
50.0
|
|
|
July 2022
|
|
Variable rate – 1.745%
|
|
50.0
|
|
|
July 2022
|
|
Variable rate – 1.758%
|
|
50.0
|
|
|
August 2022
|
|
Variable rate – 1.782%
|
|
50.0
|
|
|
December 2022
|
|
Variable rate – 1.795%
|
|
50.0
|
|
|
December 2022
|
|
Variable rate – 1.795%
|
|
24.7
|
|
|
March 2023
|
|
Fixed rate – 2.160%
|
|
20.5
|
|
|
June 2025
|
|
Fixed rate – 2.940%
|
|
$
|
1,646.7
|
|
|
|
|
|
(i)
|
Require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
|
(ii)
|
Simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value.
|
(iii)
|
Eliminate the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet.
|
(iv)
|
Require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes.
|
(v)
|
Require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments.
|
(vi)
|
Require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements.
|
(vii)
|
Clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets.
|
|
January 1, 2017
|
||||||||||||||
|
|
|
Effect of Adoption of Authoritative Guidance
|
|
|
||||||||||
|
Amounts prior to effect of adoption of authoritative guidance
|
|
Election to account for forfeitures as they occur
|
|
Recognition of excess tax benefits
|
|
As adjusted
|
||||||||
|
|
|
|
|
|
|
|
||||||||
Income tax assets
|
$
|
1,029.9
|
|
|
$
|
.3
|
|
|
$
|
15.7
|
|
|
$
|
1,045.9
|
|
Valuation allowance for deferred income tax assets
|
(240.2
|
)
|
|
—
|
|
|
(15.7
|
)
|
|
(255.9
|
)
|
||||
Income tax assets, net
|
789.7
|
|
|
.3
|
|
|
—
|
|
|
790.0
|
|
||||
Total assets
|
31,975.2
|
|
|
.3
|
|
|
—
|
|
|
31,975.5
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Additional paid-in capital
|
3,212.1
|
|
|
.9
|
|
|
—
|
|
|
3,213.0
|
|
||||
Retained earnings
|
650.7
|
|
|
(.6
|
)
|
|
—
|
|
|
650.1
|
|
||||
Total shareholders' equity
|
4,486.9
|
|
|
.3
|
|
|
—
|
|
|
4,487.2
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total liabilities and shareholders' equity
|
31,975.2
|
|
|
.3
|
|
|
—
|
|
|
31,975.5
|
|
|
December 31, 2016
|
||||||||||
|
Amounts prior to effect of adoption of authoritative guidance
|
|
Effect of adoption of authoritative guidance
|
|
As adjusted
|
||||||
Cash flows from operating activities:
|
|
|
|
|
|
||||||
Other operating costs
|
$
|
(751.2
|
)
|
|
$
|
3.3
|
|
|
$
|
(747.9
|
)
|
Net cash flow from operating activities
|
759.5
|
|
|
3.3
|
|
|
762.8
|
|
|||
|
|
|
|
|
|
||||||
Cash flows from financing activities:
|
|
|
|
|
|
||||||
Payments to repurchase common stock
|
(206.7
|
)
|
|
(3.3
|
)
|
|
(210.0
|
)
|
|||
Net cash provided by financing activities
|
29.5
|
|
|
(3.3
|
)
|
|
26.2
|
|
|||
|
|
|
|
|
|
||||||
Net increase in cash and cash equivalents
|
46.6
|
|
|
—
|
|
|
46.6
|
|
|
December 31, 2015
|
||||||||||
|
Amounts prior to effect of adoption of authoritative guidance
|
|
Effect of adoption of authoritative guidance
|
|
As adjusted
|
||||||
Cash flows from operating activities:
|
|
|
|
|
|
||||||
Other operating costs
|
$
|
(724.4
|
)
|
|
$
|
3.9
|
|
|
$
|
(720.5
|
)
|
Net cash flow from operating activities
|
743.9
|
|
|
3.9
|
|
|
747.8
|
|
|||
|
|
|
|
|
|
||||||
Cash flows from financing activities:
|
|
|
|
|
|
||||||
Payments to repurchase common stock
|
(361.5
|
)
|
|
(3.9
|
)
|
|
(365.4
|
)
|
|||
Net cash provided by financing activities
|
146.4
|
|
|
(3.9
|
)
|
|
142.5
|
|
|||
|
|
|
|
|
|
||||||
Net decrease in cash and cash equivalents
|
(179.3
|
)
|
|
—
|
|
|
(179.3
|
)
|
|
Amortized
cost
|
|
Gross
unrealized
gains
|
|
Gross
unrealized
losses
|
|
Estimated
fair
value
|
|
Other-than-temporary impairments included in accumulated other comprehensive income
|
||||||||||
Investment grade (a):
|
|
|
|
|
|
|
|
|
|
||||||||||
Corporate securities
|
$
|
12,419.3
|
|
|
$
|
1,670.7
|
|
|
$
|
(14.6
|
)
|
|
$
|
14,075.4
|
|
|
$
|
—
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
146.4
|
|
|
31.5
|
|
|
(.2
|
)
|
|
177.7
|
|
|
—
|
|
|||||
States and political subdivisions
|
1,819.9
|
|
|
234.8
|
|
|
(.4
|
)
|
|
2,054.3
|
|
|
—
|
|
|||||
Debt securities issued by foreign governments
|
79.5
|
|
|
3.8
|
|
|
(.2
|
)
|
|
83.1
|
|
|
—
|
|
|||||
Asset-backed securities
|
1,730.7
|
|
|
39.7
|
|
|
(3.2
|
)
|
|
1,767.2
|
|
|
—
|
|
|||||
Collateralized debt obligations
|
257.1
|
|
|
2.3
|
|
|
—
|
|
|
259.4
|
|
|
—
|
|
|||||
Commercial mortgage-backed securities
|
1,304.1
|
|
|
33.2
|
|
|
(9.1
|
)
|
|
1,328.2
|
|
|
—
|
|
|||||
Mortgage pass-through securities
|
1.8
|
|
|
.2
|
|
|
—
|
|
|
2.0
|
|
|
—
|
|
|||||
Collateralized mortgage obligations
|
293.9
|
|
|
16.4
|
|
|
(.2
|
)
|
|
310.1
|
|
|
(.2
|
)
|
|||||
Total investment grade fixed maturities, available for sale
|
18,052.7
|
|
|
2,032.6
|
|
|
(27.9
|
)
|
|
20,057.4
|
|
|
(.2
|
)
|
|||||
Below-investment grade (a) (b):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Corporate securities
|
867.0
|
|
|
28.4
|
|
|
(12.4
|
)
|
|
883.0
|
|
|
—
|
|
|||||
States and political subdivisions
|
2.0
|
|
|
—
|
|
|
—
|
|
|
2.0
|
|
|
—
|
|
|||||
Asset-backed securities
|
1,355.2
|
|
|
132.9
|
|
|
(.9
|
)
|
|
1,487.2
|
|
|
—
|
|
|||||
Commercial mortgage-backed securities
|
49.9
|
|
|
.6
|
|
|
(1.2
|
)
|
|
49.3
|
|
|
—
|
|
|||||
Collateralized mortgage obligations
|
375.3
|
|
|
56.8
|
|
|
(.1
|
)
|
|
432.0
|
|
|
(.8
|
)
|
|||||
Total below-investment grade fixed maturities, available for sale
|
2,649.4
|
|
|
218.7
|
|
|
(14.6
|
)
|
|
2,853.5
|
|
|
(.8
|
)
|
|||||
Total fixed maturities, available for sale
|
$
|
20,702.1
|
|
|
$
|
2,251.3
|
|
|
$
|
(42.5
|
)
|
|
$
|
22,910.9
|
|
|
$
|
(1.0
|
)
|
Equity securities
|
$
|
491.1
|
|
|
$
|
23.6
|
|
|
$
|
(3.0
|
)
|
|
$
|
511.7
|
|
|
|
(a)
|
Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody's Investor Services, Inc. ("Moody's"), S&P Global Ratings ("S&P") or Fitch Ratings ("Fitch")), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC"). NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by S&P and Fitch). NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch). References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above.
|
(b)
|
Certain structured securities rated below-investment grade by NRSROs may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the NAIC. Refer to the table below for a summary of our fixed maturity securities, available for sale, by NAIC designations.
|
NAIC Designation
|
|
NRSRO Equivalent Rating
|
1
|
|
AAA/AA/A
|
2
|
|
BBB
|
3
|
|
BB
|
4
|
|
B
|
5
|
|
CCC and lower
|
6
|
|
In or near default
|
NAIC designation
|
|
Amortized cost
|
|
Estimated fair value
|
|
Percentage of total estimated fair value
|
|||||
1
|
|
$
|
9,923.7
|
|
|
$
|
11,028.5
|
|
|
48.1
|
%
|
2
|
|
9,821.6
|
|
|
10,906.2
|
|
|
47.6
|
|
||
Total NAIC 1 and 2 (investment grade)
|
|
19,745.3
|
|
|
21,934.7
|
|
|
95.7
|
|
||
3
|
|
676.2
|
|
|
693.8
|
|
|
3.0
|
|
||
4
|
|
225.0
|
|
|
225.9
|
|
|
1.0
|
|
||
5
|
|
46.3
|
|
|
45.9
|
|
|
.2
|
|
||
6
|
|
9.3
|
|
|
10.6
|
|
|
.1
|
|
||
Total NAIC 3,4,5 and 6 (below-investment grade)
|
|
956.8
|
|
|
976.2
|
|
|
4.3
|
|
||
|
|
$
|
20,702.1
|
|
|
$
|
22,910.9
|
|
|
100.0
|
%
|
|
Amortized
cost
|
|
Gross
unrealized
gains
|
|
Gross
unrealized
losses
|
|
Estimated
fair
value
|
|
Other-than-temporary impairments included in accumulated other comprehensive income
|
||||||||||
Investment grade:
|
|
|
|
|
|
|
|
|
|
||||||||||
Corporate securities
|
$
|
11,582.6
|
|
|
$
|
1,073.9
|
|
|
$
|
(99.8
|
)
|
|
$
|
12,556.7
|
|
|
$
|
—
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
143.8
|
|
|
20.5
|
|
|
—
|
|
|
164.3
|
|
|
—
|
|
|||||
States and political subdivisions
|
1,798.2
|
|
|
186.7
|
|
|
(7.9
|
)
|
|
1,977.0
|
|
|
—
|
|
|||||
Debt securities issued by foreign governments
|
37.1
|
|
|
.2
|
|
|
(.4
|
)
|
|
36.9
|
|
|
—
|
|
|||||
Asset-backed securities
|
1,169.6
|
|
|
29.2
|
|
|
(8.7
|
)
|
|
1,190.1
|
|
|
—
|
|
|||||
Collateralized debt obligations
|
227.5
|
|
|
1.0
|
|
|
(.3
|
)
|
|
228.2
|
|
|
—
|
|
|||||
Commercial mortgage-backed securities
|
1,467.2
|
|
|
32.9
|
|
|
(26.6
|
)
|
|
1,473.5
|
|
|
—
|
|
|||||
Mortgage pass-through securities
|
2.3
|
|
|
.2
|
|
|
—
|
|
|
2.5
|
|
|
—
|
|
|||||
Collateralized mortgage obligations
|
304.8
|
|
|
14.6
|
|
|
(.2
|
)
|
|
319.2
|
|
|
—
|
|
|||||
Total investment grade fixed maturities, available for sale
|
16,733.1
|
|
|
1,359.2
|
|
|
(143.9
|
)
|
|
17,948.4
|
|
|
—
|
|
|||||
Below-investment grade:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Corporate securities
|
967.3
|
|
|
26.1
|
|
|
(39.2
|
)
|
|
954.2
|
|
|
(3.6
|
)
|
|||||
States and political subdivisions
|
13.6
|
|
|
—
|
|
|
(1.7
|
)
|
|
11.9
|
|
|
(3.0
|
)
|
|||||
Asset-backed securities
|
1,471.9
|
|
|
55.1
|
|
|
(6.8
|
)
|
|
1,520.2
|
|
|
—
|
|
|||||
Collateralized debt obligations
|
2.5
|
|
|
—
|
|
|
—
|
|
|
2.5
|
|
|
—
|
|
|||||
Commercial mortgage-backed securities
|
63.8
|
|
|
.2
|
|
|
(1.3
|
)
|
|
62.7
|
|
|
—
|
|
|||||
Collateralized mortgage obligations
|
550.9
|
|
|
46.8
|
|
|
(1.4
|
)
|
|
596.3
|
|
|
(1.4
|
)
|
|||||
Total below-investment grade fixed maturities, available for sale
|
3,070.0
|
|
|
128.2
|
|
|
(50.4
|
)
|
|
3,147.8
|
|
|
(8.0
|
)
|
|||||
Total fixed maturities, available for sale
|
$
|
19,803.1
|
|
|
$
|
1,487.4
|
|
|
$
|
(194.3
|
)
|
|
$
|
21,096.2
|
|
|
$
|
(8.0
|
)
|
Equity securities
|
$
|
580.7
|
|
|
$
|
11.5
|
|
|
$
|
(8.0
|
)
|
|
$
|
584.2
|
|
|
|
|
2017
|
|
2016
|
||||
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized
|
$
|
2.6
|
|
|
$
|
(1.1
|
)
|
Net unrealized gains on all other investments
|
2,227.3
|
|
|
1,311.9
|
|
||
Adjustment to present value of future profits (a)
|
(94.0
|
)
|
|
(106.2
|
)
|
||
Adjustment to deferred acquisition costs
|
(292.6
|
)
|
|
(223.5
|
)
|
||
Adjustment to insurance liabilities
|
(295.8
|
)
|
|
(13.5
|
)
|
||
Deferred income tax liabilities
|
(335.4
|
)
|
|
(345.2
|
)
|
||
Accumulated other comprehensive income
|
$
|
1,212.1
|
|
|
$
|
622.4
|
|
(a)
|
The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003, the date our Predecessor emerged from bankruptcy.
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
328.1
|
|
|
$
|
335.1
|
|
Due after one year through five years
|
1,947.3
|
|
|
2,052.3
|
|
||
Due after five years through ten years
|
1,508.7
|
|
|
1,601.3
|
|
||
Due after ten years
|
11,550.0
|
|
|
13,286.8
|
|
||
Subtotal
|
15,334.1
|
|
|
17,275.5
|
|
||
Structured securities
|
5,368.0
|
|
|
5,635.4
|
|
||
Total fixed maturities, available for sale
|
$
|
20,702.1
|
|
|
$
|
22,910.9
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
General account assets:
|
|
|
|
|
|
||||||
Fixed maturities
|
$
|
1,133.8
|
|
|
$
|
1,081.4
|
|
|
$
|
1,090.1
|
|
Equity securities
|
25.3
|
|
|
21.5
|
|
|
18.3
|
|
|||
Mortgage loans
|
91.5
|
|
|
91.0
|
|
|
91.4
|
|
|||
Policy loans
|
7.7
|
|
|
7.3
|
|
|
7.3
|
|
|||
Other invested assets
|
44.4
|
|
|
24.3
|
|
|
17.4
|
|
|||
Cash and cash equivalents
|
5.9
|
|
|
2.0
|
|
|
.8
|
|
|||
Policyholder and other special-purpose portfolios:
|
|
|
|
|
|
||||||
Trading securities (a)
|
12.8
|
|
|
12.2
|
|
|
10.7
|
|
|||
Options related to fixed index products:
|
|
|
|
|
|
||||||
Option income (loss)
|
110.3
|
|
|
(40.1
|
)
|
|
36.5
|
|
|||
Change in value of options
|
52.2
|
|
|
69.3
|
|
|
(72.7
|
)
|
|||
Other special-purpose portfolios
|
90.6
|
|
|
79.7
|
|
|
55.5
|
|
|||
Gross investment income
|
1,574.5
|
|
|
1,348.6
|
|
|
1,255.3
|
|
|||
Less investment expenses
|
23.2
|
|
|
23.4
|
|
|
21.7
|
|
|||
Net investment income
|
$
|
1,551.3
|
|
|
$
|
1,325.2
|
|
|
$
|
1,233.6
|
|
(a)
|
Changes in the estimated fair value for trading securities still held as of the end of the respective years and included in net investment income were
$3.8 million
,
$(.2) million
and
$.4 million
for the years ended
December 31, 2017
,
2016
and
2015
, respectively.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Fixed maturity securities, available for sale:
|
|
|
|
|
|
||||||
Gross realized gains on sale
|
$
|
68.0
|
|
|
$
|
137.7
|
|
|
$
|
95.7
|
|
Gross realized losses on sale
|
(24.2
|
)
|
|
(95.2
|
)
|
|
(88.4
|
)
|
|||
Impairments:
|
|
|
|
|
|
||||||
Total other-than-temporary impairment losses
|
(12.5
|
)
|
|
(15.2
|
)
|
|
(17.9
|
)
|
|||
Other-than-temporary impairment losses recognized in accumulated other comprehensive income
|
(.9
|
)
|
|
3.6
|
|
|
3.0
|
|
|||
Net impairment losses recognized
|
(13.4
|
)
|
|
(11.6
|
)
|
|
(14.9
|
)
|
|||
Net realized investment gains (losses) from fixed maturities
|
30.4
|
|
|
30.9
|
|
|
(7.6
|
)
|
|||
Equity securities
|
11.6
|
|
|
20.9
|
|
|
3.7
|
|
|||
Mortgage loans
|
1.1
|
|
|
—
|
|
|
(2.3
|
)
|
|||
Impairments on preferred stock and other investments
|
(9.4
|
)
|
|
(20.7
|
)
|
|
(25.0
|
)
|
|||
Gain (loss) on dissolution of variable interest entities
|
(4.3
|
)
|
|
(7.3
|
)
|
|
11.3
|
|
|||
Other (a)
|
20.9
|
|
|
(15.5
|
)
|
|
(16.7
|
)
|
|||
Net realized investment gains (losses)
|
$
|
50.3
|
|
|
$
|
8.3
|
|
|
$
|
(36.6
|
)
|
(a)
|
Changes in the estimated fair value of trading securities that we have elected the fair value option (and are still held as of the end of the respective years) were
$12.8 million
,
$(.5) million
and
$(9.2) million
for the years ended
December 31, 2017
,
2016
and
2015
, respectively.
|
|
|
|
At date of sale
|
||||||
|
Number
of issuers |
|
Amortized cost
|
|
Fair value
|
||||
Less than 6 months prior to sale
|
4
|
|
$
|
17.8
|
|
|
$
|
13.0
|
|
Greater than or equal to 6 months and less than 12 months prior to sale
|
1
|
|
2.7
|
|
|
1.9
|
|
||
Greater than 12 months prior to sale
|
1
|
|
.7
|
|
|
.5
|
|
||
|
6
|
|
$
|
21.2
|
|
|
$
|
15.4
|
|
|
Year ended
|
||||||||||
|
December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Credit losses on fixed maturity securities, available for sale, beginning of period
|
$
|
(5.5
|
)
|
|
$
|
(2.6
|
)
|
|
$
|
(1.0
|
)
|
Add: credit losses on other-than-temporary impairments not previously recognized
|
—
|
|
|
(3.0
|
)
|
|
(2.0
|
)
|
|||
Less: credit losses on securities sold
|
4.7
|
|
|
.1
|
|
|
.4
|
|
|||
Less: credit losses on securities impaired due to intent to sell (a)
|
—
|
|
|
—
|
|
|
—
|
|
|||
Add: credit losses on previously impaired securities
|
(2.0
|
)
|
|
—
|
|
|
—
|
|
|||
Less: increases in cash flows expected on previously impaired securities
|
—
|
|
|
—
|
|
|
—
|
|
|||
Credit losses on fixed maturity securities, available for sale, end of period
|
$
|
(2.8
|
)
|
|
$
|
(5.5
|
)
|
|
$
|
(2.6
|
)
|
(a)
|
Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
26.9
|
|
|
$
|
26.9
|
|
Due after one year through five years
|
195.4
|
|
|
193.3
|
|
||
Due after five years through ten years
|
108.9
|
|
|
105.2
|
|
||
Due after ten years
|
602.0
|
|
|
580.0
|
|
||
Subtotal
|
933.2
|
|
|
905.4
|
|
||
Structured securities
|
1,268.3
|
|
|
1,253.6
|
|
||
Total
|
$
|
2,201.5
|
|
|
$
|
2,159.0
|
|
|
Number
of issuers |
|
Cost
basis |
|
Unrealized
loss |
|
Estimated
fair value |
||||||
Less than 6 months
|
1
|
|
$
|
9.2
|
|
|
$
|
(1.9
|
)
|
|
$
|
7.3
|
|
|
|
|
$
|
9.2
|
|
|
$
|
(1.9
|
)
|
|
$
|
7.3
|
|
|
|
Less than 12 months
|
|
12 months or greater
|
|
Total
|
||||||||||||||||||
Description of securities
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
||||||||||||
United States Treasury securities and obligations of United States government corporations and agencies
|
|
$
|
28.2
|
|
|
$
|
(.2
|
)
|
|
$
|
.7
|
|
|
$
|
—
|
|
|
$
|
28.9
|
|
|
$
|
(.2
|
)
|
States and political subdivisions
|
|
18.3
|
|
|
(.1
|
)
|
|
14.9
|
|
|
(.3
|
)
|
|
33.2
|
|
|
(.4
|
)
|
||||||
Debt securities issued by foreign governments
|
|
7.7
|
|
|
(.1
|
)
|
|
5.4
|
|
|
(.1
|
)
|
|
13.1
|
|
|
(.2
|
)
|
||||||
Corporate securities
|
|
470.5
|
|
|
(6.8
|
)
|
|
359.7
|
|
|
(20.2
|
)
|
|
830.2
|
|
|
(27.0
|
)
|
||||||
Asset-backed securities
|
|
601.4
|
|
|
(2.0
|
)
|
|
122.2
|
|
|
(2.1
|
)
|
|
723.6
|
|
|
(4.1
|
)
|
||||||
Collateralized debt obligations
|
|
3.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.0
|
|
|
—
|
|
||||||
Commercial mortgage-backed securities
|
|
276.8
|
|
|
(1.7
|
)
|
|
218.2
|
|
|
(8.6
|
)
|
|
495.0
|
|
|
(10.3
|
)
|
||||||
Collateralized mortgage obligations
|
|
20.5
|
|
|
(.2
|
)
|
|
11.5
|
|
|
(.1
|
)
|
|
32.0
|
|
|
(.3
|
)
|
||||||
Total fixed maturities, available for sale
|
|
$
|
1,426.4
|
|
|
$
|
(11.1
|
)
|
|
$
|
732.6
|
|
|
$
|
(31.4
|
)
|
|
$
|
2,159.0
|
|
|
$
|
(42.5
|
)
|
Equity securities
|
|
$
|
58.7
|
|
|
$
|
(1.7
|
)
|
|
$
|
21.2
|
|
|
$
|
(1.3
|
)
|
|
$
|
79.9
|
|
|
$
|
(3.0
|
)
|
|
|
Less than 12 months
|
|
12 months or greater
|
|
Total
|
||||||||||||||||||
Description of securities
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
||||||||||||
United States Treasury securities and obligations of United States government corporations and agencies
|
|
$
|
8.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
8.0
|
|
|
$
|
—
|
|
States and political subdivisions
|
|
176.3
|
|
|
(7.8
|
)
|
|
18.3
|
|
|
(1.8
|
)
|
|
194.6
|
|
|
(9.6
|
)
|
||||||
Debt securities issued by foreign governments
|
|
18.9
|
|
|
(.4
|
)
|
|
—
|
|
|
—
|
|
|
18.9
|
|
|
(.4
|
)
|
||||||
Corporate securities
|
|
1,907.6
|
|
|
(75.5
|
)
|
|
559.6
|
|
|
(63.5
|
)
|
|
2,467.2
|
|
|
(139.0
|
)
|
||||||
Asset-backed securities
|
|
692.9
|
|
|
(8.5
|
)
|
|
262.5
|
|
|
(7.0
|
)
|
|
955.4
|
|
|
(15.5
|
)
|
||||||
Collateralized debt obligations
|
|
38.3
|
|
|
(.1
|
)
|
|
30.8
|
|
|
(.2
|
)
|
|
69.1
|
|
|
(.3
|
)
|
||||||
Commercial mortgage-backed securities
|
|
525.2
|
|
|
(16.6
|
)
|
|
154.0
|
|
|
(11.3
|
)
|
|
679.2
|
|
|
(27.9
|
)
|
||||||
Collateralized mortgage obligations
|
|
73.6
|
|
|
(.6
|
)
|
|
34.6
|
|
|
(1.0
|
)
|
|
108.2
|
|
|
(1.6
|
)
|
||||||
Total fixed maturities, available for sale
|
|
$
|
3,440.8
|
|
|
$
|
(109.5
|
)
|
|
$
|
1,059.8
|
|
|
$
|
(84.8
|
)
|
|
$
|
4,500.6
|
|
|
$
|
(194.3
|
)
|
Equity securities
|
|
$
|
239.4
|
|
|
$
|
(8.0
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
239.4
|
|
|
$
|
(8.0
|
)
|
|
Par
value
|
|
Amortized
cost
|
|
Estimated
fair value
|
||||||
Below 4 percent
|
$
|
2,101.7
|
|
|
$
|
1,944.8
|
|
|
$
|
2,014.9
|
|
4 percent – 5 percent
|
1,656.3
|
|
|
1,516.0
|
|
|
1,596.5
|
|
|||
5 percent – 6 percent
|
1,407.1
|
|
|
1,271.8
|
|
|
1,362.6
|
|
|||
6 percent – 7 percent
|
286.6
|
|
|
260.6
|
|
|
276.8
|
|
|||
7 percent – 8 percent
|
83.0
|
|
|
83.7
|
|
|
92.5
|
|
|||
8 percent and above
|
291.3
|
|
|
291.1
|
|
|
292.1
|
|
|||
Total structured securities
|
$
|
5,826.0
|
|
|
$
|
5,368.0
|
|
|
$
|
5,635.4
|
|
|
|
|
Estimated fair value
|
|||||||
Type
|
Amortized
cost
|
|
Amount
|
|
Percent
of fixed
maturities
|
|||||
Pass-throughs, sequential and equivalent securities
|
$
|
557.7
|
|
|
$
|
617.2
|
|
|
2.7
|
%
|
Planned amortization classes, target amortization classes and accretion-directed bonds
|
95.3
|
|
|
108.5
|
|
|
.5
|
|
||
Commercial mortgage-backed securities
|
1,354.0
|
|
|
1,377.5
|
|
|
6.0
|
|
||
Asset-backed securities
|
3,085.9
|
|
|
3,254.4
|
|
|
14.2
|
|
||
Collateralized debt obligations
|
257.1
|
|
|
259.4
|
|
|
1.1
|
|
||
Other
|
18.0
|
|
|
18.4
|
|
|
.1
|
|
||
Total structured securities
|
$
|
5,368.0
|
|
|
$
|
5,635.4
|
|
|
24.6
|
%
|
|
|
|
Estimated fair
value
|
||||||||
Loan-to-value ratio (a)
|
Carrying value
|
|
Mortgage loans
|
|
Collateral
|
||||||
Less than 60%
|
$
|
944.7
|
|
|
$
|
960.8
|
|
|
$
|
2,330.6
|
|
60% to 70%
|
439.5
|
|
|
440.2
|
|
|
671.3
|
|
|||
Greater than 70% to 80%
|
138.4
|
|
|
145.9
|
|
|
188.4
|
|
|||
Greater than 80% to 90%
|
52.3
|
|
|
52.9
|
|
|
60.1
|
|
|||
Greater than 90%
|
38.6
|
|
|
40.2
|
|
|
41.7
|
|
|||
Total
|
$
|
1,613.5
|
|
|
$
|
1,640.0
|
|
|
$
|
3,292.1
|
|
(a)
|
Loan-to-value ratios are calculated as the ratio of: (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral.
|
•
|
Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.
|
•
|
Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include: certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.
|
•
|
Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.
|
•
|
Investments held by VIEs
|
•
|
Other invested assets - derivatives
|
|
Quoted prices in active markets
for identical assets or liabilities (Level 1) |
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
$
|
—
|
|
|
$
|
14,728.0
|
|
|
$
|
230.4
|
|
|
$
|
14,958.4
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
177.7
|
|
|
—
|
|
|
177.7
|
|
||||
States and political subdivisions
|
—
|
|
|
2,056.3
|
|
|
—
|
|
|
2,056.3
|
|
||||
Debt securities issued by foreign governments
|
—
|
|
|
79.2
|
|
|
3.9
|
|
|
83.1
|
|
||||
Asset-backed securities
|
—
|
|
|
3,230.2
|
|
|
24.2
|
|
|
3,254.4
|
|
||||
Collateralized debt obligations
|
—
|
|
|
259.4
|
|
|
—
|
|
|
259.4
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
1,377.5
|
|
|
—
|
|
|
1,377.5
|
|
||||
Mortgage pass-through securities
|
—
|
|
|
2.0
|
|
|
—
|
|
|
2.0
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
742.1
|
|
|
—
|
|
|
742.1
|
|
||||
Total fixed maturities, available for sale
|
—
|
|
|
22,652.4
|
|
|
258.5
|
|
|
22,910.9
|
|
||||
Equity securities - corporate securities
|
287.8
|
|
|
202.7
|
|
|
21.2
|
|
|
511.7
|
|
||||
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate securities
|
—
|
|
|
21.6
|
|
|
—
|
|
|
21.6
|
|
||||
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
.5
|
|
|
—
|
|
|
.5
|
|
||||
Asset-backed securities
|
—
|
|
|
95.8
|
|
|
—
|
|
|
95.8
|
|
||||
Collateralized debt obligations
|
—
|
|
|
2.7
|
|
|
—
|
|
|
2.7
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
92.5
|
|
|
—
|
|
|
92.5
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
68.7
|
|
|
—
|
|
|
68.7
|
|
||||
Equity securities
|
2.8
|
|
|
—
|
|
|
—
|
|
|
2.8
|
|
||||
Total trading securities
|
2.8
|
|
|
281.8
|
|
|
—
|
|
|
284.6
|
|
||||
Investments held by variable interest entities - corporate securities
|
—
|
|
|
1,522.0
|
|
|
4.9
|
|
|
1,526.9
|
|
||||
Other invested assets - derivatives
|
—
|
|
|
170.2
|
|
|
—
|
|
|
170.2
|
|
||||
Assets held in separate accounts
|
—
|
|
|
5.0
|
|
|
—
|
|
|
5.0
|
|
||||
Total assets carried at fair value by category
|
$
|
290.6
|
|
|
$
|
24,834.1
|
|
|
$
|
284.6
|
|
|
$
|
25,409.3
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,334.8
|
|
|
$
|
1,334.8
|
|
|
Quoted prices in active markets
for identical assets or liabilities
(Level 1)
|
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
$
|
—
|
|
|
$
|
13,252.4
|
|
|
$
|
258.5
|
|
|
$
|
13,510.9
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
164.3
|
|
|
—
|
|
|
164.3
|
|
||||
States and political subdivisions
|
—
|
|
|
1,988.9
|
|
|
—
|
|
|
1,988.9
|
|
||||
Debt securities issued by foreign governments
|
—
|
|
|
33.0
|
|
|
3.9
|
|
|
36.9
|
|
||||
Asset-backed securities
|
—
|
|
|
2,649.9
|
|
|
60.4
|
|
|
2,710.3
|
|
||||
Collateralized debt obligations
|
—
|
|
|
225.3
|
|
|
5.4
|
|
|
230.7
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
1,504.2
|
|
|
32.0
|
|
|
1,536.2
|
|
||||
Mortgage pass-through securities
|
—
|
|
|
2.5
|
|
|
—
|
|
|
2.5
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
915.5
|
|
|
—
|
|
|
915.5
|
|
||||
Total fixed maturities, available for sale
|
—
|
|
|
20,736.0
|
|
|
360.2
|
|
|
21,096.2
|
|
||||
Equity securities - corporate securities
|
359.9
|
|
|
199.1
|
|
|
25.2
|
|
|
584.2
|
|
||||
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate securities
|
—
|
|
|
19.0
|
|
|
—
|
|
|
19.0
|
|
||||
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
.5
|
|
|
—
|
|
|
.5
|
|
||||
Asset-backed securities
|
—
|
|
|
94.3
|
|
|
—
|
|
|
94.3
|
|
||||
Collateralized debt obligations
|
—
|
|
|
2.4
|
|
|
—
|
|
|
2.4
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
163.9
|
|
|
—
|
|
|
163.9
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
78.4
|
|
|
—
|
|
|
78.4
|
|
||||
Equity securities
|
4.9
|
|
|
—
|
|
|
—
|
|
|
4.9
|
|
||||
Total trading securities
|
4.9
|
|
|
358.5
|
|
|
—
|
|
|
363.4
|
|
||||
Investments held by variable interest entities - corporate securities
|
—
|
|
|
1,724.3
|
|
|
—
|
|
|
1,724.3
|
|
||||
Other invested assets - derivatives
|
—
|
|
|
111.9
|
|
|
—
|
|
|
111.9
|
|
||||
Assets held in separate accounts
|
—
|
|
|
4.7
|
|
|
—
|
|
|
4.7
|
|
||||
Total assets carried at fair value by category
|
$
|
364.8
|
|
|
$
|
23,134.5
|
|
|
$
|
385.4
|
|
|
$
|
23,884.7
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,092.3
|
|
|
$
|
1,092.3
|
|
|
December 31, 2016
|
||||||||||||||||||
|
Quoted prices in active markets for identical assets or liabilities
(Level 1)
|
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total estimated fair value
|
|
Total carrying amount
|
||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Mortgage loans
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,800.1
|
|
|
$
|
1,800.1
|
|
|
$
|
1,768.0
|
|
Policy loans
|
—
|
|
|
—
|
|
|
112.0
|
|
|
112.0
|
|
|
112.0
|
|
|||||
Other invested assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Company-owned life insurance
|
—
|
|
|
165.0
|
|
|
—
|
|
|
165.0
|
|
|
165.0
|
|
|||||
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
||||||||||
Unrestricted
|
473.6
|
|
|
5.3
|
|
|
—
|
|
|
478.9
|
|
|
478.9
|
|
|||||
Held by variable interest entities
|
189.3
|
|
|
—
|
|
|
—
|
|
|
189.3
|
|
|
189.3
|
|
|||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Policyholder account balances
|
—
|
|
|
—
|
|
|
10,912.7
|
|
|
10,912.7
|
|
|
10,912.7
|
|
|||||
Investment borrowings
|
—
|
|
|
1,650.0
|
|
|
—
|
|
|
1,650.0
|
|
|
1,647.4
|
|
|||||
Borrowings related to variable interest entities
|
—
|
|
|
1,675.2
|
|
|
—
|
|
|
1,675.2
|
|
|
1,662.8
|
|
|||||
Notes payable – direct corporate obligations
|
—
|
|
|
931.9
|
|
|
—
|
|
|
931.9
|
|
|
912.9
|
|
|
|
December 31, 2017
|
|
|
||||||||||||||||||||||||||||
|
|
Beginning balance as of December 31, 2016
|
|
Purchases, sales, issuances and settlements, net (b)
|
|
Total realized and unrealized gains (losses) included in net income
|
|
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)
|
|
Transfers into Level 3 (a)
|
|
Transfers out of Level 3 (a)
|
|
Ending balance as of December 31, 2017
|
|
Amount of total gains (losses) for the year ended December 31, 2017 included in our net income relating to assets and liabilities still held as of the reporting date
|
||||||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate securities
|
|
$
|
258.5
|
|
|
$
|
(70.4
|
)
|
|
$
|
5.8
|
|
|
$
|
5.3
|
|
|
$
|
31.2
|
|
|
$
|
—
|
|
|
$
|
230.4
|
|
|
$
|
(8.0
|
)
|
Debt securities issued by foreign governments
|
|
3.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.9
|
|
|
—
|
|
||||||||
Asset-backed securities
|
|
60.4
|
|
|
(4.3
|
)
|
|
—
|
|
|
.7
|
|
|
—
|
|
|
(32.6
|
)
|
|
24.2
|
|
|
—
|
|
||||||||
Collateralized debt obligations
|
|
5.4
|
|
|
(2.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2.9
|
)
|
|
—
|
|
|
—
|
|
||||||||
Commercial mortgage-backed securities
|
|
32.0
|
|
|
(1.2
|
)
|
|
.1
|
|
|
(.1
|
)
|
|
—
|
|
|
(30.8
|
)
|
|
—
|
|
|
—
|
|
||||||||
Total fixed maturities, available for sale
|
|
360.2
|
|
|
(78.4
|
)
|
|
5.9
|
|
|
5.9
|
|
|
31.2
|
|
|
(66.3
|
)
|
|
258.5
|
|
|
(8.0
|
)
|
||||||||
Equity securities - corporate securities
|
|
25.2
|
|
|
(8.5
|
)
|
|
6.3
|
|
|
(1.8
|
)
|
|
—
|
|
|
—
|
|
|
21.2
|
|
|
—
|
|
||||||||
Investments held by variable interest entities - corporate securities
|
|
—
|
|
|
4.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.9
|
|
|
—
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
|
(1,092.3
|
)
|
|
(267.5
|
)
|
|
25.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,334.8
|
)
|
|
25.0
|
|
(a)
|
Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.
|
(b)
|
Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the year ended
December 31, 2017
(dollars in millions):
|
|
Purchases
|
|
Sales
|
|
Issuances
|
|
Settlements
|
|
Purchases, sales, issuances and settlements, net
|
||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
||||||||||
Corporate securities
|
$
|
76.6
|
|
|
$
|
(147.0
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(70.4
|
)
|
Asset-backed securities
|
—
|
|
|
(4.3
|
)
|
|
—
|
|
|
—
|
|
|
(4.3
|
)
|
|||||
Collateralized debt obligations
|
—
|
|
|
(2.5
|
)
|
|
—
|
|
|
—
|
|
|
(2.5
|
)
|
|||||
Commercial mortgage-backed securities
|
—
|
|
|
(1.2
|
)
|
|
—
|
|
|
—
|
|
|
(1.2
|
)
|
|||||
Total fixed maturities, available for sale
|
76.6
|
|
|
(155.0
|
)
|
|
—
|
|
|
—
|
|
|
(78.4
|
)
|
|||||
Equity securities - corporate securities
|
—
|
|
|
(8.5
|
)
|
|
—
|
|
|
—
|
|
|
(8.5
|
)
|
|||||
Investments held by variable interest entities - corporate securities
|
8.9
|
|
|
(4.0
|
)
|
|
—
|
|
|
—
|
|
|
4.9
|
|
|||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
(178.9
|
)
|
|
5.4
|
|
|
(159.3
|
)
|
|
65.3
|
|
|
(267.5
|
)
|
|
December 31, 2016
|
|
|
||||||||||||||||||||||||||||
|
Beginning balance as of December 31, 2015
|
|
Purchases, sales, issuances and settlements, net (b)
|
|
Total realized and unrealized gains (losses) included in net income
|
|
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)
|
|
Transfers into Level 3 (a)
|
|
Transfers out of Level 3 (a)
|
|
Ending balance as of December 31, 2016
|
|
Amount of total gains (losses) for the year ended December 31, 2016 included in our net income relating to assets and liabilities still held as of the reporting date
|
||||||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate securities
|
$
|
170.4
|
|
|
$
|
76.5
|
|
|
$
|
(10.7
|
)
|
|
$
|
9.1
|
|
|
$
|
20.3
|
|
|
$
|
(7.1
|
)
|
|
$
|
258.5
|
|
|
$
|
(10.9
|
)
|
Debt securities issued by foreign governments
|
—
|
|
|
4.0
|
|
|
—
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
3.9
|
|
|
—
|
|
||||||||
Asset-backed securities
|
35.9
|
|
|
9.7
|
|
|
—
|
|
|
2.2
|
|
|
26.3
|
|
|
(13.7
|
)
|
|
60.4
|
|
|
—
|
|
||||||||
Collateralized debt obligations
|
—
|
|
|
5.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.4
|
|
|
—
|
|
||||||||
Commercial mortgage-backed securities
|
1.1
|
|
|
16.9
|
|
|
—
|
|
|
.1
|
|
|
13.9
|
|
|
—
|
|
|
32.0
|
|
|
—
|
|
||||||||
Mortgage pass-through securities
|
.1
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Total fixed maturities, available for sale
|
207.5
|
|
|
112.4
|
|
|
(10.7
|
)
|
|
11.3
|
|
|
60.5
|
|
|
(20.8
|
)
|
|
360.2
|
|
|
(10.9
|
)
|
||||||||
Equity securities - corporate securities
|
32.0
|
|
|
5.5
|
|
|
(12.7
|
)
|
|
.4
|
|
|
—
|
|
|
—
|
|
|
25.2
|
|
|
(12.7
|
)
|
||||||||
Trading securities - commercial mortgage-backed securities
|
39.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(39.9
|
)
|
|
—
|
|
|
—
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
(1,057.1
|
)
|
|
(96.0
|
)
|
|
60.8
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,092.3
|
)
|
|
60.8
|
|
(a)
|
Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.
|
(b)
|
Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. In addition, such activity includes the investments received upon the recapture of reinsurance agreements with BRe on September 29, 2016. The following summarizes such activity for the year ended
December 31, 2016
(dollars in millions):
|
|
Purchases
|
|
Received in reinsurance recapture
|
|
Sales
|
|
Issuances
|
|
Settlements
|
|
Purchases, sales, issuances and settlements, net
|
||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Corporate securities
|
$
|
18.5
|
|
|
$
|
89.2
|
|
|
$
|
(31.2
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
76.5
|
|
Debt securities issued by foreign governments
|
4.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.0
|
|
||||||
Asset-backed securities
|
16.9
|
|
|
—
|
|
|
(7.2
|
)
|
|
—
|
|
|
—
|
|
|
9.7
|
|
||||||
Collateralized debt obligations
|
5.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.4
|
|
||||||
Commercial mortgage-backed securities
|
17.0
|
|
|
—
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
16.9
|
|
||||||
Mortgage pass-through securities
|
—
|
|
|
—
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
(.1
|
)
|
||||||
Total fixed maturities, available for sale
|
61.8
|
|
|
89.2
|
|
|
(38.6
|
)
|
|
—
|
|
|
—
|
|
|
112.4
|
|
||||||
Equity securities - corporate securities
|
3.3
|
|
|
2.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.5
|
|
||||||
Trading securities - corporate securities
|
.2
|
|
|
—
|
|
|
(.2
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
(148.3
|
)
|
|
—
|
|
|
21.2
|
|
|
(28.9
|
)
|
|
60.0
|
|
|
(96.0
|
)
|
|
Fair value at December 31, 2017
|
|
Valuation techniques
|
|
Unobservable inputs
|
|
Range (weighted average)
|
||
Assets:
|
|
|
|
|
|
|
|
||
Corporate securities (a)
|
$
|
149.2
|
|
|
Discounted cash flow analysis
|
|
Discount margins
|
|
1.45% - 71.29% (6.96%)
|
Corporate securities (b)
|
2.8
|
|
|
Recovery method
|
|
Percent of recovery expected
|
|
0% - 21.73% (18.42%)
|
|
Asset-backed securities (c)
|
24.2
|
|
|
Discounted cash flow analysis
|
|
Discount margins
|
|
1.80% - 3.71% (2.67%)
|
|
Equity securities (d)
|
21.2
|
|
|
Market comparables
|
|
EBITDA multiples
|
|
1.1X - 8.9X (1.1X)
|
|
Other assets categorized as Level 3 (e)
|
87.2
|
|
|
Unadjusted third-party price source
|
|
Not applicable
|
|
Not applicable
|
|
Total
|
284.6
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
||
Future policy benefits (f)
|
1,334.8
|
|
|
Discounted projected embedded derivatives
|
|
Projected portfolio yields
|
|
5.15% - 5.61% (5.60%)
|
|
|
|
|
|
|
Discount rates
|
|
0.92 - 2.51% (2.00%)
|
||
|
|
|
|
|
Surrender rates
|
|
1.20% - 46.40% (12.30%)
|
(a)
|
Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.
|
(b)
|
Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement.
|
(c)
|
Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.
|
(d)
|
Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is multiples of earnings before interest, taxes, depreciation and amortization ("EBITDA"). Generally, increases (decreases) in the EBITDA multiples would result in higher (lower) fair value measurements.
|
(e)
|
Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.
|
(f)
|
Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.
|
|
Fair value at December 31, 2016
|
|
Valuation techniques
|
|
Unobservable inputs
|
|
Range (weighted average)
|
||
Assets:
|
|
|
|
|
|
|
|
||
Corporate securities (a)
|
$
|
148.5
|
|
|
Discounted cash flow analysis
|
|
Discount margins
|
|
1.35% - 27.71% (13.52%)
|
Corporate securities (b)
|
14.8
|
|
|
Recovery method
|
|
Percent of recovery expected
|
|
5% - 69% (55%)
|
|
Asset-backed securities (c)
|
24.0
|
|
|
Discounted cash flow analysis
|
|
Discount margins
|
|
2.06% - 3.64% (2.76%)
|
|
Equity securities (d)
|
25.2
|
|
|
Market comparables
|
|
EBITDA multiples
|
|
0.4X - 6.2X (5.9X)
|
|
Other assets categorized as Level 3 (e)
|
172.9
|
|
|
Unadjusted third-party price source
|
|
Not applicable
|
|
Not applicable
|
|
Total
|
385.4
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
||
Future policy benefits (f)
|
1,092.3
|
|
|
Discounted projected embedded derivatives
|
|
Projected portfolio yields
|
|
5.15% - 5.61% (5.59%)
|
|
|
|
|
|
|
Discount rates
|
|
0.18 - 3.06% (2.07%)
|
||
|
|
|
|
|
Surrender rates
|
|
0.94% - 46.48% (13.52%)
|
(a)
|
Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.
|
(b)
|
Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement.
|
(c)
|
Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.
|
(d)
|
Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is EBITDA multiples. Generally, increases (decreases) in EBITDA multiples would result in higher (lower) fair value measurements.
|
(e)
|
Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.
|
(f)
|
Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.
|
|
Withdrawal assumption
|
|
Morbidity assumption
|
|
Mortality assumption
|
|
Interest rate assumption
|
|
2017
|
|
2016
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||
Long-term care
|
Company experience
|
|
Company experience
|
|
Company experience
|
|
6%
|
|
$
|
5,669.0
|
|
|
$
|
5,346.1
|
|
Traditional life insurance contracts
|
Company experience
|
|
Company experience
|
|
(a)
|
|
5%
|
|
2,401.2
|
|
|
2,322.1
|
|
||
Accident and health contracts
|
Company experience
|
|
Company experience
|
|
Company experience
|
|
5%
|
|
2,812.0
|
|
|
2,695.6
|
|
||
Interest-sensitive life insurance contracts
|
Company experience
|
|
Company experience
|
|
Company experience
|
|
5%
|
|
44.9
|
|
|
52.2
|
|
||
Annuities and supplemental contracts with life contingencies
|
Company experience
|
|
Company experience
|
|
(b)
|
|
4%
|
|
594.2
|
|
|
537.3
|
|
||
Total
|
|
|
|
|
|
|
|
|
$
|
11,521.3
|
|
|
$
|
10,953.3
|
|
(a)
|
Principally, modifications of: (i) the 1965 ‑ 70 and 1975 - 80 Basic Tables; and (ii) the 1941, 1958 and 1980 Commissioners' Standard Ordinary Tables; as well as Company experience.
|
(b)
|
Principally, modifications of: (i) the 1971 Individual Annuity Mortality Table; (ii) the 1983 Table "A"; and (iii) the Annuity 2000 Mortality Table; as well as Company experience.
|
|
|
2017
|
|
2016
|
||||
Fixed index annuities
|
|
$
|
5,942.2
|
|
|
$
|
5,324.5
|
|
Other annuities
|
|
4,183.8
|
|
|
4,541.8
|
|
||
Interest-sensitive life insurance contracts
|
|
1,094.7
|
|
|
1,046.4
|
|
||
Total
|
|
$
|
11,220.7
|
|
|
$
|
10,912.7
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Balance, beginning of year
|
$
|
1,777.6
|
|
|
$
|
1,731.8
|
|
|
$
|
1,679.5
|
|
Less reinsurance (receivables) payables
|
14.0
|
|
|
(130.0
|
)
|
|
(125.0
|
)
|
|||
Net balance, beginning of year
|
1,791.6
|
|
|
1,601.8
|
|
|
1,554.5
|
|
|||
Incurred claims related to:
|
|
|
|
|
|
||||||
Current year
|
1,548.1
|
|
|
1,526.4
|
|
|
1,481.0
|
|
|||
Prior years (a)
|
(26.7
|
)
|
|
96.6
|
|
|
(13.3
|
)
|
|||
Total incurred
|
1,521.4
|
|
|
1,623.0
|
|
|
1,467.7
|
|
|||
Interest on claim reserves
|
78.4
|
|
|
75.3
|
|
|
71.0
|
|
|||
Paid claims related to:
|
|
|
|
|
|
||||||
Current year
|
845.5
|
|
|
837.2
|
|
|
841.8
|
|
|||
Prior years
|
702.6
|
|
|
671.3
|
|
|
649.6
|
|
|||
Total paid
|
1,548.1
|
|
|
1,508.5
|
|
|
1,491.4
|
|
|||
Net balance, end of year
|
1,843.3
|
|
|
1,791.6
|
|
|
1,601.8
|
|
|||
Add reinsurance receivables (payables)
|
(15.1
|
)
|
|
(14.0
|
)
|
|
130.0
|
|
|||
Balance, end of year
|
$
|
1,828.2
|
|
|
$
|
1,777.6
|
|
|
$
|
1,731.8
|
|
(a)
|
The reserves and liabilities we establish are necessarily based on estimates, assumptions and prior years' statistics. Such amounts will fluctuate based upon the estimation procedures used to determine the amount of unpaid losses. It is possible that actual claims will exceed our reserves and have a material adverse effect on our results of operations and financial condition.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Current tax expense (benefit)
|
$
|
90.8
|
|
|
$
|
(45.2
|
)
|
|
$
|
10.7
|
|
Deferred tax expense
|
72.0
|
|
|
173.0
|
|
|
118.6
|
|
|||
Valuation allowance applicable to current year income
|
(15.3
|
)
|
|
(14.0
|
)
|
|
—
|
|
|||
Income tax expense calculated based on annual effective tax rate
|
147.5
|
|
|
113.8
|
|
|
129.3
|
|
|||
Income tax expense on discrete items:
|
|
|
|
|
|
||||||
Change in valuation allowance
|
(13.4
|
)
|
|
40.7
|
|
|
(32.5
|
)
|
|||
Impact of federal tax reform
|
310.6
|
|
|
—
|
|
|
—
|
|
|||
Change in valuation allowance related to federal tax reform
|
(138.1
|
)
|
|
—
|
|
|
—
|
|
|||
IRS settlement
|
—
|
|
|
(170.4
|
)
|
|
—
|
|
|||
Other items
|
(1.7
|
)
|
|
10.9
|
|
|
.2
|
|
|||
Total income tax expense (benefit)
|
$
|
304.9
|
|
|
$
|
(5.0
|
)
|
|
$
|
97.0
|
|
|
2017
|
|
2016
|
|
2015
|
|||
U.S. statutory corporate rate
|
35.0
|
%
|
|
35.0
|
%
|
|
35.0
|
%
|
Valuation allowance
|
(6.0
|
)
|
|
7.6
|
|
|
(8.8
|
)
|
Non-taxable income and nondeductible benefits, net
|
(2.0
|
)
|
|
(1.1
|
)
|
|
(.2
|
)
|
State taxes
|
.6
|
|
|
2.2
|
|
|
2.1
|
|
Impact of federal tax reform
|
64.7
|
|
|
—
|
|
|
—
|
|
Change in valuation allowance related to federal tax reform
|
(28.8
|
)
|
|
—
|
|
|
—
|
|
Impact of IRS settlement
|
—
|
|
|
(48.2
|
)
|
|
—
|
|
Other items
|
—
|
|
|
3.1
|
|
|
(1.7
|
)
|
Effective tax rate
|
63.5
|
%
|
|
(1.4
|
)%
|
|
26.4
|
%
|
|
2017
|
|
2016
|
||||
Deferred tax assets:
|
|
|
|
||||
Net federal operating loss carryforwards
|
$
|
489.6
|
|
|
$
|
882.9
|
|
Net state operating loss carryforwards
|
9.3
|
|
|
12.3
|
|
||
Investments
|
4.3
|
|
|
17.8
|
|
||
Insurance liabilities
|
415.8
|
|
|
668.4
|
|
||
Other
|
48.9
|
|
|
66.3
|
|
||
Gross deferred tax assets
|
967.9
|
|
|
1,647.7
|
|
||
Deferred tax liabilities:
|
|
|
|
|
|
||
Present value of future profits and deferred acquisition costs
|
(165.4
|
)
|
|
(277.8
|
)
|
||
Accumulated other comprehensive income
|
(337.2
|
)
|
|
(344.1
|
)
|
||
Gross deferred tax liabilities
|
(502.6
|
)
|
|
(621.9
|
)
|
||
Net deferred tax assets before valuation allowance
|
465.3
|
|
|
1,025.8
|
|
||
Valuation allowance
|
(89.1
|
)
|
|
(240.2
|
)
|
||
Net deferred tax assets
|
376.2
|
|
|
785.6
|
|
||
Current income taxes prepaid (accrued)
|
(9.3
|
)
|
|
4.1
|
|
||
Income tax assets, net
|
$
|
366.9
|
|
|
$
|
789.7
|
|
Balance, December 31, 2014
|
$
|
246.0
|
|
|
Decrease in 2015
|
(32.5
|
)
|
(a)
|
|
Balance, December 31, 2015
|
213.5
|
|
|
|
Increase in 2016
|
26.7
|
|
(b)
|
|
Balance, December 31, 2016
|
240.2
|
|
|
|
Decrease in 2017
|
(166.8
|
)
|
(c)
|
|
Cumulative effect of accounting change
|
15.7
|
|
(d)
|
|
Balance, December 31, 2017
|
$
|
89.1
|
|
|
(a)
|
The
2015
reduction to the deferred tax valuation allowance primarily resulted from higher actual and projected non-life income.
|
(b)
|
The
2016
increase to the deferred tax valuation allowance primarily resulted from additional non-life NOLs due to the settlement with the Internal Revenue Service (the "IRS").
|
(c)
|
The
2017
decrease to the deferred tax valuation allowance includes: (i)
$138.1 million
related to a reduction in the federal corporate income tax rate and other changes from the Tax Reform Act; (ii)
$13.4 million
of reductions to the deferred tax valuation allowance primarily related to the recognition of capital gains; and (iii)
$15.3 million
of
|
(d)
|
Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences. Under the new guidance, any excess tax benefits are recognized as an income tax benefit in the income statement. The new guidance is applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings for all tax benefits that were not previously recognized because the related tax deduction had not reduced taxes payable. The Company had NOL carryforwards of
$15.7 million
related to deductions for stock options and restricted stock on the date of adoption. However, a corresponding valuation allowance of
$15.7 million
was recognized as a result of adopting this guidance. Therefore, there was no impact to our consolidated financial statements related to the initial adoption of this provision of the new guidance.
|
|
|
Net operating loss
|
||
Year of expiration
|
|
carryforwards
|
||
2023
|
|
$
|
1,744.8
|
|
2025
|
|
85.2
|
|
|
2026
|
|
149.9
|
|
|
2027
|
|
10.8
|
|
|
2028
|
|
80.3
|
|
|
2029
|
|
213.2
|
|
|
2030
|
|
.3
|
|
|
2031
|
|
.2
|
|
|
2032
|
|
44.4
|
|
|
2033
|
|
.6
|
|
|
2034
|
|
.9
|
|
|
2035
|
|
.8
|
|
|
Total federal NOLs
|
|
$
|
2,331.4
|
|
|
2016
|
||
|
|
||
Balance at beginning of year
|
$
|
234.2
|
|
Increase based on tax positions taken in prior years
|
3.4
|
|
|
Decrease in unrecognized tax benefits related to settlements with taxing authorities
|
(237.6
|
)
|
|
Balance at end of year
|
$
|
—
|
|
|
2017
|
|
2016
|
||||
4.500% Senior Notes due May 2020
|
$
|
325.0
|
|
|
$
|
325.0
|
|
5.250% Senior Notes due May 2025
|
500.0
|
|
|
500.0
|
|
||
Revolving Credit Agreement (as defined below)
|
100.0
|
|
|
100.0
|
|
||
Unamortized debt issuance costs
|
(10.4
|
)
|
|
(12.1
|
)
|
||
Direct corporate obligations
|
$
|
914.6
|
|
|
$
|
912.9
|
|
•
|
incur certain subsidiary indebtedness without also guaranteeing the Notes;
|
•
|
create liens;
|
•
|
enter into sale and leaseback transactions;
|
•
|
issue, sell, transfer or otherwise dispose of any shares of capital stock of any Insurance Subsidiary (as defined in the Indenture); and
|
•
|
consolidate or merge with or into other companies or transfer all or substantially all of the Company’s assets.
|
•
|
subsidiary debt;
|
•
|
liens;
|
•
|
restrictive agreements;
|
•
|
restricted payments during the continuance of an event of default;
|
•
|
disposition of assets and sale and leaseback transactions;
|
•
|
transactions with affiliates;
|
•
|
change in business;
|
•
|
fundamental changes;
|
•
|
modification of certain agreements; and
|
•
|
changes to fiscal year.
|
•
|
non-payment;
|
•
|
breach of representations, warranties or covenants;
|
•
|
cross-default and cross-acceleration;
|
•
|
bankruptcy and insolvency events;
|
•
|
judgment defaults;
|
•
|
actual or asserted invalidity of documentation with respect to the Revolving Credit Agreement;
|
•
|
change of control; and
|
•
|
customary ERISA defaults.
|
Year ending December 31,
|
|
|
||
2018
|
$
|
—
|
|
|
2019
|
100.0
|
|
(a)
|
|
2020
|
325.0
|
|
|
|
2021
|
—
|
|
|
|
2022
|
—
|
|
|
|
Thereafter
|
500.0
|
|
|
|
|
$
|
925.0
|
|
|
(a)
|
The maturity date of the Revolving Credit Agreement is the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the Company’s
4.50%
senior notes due 2020, which is November 30, 2019.
|
2018
|
$
|
33.5
|
|
2019
|
18.2
|
|
|
2020
|
11.8
|
|
|
2021
|
8.0
|
|
|
2022
|
5.6
|
|
|
Thereafter
|
3.6
|
|
|
Total
|
$
|
80.7
|
|
|
2017
|
|
2016
|
||
Benefit obligations:
|
|
|
|
||
Discount rate
|
3.75
|
%
|
|
4.25
|
%
|
Net periodic cost:
|
|
|
|
||
Discount rate
|
4.25
|
%
|
|
4.50
|
%
|
2018
|
$
|
7.4
|
|
2019
|
7.6
|
|
|
2020
|
7.9
|
|
|
2021
|
8.0
|
|
|
2022
|
8.3
|
|
|
2023 - 2027
|
45.2
|
|
|
|
Fair value
|
||||||
|
|
2017
|
|
2016
|
||||
Assets:
|
|
|
|
|
||||
Other invested assets:
|
|
|
|
|
||||
Fixed index call options
|
|
$
|
170.2
|
|
|
$
|
111.9
|
|
Reinsurance receivables
|
|
(1.4
|
)
|
|
(4.2
|
)
|
||
Total assets
|
|
$
|
168.8
|
|
|
$
|
107.7
|
|
Liabilities:
|
|
|
|
|
||||
Future policy benefits:
|
|
|
|
|
||||
Fixed index products
|
|
$
|
1,334.8
|
|
|
$
|
1,092.3
|
|
Total liabilities
|
|
$
|
1,334.8
|
|
|
$
|
1,092.3
|
|
|
|
Measurement
|
|
December 31, 2016
|
|
Additions
|
|
Maturities/terminations
|
|
December 31, 2017
|
||||||||
Fixed index annuities - embedded derivative
|
|
Policies
|
|
100,812
|
|
|
11,437
|
|
|
(7,560
|
)
|
|
104,689
|
|
||||
Fixed index call options
|
|
Notional (a)
|
|
$
|
2,455.1
|
|
|
$
|
3,021.8
|
|
|
$
|
(2,471.1
|
)
|
|
$
|
3,005.8
|
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net investment income from policyholder and other special-purpose portfolios:
|
|
|
|
|
|
|
||||||
Fixed index call options
|
|
$
|
162.5
|
|
|
$
|
29.2
|
|
|
$
|
(36.2
|
)
|
Net realized gains (losses):
|
|
|
|
|
|
|
||||||
Interest rate futures
|
|
—
|
|
|
(1.1
|
)
|
|
(2.7
|
)
|
|||
Embedded derivative related to modified coinsurance agreement
|
|
2.8
|
|
|
.8
|
|
|
(7.0
|
)
|
|||
Total
|
|
2.8
|
|
|
(.3
|
)
|
|
(9.7
|
)
|
|||
Insurance policy benefits:
|
|
|
|
|
|
|
||||||
Embedded derivative related to fixed index annuities
|
|
25.0
|
|
|
60.8
|
|
|
36.3
|
|
|||
Total
|
|
$
|
190.3
|
|
|
$
|
89.7
|
|
|
$
|
(9.6
|
)
|
|
|
|
|
|
|
|
|
|
Gross amounts not offset in the balance sheet
|
|
|
||||||||||||||
|
|
|
Gross amounts recognized
|
|
Gross amounts offset in the balance sheet
|
|
Net amounts of assets presented in the balance sheet
|
|
Financial instruments
|
|
Cash collateral received
|
|
Net amount
|
||||||||||||
December 31, 2017:
|
|
|
|||||||||||||||||||||||
|
Fixed index call options
|
|
$
|
170.2
|
|
|
$
|
—
|
|
|
$
|
170.2
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
170.2
|
|
December 31, 2016:
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Fixed index call options
|
|
111.9
|
|
|
—
|
|
|
111.9
|
|
|
—
|
|
|
—
|
|
|
111.9
|
|
|
2017
|
|
2016
|
|
2015
|
|||
Balance, beginning of year
|
173,754
|
|
|
184,029
|
|
|
203,324
|
|
Treasury stock purchased and retired
|
(7,808
|
)
|
|
(11,688
|
)
|
|
(20,582
|
)
|
Stock options exercised
|
725
|
|
|
978
|
|
|
769
|
|
Restricted and performance stock vested (a)
|
187
|
|
|
435
|
|
|
518
|
|
Balance, end of year
|
166,858
|
|
|
173,754
|
|
|
184,029
|
|
(a)
|
In
2017
,
2016
and
2015
, such amount was reduced by
103 thousand
,
191 thousand
and
237 thousand
shares, respectively, which were tendered to the Company for the payment of required federal and state tax withholdings owed on the vesting of restricted and performance stock.
|
|
Shares
|
|
Weighted average exercise price
|
|
Weighted average remaining life (in years)
|
|
Aggregate intrinsic value
|
|||||
Outstanding at the beginning of the year
|
5,354
|
|
|
$
|
14.73
|
|
|
|
|
|
||
Options granted
|
729
|
|
|
21.06
|
|
|
|
|
|
|||
Exercised
|
(237
|
)
|
|
(17.81
|
)
|
|
|
|
$
|
5.2
|
|
|
Forfeited or terminated
|
(725
|
)
|
|
(11.43
|
)
|
|
|
|
|
|||
Outstanding at the end of the year
|
5,121
|
|
|
15.95
|
|
|
5.4
|
|
$
|
37.2
|
|
|
Options exercisable at the end of the year
|
2,440
|
|
|
|
|
3.0
|
|
$
|
19.2
|
|
||
Available for future grant
|
7,488
|
|
|
|
|
|
|
|
|
Shares
|
|
Weighted average exercise price
|
|
Weighted average remaining life (in years)
|
|
Aggregate intrinsic value
|
|||||
Outstanding at the beginning of the year
|
5,199
|
|
|
$
|
13.32
|
|
|
|
|
|
||
Options granted
|
1,706
|
|
|
17.45
|
|
|
|
|
|
|||
Exercised
|
(978
|
)
|
|
(8.70
|
)
|
|
|
|
$
|
6.1
|
|
|
Forfeited or terminated
|
(573
|
)
|
|
(20.41
|
)
|
|
|
|
|
|||
Outstanding at the end of the year
|
5,354
|
|
|
14.73
|
|
|
5.9
|
|
$
|
37.1
|
|
|
Options exercisable at the end of the year
|
2,187
|
|
|
|
|
2.7
|
|
$
|
15.1
|
|
||
Available for future grant
|
4,620
|
|
|
|
|
|
|
|
|
Shares
|
|
Weighted average exercise price
|
|
Weighted average remaining life (in years)
|
|
Aggregate intrinsic value
|
|||||
Outstanding at the beginning of the year
|
5,011
|
|
|
$
|
12.04
|
|
|
|
|
|
||
Options granted
|
1,361
|
|
|
16.45
|
|
|
|
|
|
|||
Exercised
|
(769
|
)
|
|
(8.20
|
)
|
|
|
|
$
|
4.8
|
|
|
Forfeited or terminated
|
(404
|
)
|
|
(17.70
|
)
|
|
|
|
|
|||
Outstanding at the end of the year
|
5,199
|
|
|
13.32
|
|
|
4.8
|
|
$
|
38.4
|
|
|
Options exercisable at the end of the year
|
2,399
|
|
|
|
|
2.5
|
|
$
|
15.3
|
|
||
Available for future grant
|
6,882
|
|
|
|
|
|
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Grants
|
|
Grants
|
|
Grants
|
||||||
Weighted average risk-free interest rates
|
2.2
|
%
|
|
1.4
|
%
|
|
1.7
|
%
|
|||
Weighted average dividend yields
|
1.5
|
%
|
|
1.6
|
%
|
|
1.5
|
%
|
|||
Volatility factors
|
32
|
%
|
|
36
|
%
|
|
85
|
%
|
|||
Weighted average expected life (in years)
|
6.3
|
|
|
6.3
|
|
|
6.3
|
|
|||
Weighted average fair value per share
|
$
|
6.20
|
|
|
$
|
5.48
|
|
|
$
|
10.83
|
|
|
|
|
|
Options outstanding
|
|
Options exercisable
|
||||||||||
Range of exercise prices
|
|
Number outstanding
|
|
Remaining life (in years)
|
|
Average exercise price
|
|
Number exercisable
|
|
Average exercise price
|
||||||
$6.77 - $7.51
|
|
605
|
|
|
0.9
|
|
$
|
7.47
|
|
|
605
|
|
|
$
|
7.47
|
|
$10.88 - $16.22
|
|
683
|
|
|
2.3
|
|
11.12
|
|
|
670
|
|
|
11.02
|
|
||
$16.42 - $21.48
|
|
3,833
|
|
|
6.7
|
|
18.15
|
|
|
1,165
|
|
|
18.04
|
|
||
|
|
5,121
|
|
|
|
|
|
|
2,440
|
|
|
|
|
Shares
|
|
Weighted average grant date fair value
|
|||
Non-vested shares, beginning of year
|
369
|
|
|
$
|
18.10
|
|
Granted
|
330
|
|
|
20.87
|
|
|
Vested
|
(147
|
)
|
|
(18.38
|
)
|
|
Forfeited
|
(17
|
)
|
|
(20.59
|
)
|
|
Non-vested shares, end of year
|
535
|
|
|
19.65
|
|
|
Total shareholder return awards
|
|
Operating return on equity awards
|
|
Pre-tax operating income awards
|
|||
Awards outstanding at December 31, 2014
|
519
|
|
|
343
|
|
|
176
|
|
Granted in 2015
|
258
|
|
|
258
|
|
|
—
|
|
Additional shares issued pursuant to achieving certain performance criteria (a)
|
85
|
|
|
—
|
|
|
85
|
|
Shares vested in 2015
|
(260
|
)
|
|
—
|
|
|
(260
|
)
|
Forfeited
|
(53
|
)
|
|
(52
|
)
|
|
(1
|
)
|
Awards outstanding at December 31, 2015
|
549
|
|
|
549
|
|
|
—
|
|
Granted in 2016
|
254
|
|
|
254
|
|
|
—
|
|
Additional shares issued pursuant to achieving certain performance criteria (a)
|
87
|
|
|
65
|
|
|
—
|
|
Shares vested in 2016
|
(261
|
)
|
|
(239
|
)
|
|
—
|
|
Forfeited
|
(59
|
)
|
|
(59
|
)
|
|
—
|
|
Awards outstanding at December 31, 2016
|
570
|
|
|
570
|
|
|
—
|
|
Granted in 2017
|
226
|
|
|
226
|
|
|
—
|
|
Additional shares issued pursuant to achieving certain performance criteria (a)
|
—
|
|
|
30
|
|
|
—
|
|
Shares vested in 2017
|
—
|
|
|
(144
|
)
|
|
—
|
|
Forfeited
|
(167
|
)
|
|
(53
|
)
|
|
—
|
|
Awards outstanding at December 31, 2017
|
629
|
|
|
629
|
|
|
—
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net income for diluted earnings per share
|
$
|
175.6
|
|
|
$
|
358.2
|
|
|
$
|
270.7
|
|
Shares:
|
|
|
|
|
|
|
|
||||
Weighted average shares outstanding for basic earnings per share
|
170,025
|
|
|
176,638
|
|
|
193,054
|
|
|||
Effect of dilutive securities on weighted average shares:
|
|
|
|
|
|
|
|||||
Stock options, restricted stock and performance units
|
2,119
|
|
|
1,685
|
|
|
2,112
|
|
|||
Weighted average shares outstanding for diluted earnings per share
|
172,144
|
|
|
178,323
|
|
|
195,166
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Direct premiums collected
|
$
|
4,013.4
|
|
|
$
|
3,942.7
|
|
|
$
|
3,769.6
|
|
Reinsurance assumed
|
30.2
|
|
|
33.8
|
|
|
38.4
|
|
|||
Reinsurance ceded
|
(114.4
|
)
|
|
(132.9
|
)
|
|
(142.8
|
)
|
|||
Premiums collected, net of reinsurance
|
3,929.2
|
|
|
3,843.6
|
|
|
3,665.2
|
|
|||
Change in unearned premiums
|
19.0
|
|
|
6.2
|
|
|
5.9
|
|
|||
Less premiums on interest-sensitive life and products without mortality and morbidity risk which are recorded as additions to insurance liabilities
|
(1,445.9
|
)
|
|
(1,386.7
|
)
|
|
(1,241.9
|
)
|
|||
Premiums on traditional products with mortality or morbidity risk
|
2,502.3
|
|
|
2,463.1
|
|
|
2,429.2
|
|
|||
Fees and surrender charges on interest-sensitive products
|
145.0
|
|
|
138.0
|
|
|
126.8
|
|
|||
Insurance policy income
|
$
|
2,647.3
|
|
|
$
|
2,601.1
|
|
|
$
|
2,556.0
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Commission expense
|
$
|
115.6
|
|
|
$
|
110.5
|
|
|
$
|
103.8
|
|
Salaries and wages
|
237.3
|
|
|
231.0
|
|
|
205.2
|
|
|||
Other
|
488.6
|
|
|
454.8
|
|
|
430.2
|
|
|||
Total other operating costs and expenses
|
$
|
841.5
|
|
|
$
|
796.3
|
|
|
$
|
739.2
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Balance, beginning of year
|
$
|
401.8
|
|
|
$
|
449.0
|
|
|
$
|
489.4
|
|
Amortization
|
(54.4
|
)
|
|
(62.2
|
)
|
|
(69.1
|
)
|
|||
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale
|
12.2
|
|
|
15.0
|
|
|
28.7
|
|
|||
Balance, end of year
|
$
|
359.6
|
|
|
$
|
401.8
|
|
|
$
|
449.0
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Balance, beginning of year
|
$
|
1,044.7
|
|
|
$
|
1,083.3
|
|
|
$
|
770.6
|
|
Additions
|
236.1
|
|
|
242.7
|
|
|
246.4
|
|
|||
Amortization
|
(184.9
|
)
|
|
(191.1
|
)
|
|
(190.9
|
)
|
|||
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale
|
(69.1
|
)
|
|
(90.2
|
)
|
|
257.2
|
|
|||
Balance, end of year
|
$
|
1,026.8
|
|
|
$
|
1,044.7
|
|
|
$
|
1,083.3
|
|
|
2017
|
|
2016
|
|
2015
|
|
||||||
Cash flows from operating activities:
|
|
|
|
|
|
|
||||||
Net income
|
$
|
175.6
|
|
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
Adjustments to reconcile net income to net cash from operating activities:
|
|
|
|
|
|
|
|
|||||
Amortization and depreciation
|
265.4
|
|
|
275.0
|
|
|
283.4
|
|
|
|||
Income taxes
|
227.5
|
|
|
(11.7
|
)
|
|
92.9
|
|
|
|||
Insurance liabilities
|
464.7
|
|
|
332.8
|
|
|
297.4
|
|
|
|||
Accrual and amortization of investment income
|
(321.6
|
)
|
|
(124.2
|
)
|
|
(27.6
|
)
|
|
|||
Deferral of policy acquisition costs
|
(236.1
|
)
|
|
(242.7
|
)
|
|
(246.4
|
)
|
|
|||
Net realized investment (gains) losses
|
(50.3
|
)
|
|
(8.3
|
)
|
|
36.6
|
|
|
|||
Loss on reinsurance transactions and transition expenses
|
—
|
|
|
75.4
|
|
|
9.0
|
|
|
|||
Cash and cash equivalents received upon recapture of reinsurance
|
—
|
|
|
73.6
|
|
|
—
|
|
|
|||
Loss on extinguishment of borrowings related to variable interest entities
|
9.5
|
|
|
—
|
|
|
—
|
|
|
|||
Loss on extinguishment of debt
|
—
|
|
|
—
|
|
|
32.8
|
|
|
|||
Other
|
78.4
|
|
|
34.7
|
|
|
(1.0
|
)
|
|
|||
Net cash from operating activities
|
$
|
613.1
|
|
|
$
|
762.8
|
|
|
$
|
747.8
|
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Stock options, restricted stock and performance units
|
$
|
21.4
|
|
|
$
|
23.0
|
|
|
$
|
17.1
|
|
Market value of investments recaptured in connection with the termination of reinsurance agreements with BRe
|
—
|
|
|
431.1
|
|
|
—
|
|
|
2017
|
|
2016
|
||||
Statutory capital and surplus
|
$
|
1,904.4
|
|
|
$
|
1,956.8
|
|
Asset valuation reserve
|
246.8
|
|
|
253.3
|
|
||
Interest maintenance reserve
|
487.0
|
|
|
486.9
|
|
||
Total
|
$
|
2,638.2
|
|
|
$
|
2,697.0
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Bankers Life:
|
|
|
|
|
|
||||||
Insurance policy income:
|
|
|
|
|
|
||||||
Annuities
|
$
|
20.3
|
|
|
$
|
22.0
|
|
|
$
|
22.4
|
|
Health
|
1,231.1
|
|
|
1,244.1
|
|
|
1,251.0
|
|
|||
Life
|
415.2
|
|
|
393.0
|
|
|
375.3
|
|
|||
Net investment income (a)
|
1,107.3
|
|
|
936.8
|
|
|
884.7
|
|
|||
Fee revenue and other income (a)
|
44.1
|
|
|
34.4
|
|
|
27.7
|
|
|||
Total Bankers Life revenues
|
2,818.0
|
|
|
2,630.3
|
|
|
2,561.1
|
|
|||
Washington National:
|
|
|
|
|
|
|
|
||||
Insurance policy income:
|
|
|
|
|
|
|
|
||||
Annuities
|
2.1
|
|
|
2.9
|
|
|
3.0
|
|
|||
Health
|
642.9
|
|
|
627.9
|
|
|
615.4
|
|
|||
Life
|
26.4
|
|
|
25.0
|
|
|
25.4
|
|
|||
Net investment income (a)
|
270.2
|
|
|
259.3
|
|
|
253.6
|
|
|||
Fee revenue and other income (a)
|
1.0
|
|
|
1.3
|
|
|
1.3
|
|
|||
Total Washington National revenues
|
942.6
|
|
|
916.4
|
|
|
898.7
|
|
|||
Colonial Penn:
|
|
|
|
|
|
|
|
||||
Insurance policy income:
|
|
|
|
|
|
|
|
||||
Health
|
2.1
|
|
|
2.6
|
|
|
3.0
|
|
|||
Life
|
289.7
|
|
|
278.8
|
|
|
260.5
|
|
|||
Net investment income (a)
|
44.4
|
|
|
44.2
|
|
|
43.0
|
|
|||
Fee revenue and other income (a)
|
1.3
|
|
|
1.1
|
|
|
1.0
|
|
|||
Total Colonial Penn revenues
|
337.5
|
|
|
326.7
|
|
|
307.5
|
|
|||
Long-term care in run-off:
|
|
|
|
|
|
|
|
||||
Insurance policy income - health
|
17.5
|
|
|
4.8
|
|
|
—
|
|
|||
Net investment income (a)
|
34.6
|
|
|
9.4
|
|
|
—
|
|
|||
Total Long-term care in run-off revenues
|
52.1
|
|
|
14.2
|
|
|
—
|
|
|||
Corporate operations:
|
|
|
|
|
|
|
|
||||
Net investment income
|
35.5
|
|
|
16.6
|
|
|
11.3
|
|
|||
Fee revenue and other income
|
8.5
|
|
|
10.0
|
|
|
8.6
|
|
|||
Total corporate revenues
|
44.0
|
|
|
26.6
|
|
|
19.9
|
|
|||
Total revenues
|
$
|
4,194.2
|
|
|
$
|
3,914.2
|
|
|
$
|
3,787.2
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Expenses:
|
|
|
|
|
|
||||||
Bankers Life:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
1,771.8
|
|
|
$
|
1,620.6
|
|
|
$
|
1,588.4
|
|
Amortization
|
163.6
|
|
|
176.5
|
|
|
187.1
|
|
|||
Interest expense on investment borrowings
|
19.8
|
|
|
13.2
|
|
|
8.8
|
|
|||
Other operating costs and expenses
|
443.9
|
|
|
422.1
|
|
|
407.2
|
|
|||
Total Bankers Life expenses
|
2,399.1
|
|
|
2,232.4
|
|
|
2,191.5
|
|
|||
Washington National:
|
|
|
|
|
|
|
|
||||
Insurance policy benefits
|
581.1
|
|
|
561.7
|
|
|
546.6
|
|
|||
Amortization
|
58.8
|
|
|
59.1
|
|
|
55.2
|
|
|||
Interest expense on investment borrowings
|
6.3
|
|
|
3.7
|
|
|
2.0
|
|
|||
Other operating costs and expenses
|
198.1
|
|
|
189.0
|
|
|
183.4
|
|
|||
Total Washington National expenses
|
844.3
|
|
|
813.5
|
|
|
787.2
|
|
|||
Colonial Penn:
|
|
|
|
|
|
|
|
||||
Insurance policy benefits
|
199.6
|
|
|
201.9
|
|
|
189.0
|
|
|||
Amortization
|
16.3
|
|
|
15.3
|
|
|
14.4
|
|
|||
Interest expense on investment borrowings
|
.9
|
|
|
.6
|
|
|
.1
|
|
|||
Other operating costs and expenses
|
98.1
|
|
|
107.2
|
|
|
98.4
|
|
|||
Total Colonial Penn expenses
|
314.9
|
|
|
325.0
|
|
|
301.9
|
|
|||
Long-term care in run-off:
|
|
|
|
|
|
|
|
||||
Insurance policy benefits
|
47.3
|
|
|
17.6
|
|
|
—
|
|
|||
Other operating costs and expenses
|
3.1
|
|
|
.5
|
|
|
—
|
|
|||
Total Long-term care in run-off expenses
|
50.4
|
|
|
18.1
|
|
|
—
|
|
|||
Corporate operations:
|
|
|
|
|
|
|
|
||||
Interest expense on corporate debt
|
46.5
|
|
|
45.8
|
|
|
45.0
|
|
|||
Interest expense on investment borrowings
|
—
|
|
|
—
|
|
|
.2
|
|
|||
Other operating costs and expenses
|
84.3
|
|
|
69.1
|
|
|
38.6
|
|
|||
Total corporate expenses
|
130.8
|
|
|
114.9
|
|
|
83.8
|
|
|||
Total expenses
|
3,739.5
|
|
|
3,503.9
|
|
|
3,364.4
|
|
|||
Pre-tax operating earnings by segment:
|
|
|
|
|
|
|
|
||||
Bankers Life
|
418.9
|
|
|
397.9
|
|
|
369.6
|
|
|||
Washington National
|
98.3
|
|
|
102.9
|
|
|
111.5
|
|
|||
Colonial Penn
|
22.6
|
|
|
1.7
|
|
|
5.6
|
|
|||
Long-term care in run-off
|
1.7
|
|
|
(3.9
|
)
|
|
—
|
|
|||
Corporate operations
|
(86.8
|
)
|
|
(88.3
|
)
|
|
(63.9
|
)
|
|||
Pre-tax operating earnings
|
$
|
454.7
|
|
|
$
|
410.3
|
|
|
$
|
422.8
|
|
(a)
|
It is not practicable to provide additional components of revenue by product or services.
|
|
2017
|
|
2016
|
|
2015
|
||||||
Total segment revenues
|
$
|
4,194.2
|
|
|
$
|
3,914.2
|
|
|
$
|
3,787.2
|
|
Net realized investment gains (losses)
|
50.3
|
|
|
8.3
|
|
|
(36.6
|
)
|
|||
Revenues related to certain non-strategic investments and earnings attributable to VIEs
|
52.7
|
|
|
52.6
|
|
|
36.3
|
|
|||
Fee revenue related to transition and support services agreements
|
—
|
|
|
10.0
|
|
|
25.0
|
|
|||
Consolidated revenues
|
4,297.2
|
|
|
3,985.1
|
|
|
3,811.9
|
|
|||
|
|
|
|
|
|
||||||
Total segment expenses
|
3,739.5
|
|
|
3,503.9
|
|
|
3,364.4
|
|
|||
Insurance policy benefits - fair value changes in embedded derivative liabilities
|
2.9
|
|
|
(11.3
|
)
|
|
(15.7
|
)
|
|||
Amortization related to fair value changes in embedded derivative liabilities
|
(.4
|
)
|
|
1.7
|
|
|
3.8
|
|
|||
Amortization related to net realized investment gains (losses)
|
1.0
|
|
|
.7
|
|
|
(.5
|
)
|
|||
Expenses related to certain non-strategic investments and expenses attributable to VIEs
|
61.5
|
|
|
54.6
|
|
|
43.0
|
|
|||
Fair value changes and amendment related to agent deferred compensation plan
|
12.2
|
|
|
(3.1
|
)
|
|
(15.1
|
)
|
|||
Loss on extinguishment of debt
|
—
|
|
|
—
|
|
|
32.8
|
|
|||
Loss on reinsurance transaction and transition expenses
|
—
|
|
|
75.4
|
|
|
9.0
|
|
|||
Expenses related to transition and support services agreements
|
—
|
|
|
10.0
|
|
|
22.5
|
|
|||
Consolidated expenses
|
3,816.7
|
|
|
3,631.9
|
|
|
3,444.2
|
|
|||
Income before tax
|
480.5
|
|
|
353.2
|
|
|
367.7
|
|
|||
Income tax expense:
|
|
|
|
|
|
||||||
Tax expense on period income
|
162.8
|
|
|
127.8
|
|
|
129.5
|
|
|||
Valuation allowance for deferred tax assets and other tax items
|
142.1
|
|
|
(132.8
|
)
|
|
(32.5
|
)
|
|||
Net income
|
$
|
175.6
|
|
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
2017
|
|
2016
|
||||
Assets:
|
|
|
|
||||
Bankers Life
|
$
|
21,134.9
|
|
|
$
|
19,876.4
|
|
Washington National
|
7,674.3
|
|
|
7,555.7
|
|
||
Colonial Penn
|
1,059.3
|
|
|
1,022.9
|
|
||
Long-term care in run-off
|
692.9
|
|
|
656.2
|
|
||
Corporate operations
|
2,548.9
|
|
|
2,864.0
|
|
||
Total assets
|
$
|
33,110.3
|
|
|
$
|
31,975.2
|
|
Liabilities:
|
|
|
|
||||
Bankers Life
|
$
|
18,031.6
|
|
|
$
|
17,144.9
|
|
Washington National
|
6,101.5
|
|
|
6,096.9
|
|
||
Colonial Penn
|
921.0
|
|
|
898.5
|
|
||
Long-term care in run-off
|
580.4
|
|
|
562.2
|
|
||
Corporate operations
|
2,628.3
|
|
|
2,785.8
|
|
||
Total liabilities
|
$
|
28,262.8
|
|
|
$
|
27,488.3
|
|
Segment
|
Present value of future profits
|
|
Deferred acquisition costs
|
|
Insurance liabilities
|
||||||
2017
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
81.1
|
|
|
$
|
606.5
|
|
|
$
|
16,541.2
|
|
Washington National
|
243.7
|
|
|
310.8
|
|
|
5,590.7
|
|
|||
Colonial Penn
|
34.8
|
|
|
109.5
|
|
|
834.4
|
|
|||
Long-term care in run-off
|
—
|
|
|
—
|
|
|
572.7
|
|
|||
Total
|
$
|
359.6
|
|
|
$
|
1,026.8
|
|
|
$
|
23,539.0
|
|
2016
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
95.5
|
|
|
$
|
646.2
|
|
|
$
|
15,702.8
|
|
Washington National
|
266.8
|
|
|
299.9
|
|
|
5,586.7
|
|
|||
Colonial Penn
|
39.5
|
|
|
98.6
|
|
|
809.6
|
|
|||
Long-term care in run-off
|
—
|
|
|
—
|
|
|
554.7
|
|
|||
Total
|
$
|
401.8
|
|
|
$
|
1,044.7
|
|
|
$
|
22,653.8
|
|
2017
|
1st Qtr.
|
|
2nd Qtr.
|
|
3rd Qtr.
|
|
4th Qtr. (a)
|
||||||||
Revenues
|
$
|
1,070.7
|
|
|
$
|
1,057.1
|
|
|
$
|
1,079.3
|
|
|
$
|
1,090.1
|
|
Income before income taxes
|
$
|
96.7
|
|
|
$
|
128.5
|
|
|
$
|
129.9
|
|
|
$
|
125.4
|
|
Income tax expense
|
34.4
|
|
|
45.1
|
|
|
29.1
|
|
|
196.3
|
|
||||
Net income (loss)
|
$
|
62.3
|
|
|
$
|
83.4
|
|
|
$
|
100.8
|
|
|
$
|
(70.9
|
)
|
Earnings per common share:
|
|
|
|
|
|
|
|
||||||||
Basic:
|
|
|
|
|
|
|
|
||||||||
Net income (loss)
|
$
|
.36
|
|
|
$
|
.49
|
|
|
$
|
.60
|
|
|
$
|
(.42
|
)
|
Diluted:
|
|
|
|
|
|
|
|
||||||||
Net income (loss)
|
$
|
.36
|
|
|
$
|
.48
|
|
|
$
|
.59
|
|
|
$
|
(.42
|
)
|
|
|
|
|
|
|
|
|
||||||||
2016
|
1st Qtr.
|
|
2nd Qtr.
|
|
3rd Qtr.
|
|
4th Qtr.
|
||||||||
Revenues
|
$
|
960.4
|
|
|
$
|
1,003.9
|
|
|
$
|
1,015.9
|
|
|
$
|
1,004.9
|
|
Income before income taxes
|
$
|
40.5
|
|
|
$
|
82.7
|
|
|
$
|
49.3
|
|
|
$
|
180.7
|
|
Income tax expense (benefit)
|
(5.0
|
)
|
|
22.8
|
|
|
30.7
|
|
|
(53.5
|
)
|
||||
Net income
|
$
|
45.5
|
|
|
$
|
59.9
|
|
|
$
|
18.6
|
|
|
$
|
234.2
|
|
Earnings per common share:
|
|
|
|
|
|
|
|
||||||||
Basic:
|
|
|
|
|
|
|
|
||||||||
Net income
|
$
|
.25
|
|
|
$
|
.34
|
|
|
$
|
.11
|
|
|
$
|
1.35
|
|
Diluted:
|
|
|
|
|
|
|
|
||||||||
Net income
|
$
|
.25
|
|
|
$
|
.33
|
|
|
$
|
.11
|
|
|
$
|
1.34
|
|
(a)
|
In the fourth quarter of 2017, our net loss reflected the unfavorable impact of
$172.5 million
related to the Tax Reform Act which was enacted in December 2017.
|
|
December 31, 2017
|
||||||||||
|
VIEs
|
|
Eliminations
|
|
Net effect on
consolidated
balance sheet
|
||||||
Assets:
|
|
|
|
|
|
||||||
Investments held by variable interest entities
|
$
|
1,526.9
|
|
|
$
|
—
|
|
|
$
|
1,526.9
|
|
Notes receivable of VIEs held by insurance subsidiaries
|
—
|
|
|
(155.5
|
)
|
|
(155.5
|
)
|
|||
Cash and cash equivalents held by variable interest entities
|
178.9
|
|
|
—
|
|
|
178.9
|
|
|||
Accrued investment income
|
2.6
|
|
|
(.1
|
)
|
|
2.5
|
|
|||
Income tax assets, net
|
.7
|
|
|
—
|
|
|
.7
|
|
|||
Other assets
|
10.0
|
|
|
(1.5
|
)
|
|
8.5
|
|
|||
Total assets
|
$
|
1,719.1
|
|
|
$
|
(157.1
|
)
|
|
$
|
1,562.0
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|||
Other liabilities
|
$
|
158.3
|
|
|
$
|
(4.4
|
)
|
|
$
|
153.9
|
|
Borrowings related to variable interest entities
|
1,410.7
|
|
|
—
|
|
|
1,410.7
|
|
|||
Notes payable of VIEs held by insurance subsidiaries
|
167.6
|
|
|
(167.6
|
)
|
|
—
|
|
|||
Total liabilities
|
$
|
1,736.6
|
|
|
$
|
(172.0
|
)
|
|
$
|
1,564.6
|
|
|
December 31, 2016
|
||||||||||
|
VIEs
|
|
Eliminations
|
|
Net effect on
consolidated
balance sheet
|
||||||
Assets:
|
|
|
|
|
|
||||||
Investments held by variable interest entities
|
$
|
1,724.3
|
|
|
$
|
—
|
|
|
$
|
1,724.3
|
|
Notes receivable of VIEs held by insurance subsidiaries
|
—
|
|
|
(204.2
|
)
|
|
(204.2
|
)
|
|||
Cash and cash equivalents held by variable interest entities
|
189.3
|
|
|
—
|
|
|
189.3
|
|
|||
Accrued investment income
|
3.0
|
|
|
(.1
|
)
|
|
2.9
|
|
|||
Income tax assets, net
|
6.4
|
|
|
(1.3
|
)
|
|
5.1
|
|
|||
Other assets
|
13.1
|
|
|
(1.8
|
)
|
|
11.3
|
|
|||
Total assets
|
$
|
1,936.1
|
|
|
$
|
(207.4
|
)
|
|
$
|
1,728.7
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|||
Other liabilities
|
$
|
81.8
|
|
|
$
|
(6.4
|
)
|
|
$
|
75.4
|
|
Borrowings related to variable interest entities
|
1,662.8
|
|
|
—
|
|
|
1,662.8
|
|
|||
Notes payable of VIEs held by insurance subsidiaries
|
203.3
|
|
|
(203.3
|
)
|
|
—
|
|
|||
Total liabilities
|
$
|
1,947.9
|
|
|
$
|
(209.7
|
)
|
|
$
|
1,738.2
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Net investment income – policyholder and other special-purpose portfolios
|
$
|
69.8
|
|
|
$
|
78.9
|
|
|
$
|
62.1
|
|
Fee revenue and other income
|
5.9
|
|
|
6.4
|
|
|
1.6
|
|
|||
Total revenues
|
75.7
|
|
|
85.3
|
|
|
63.7
|
|
|||
Expenses:
|
|
|
|
|
|
||||||
Interest expense
|
50.2
|
|
|
53.1
|
|
|
38.8
|
|
|||
Other operating expenses
|
1.8
|
|
|
1.5
|
|
|
2.0
|
|
|||
Total expenses
|
52.0
|
|
|
54.6
|
|
|
40.8
|
|
|||
Income before net realized investment losses and income taxes
|
23.7
|
|
|
30.7
|
|
|
22.9
|
|
|||
Net realized investment losses
|
(5.6
|
)
|
|
(20.4
|
)
|
|
(6.4
|
)
|
|||
Loss on extinguishment of borrowings
|
(9.5
|
)
|
|
—
|
|
|
—
|
|
|||
Income before income taxes
|
$
|
8.6
|
|
|
$
|
10.3
|
|
|
$
|
16.5
|
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
11.2
|
|
|
$
|
11.2
|
|
Due after one year through five years
|
541.8
|
|
|
542.0
|
|
||
Due after five years through ten years
|
971.9
|
|
|
973.7
|
|
||
Total
|
$
|
1,524.9
|
|
|
$
|
1,526.9
|
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
2.4
|
|
|
$
|
2.4
|
|
Due after one year through five years
|
178.2
|
|
|
174.3
|
|
||
Due after five years through ten years
|
299.8
|
|
|
297.1
|
|
||
Total
|
$
|
480.4
|
|
|
$
|
473.8
|
|
ITEM 9.
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.
|
|
|
|
Page
|
(a)
|
1.
|
Financial Statements. See Index to Consolidated Financial Statements for a list of financial statements included in this Report.
|
|
|
2.
|
Financial Statement Schedules:
|
|
|
|
Schedule II ‑‑ Condensed Financial Information of Registrant (Parent Company)
|
|
|
|
Balance Sheet at December 31, 2017 and 2016
|
|
|
|
Statement of Operations for the years ended December 31, 2017, 2016 and 2015
|
203
|
|
|
Statement of Cash Flows for the years ended December 31, 2017, 2016 and 2015
|
204
|
|
|
Notes to Condensed Financial Information
|
205
|
|
|
Schedule IV ‑‑ Reinsurance for the years ended December 31, 2017, 2016 and 2015
|
3.
|
Exhibits. See Exhibit Index immediately preceding the Exhibits filed with this report.
|
|
By:
|
/s/ Gary C. Bhojwani
|
|
|
Gary C. Bhojwani
|
|
|
Chief Executive Officer
|
|
|
|
Signature
|
Title (Capacity)
|
Date
|
/s/ GARY C. BHOJWANI
|
Director and Chief Executive Officer
|
February 23, 2018
|
Gary C. Bhojwani
|
(Principal Executive Officer)
|
|
|
|
|
/s/ ERIK M. HELDING
|
Executive Vice President
|
February 23, 2018
|
Erik M. Helding
|
and Chief Financial Officer
|
|
|
(Principal Financial Officer)
|
|
|
|
|
/s/ JOHN R. KLINE
|
Senior Vice President
|
February 23, 2018
|
John R. Kline
|
and Chief Accounting Officer
|
|
|
(Principal Accounting Officer)
|
|
|
|
|
/s/ ELLYN L. BROWN
|
Director
|
February 23, 2018
|
Ellyn L. Brown
|
|
|
|
|
|
/s/ STEPHEN DAVID
|
Director
|
February 23, 2018
|
Stephen David
|
|
|
|
|
|
/s/ ROBERT C. GREVING
|
Director
|
February 23, 2018
|
Robert C. Greving
|
|
|
|
|
|
/s/ MARY R. HENDERSON
|
Director
|
February 23, 2018
|
Mary R. Henderson
|
|
|
|
|
|
/s/ CHARLES J. JACKLIN
|
Director
|
February 23, 2018
|
Charles J. Jacklin
|
|
|
|
|
|
/s/ DANIEL R. MAURER
|
Director
|
February 23, 2018
|
Daniel R. Maurer
|
|
|
|
|
|
/s/ NEAL C. SCHNEIDER
|
Director
|
February 23, 2018
|
Neal C. Schneider
|
|
|
|
|
|
/s/ FREDERICK J. SIEVERT
|
Director
|
February 23, 2018
|
Frederick J. Sievert
|
|
|
ASSETS
|
|||||||
|
2017
|
|
2016
|
||||
Cash and cash equivalents - unrestricted
|
$
|
161.1
|
|
|
$
|
106.1
|
|
Equity securities at fair value (cost: 2017 - $225.7; 2016 - $166.5)
|
243.6
|
|
|
167.9
|
|
||
Investment in wholly-owned subsidiaries (eliminated in consolidation)
|
5,440.7
|
|
|
5,220.3
|
|
||
Income tax assets, net
|
129.6
|
|
|
99.5
|
|
||
Receivable from subsidiaries (eliminated in consolidation)
|
6.3
|
|
|
2.0
|
|
||
Other assets
|
12.7
|
|
|
1.8
|
|
||
Total assets
|
$
|
5,994.0
|
|
|
$
|
5,597.6
|
|
|
|
|
|
||||
LIABILITIES AND SHAREHOLDERS' EQUITY
|
|||||||
Liabilities:
|
|
|
|
||||
Notes payable
|
$
|
914.6
|
|
|
$
|
912.9
|
|
Payable to subsidiaries (eliminated in consolidation)
|
143.0
|
|
|
128.4
|
|
||
Other liabilities
|
88.9
|
|
|
69.4
|
|
||
Total liabilities
|
1,146.5
|
|
|
1,110.7
|
|
||
Commitments and Contingencies
|
|
|
|
||||
Shareholders' equity:
|
|
|
|
||||
Common stock and additional paid-in capital ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2017 - 166,857,931; 2016 - 173,753,614)
|
3,075.0
|
|
|
3,213.8
|
|
||
Accumulated other comprehensive income
|
1,212.1
|
|
|
622.4
|
|
||
Retained earnings
|
560.4
|
|
|
650.7
|
|
||
Total shareholders' equity
|
4,847.5
|
|
|
4,486.9
|
|
||
Total liabilities and shareholders' equity
|
$
|
5,994.0
|
|
|
$
|
5,597.6
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Net investment income
|
$
|
14.2
|
|
|
$
|
15.6
|
|
|
$
|
16.9
|
|
Net realized investment gains
|
2.4
|
|
|
17.7
|
|
|
3.5
|
|
|||
Intercompany losses (eliminated in consolidation)
|
—
|
|
|
—
|
|
|
(1.5
|
)
|
|||
Total revenues
|
16.6
|
|
|
33.3
|
|
|
18.9
|
|
|||
Expenses:
|
|
|
|
|
|
||||||
Interest expense
|
46.5
|
|
|
45.8
|
|
|
45.2
|
|
|||
Intercompany expenses (eliminated in consolidation)
|
1.7
|
|
|
.9
|
|
|
.4
|
|
|||
Operating costs and expenses
|
75.4
|
|
|
48.2
|
|
|
21.0
|
|
|||
Loss on extinguishment of debt
|
—
|
|
|
—
|
|
|
32.8
|
|
|||
Total expenses
|
123.6
|
|
|
94.9
|
|
|
99.4
|
|
|||
Loss before income taxes and equity in undistributed earnings of subsidiaries
|
(107.0
|
)
|
|
(61.6
|
)
|
|
(80.5
|
)
|
|||
Income tax expense (benefit)
|
27.4
|
|
|
(54.6
|
)
|
|
(37.9
|
)
|
|||
Loss before equity in undistributed earnings of subsidiaries
|
(134.4
|
)
|
|
(7.0
|
)
|
|
(42.6
|
)
|
|||
Equity in undistributed earnings of subsidiaries (eliminated in consolidation)
|
310.0
|
|
|
365.2
|
|
|
313.3
|
|
|||
Net income
|
$
|
175.6
|
|
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
|
|
|
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Cash flows from operating activities
|
$
|
(181.8
|
)
|
|
$
|
(110.7
|
)
|
|
$
|
(51.2
|
)
|
Cash flows from investing activities:
|
|
|
|
|
|
||||||
Sales of investments
|
54.9
|
|
|
305.0
|
|
|
66.5
|
|
|||
Sales of investments - affiliated*
|
—
|
|
|
—
|
|
|
16.0
|
|
|||
Maturities and redemptions of investments - affiliated*
|
—
|
|
|
—
|
|
|
8.3
|
|
|||
Purchases of investments
|
(123.6
|
)
|
|
(198.4
|
)
|
|
(68.6
|
)
|
|||
Purchases of investments - affiliated*
|
—
|
|
|
—
|
|
|
(3.4
|
)
|
|||
Net sales of trading securities
|
9.1
|
|
|
12.0
|
|
|
11.8
|
|
|||
Dividends received from consolidated subsidiary, net of capital contributions of nil in 2017, $200.0 in 2016 and nil in 2015*
|
363.5
|
|
|
92.5
|
|
|
269.7
|
|
|||
Net cash provided by investing activities
|
303.9
|
|
|
211.1
|
|
|
300.3
|
|
|||
Cash flows from financing activities:
|
|
|
|
|
|
||||||
Issuance of notes payable, net
|
—
|
|
|
—
|
|
|
910.0
|
|
|||
Payments on notes payable
|
—
|
|
|
—
|
|
|
(797.1
|
)
|
|||
Expenses related to extinguishment of debt
|
—
|
|
|
—
|
|
|
(17.8
|
)
|
|||
Issuance of common stock
|
8.3
|
|
|
8.4
|
|
|
6.3
|
|
|||
Payments to repurchase common stock
|
(168.3
|
)
|
|
(210.0
|
)
|
|
(365.4
|
)
|
|||
Common stock dividends paid
|
(59.6
|
)
|
|
(54.8
|
)
|
|
(52.0
|
)
|
|||
Investment borrowings - repurchase agreements, net
|
—
|
|
|
—
|
|
|
(20.4
|
)
|
|||
Issuance of notes payable to affiliates*
|
310.8
|
|
|
217.1
|
|
|
234.4
|
|
|||
Payments on notes payable to affiliates*
|
(158.3
|
)
|
|
(83.9
|
)
|
|
(104.8
|
)
|
|||
Net cash used by financing activities
|
(67.1
|
)
|
|
(123.2
|
)
|
|
(206.8
|
)
|
|||
Net increase (decrease) in cash and cash equivalents
|
55.0
|
|
|
(22.8
|
)
|
|
42.3
|
|
|||
Cash and cash equivalents, beginning of the year
|
106.1
|
|
|
128.9
|
|
|
86.6
|
|
|||
Cash and cash equivalents, end of the year
|
$
|
161.1
|
|
|
$
|
106.1
|
|
|
$
|
128.9
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Life insurance inforce:
|
|
|
|
|
|
||||||
Direct
|
$
|
27,154.3
|
|
|
$
|
27,048.1
|
|
|
$
|
25,807.0
|
|
Assumed
|
120.5
|
|
|
128.7
|
|
|
137.4
|
|
|||
Ceded
|
(3,452.6
|
)
|
|
(3,604.0
|
)
|
|
(3,780.8
|
)
|
|||
Net insurance inforce
|
$
|
23,822.2
|
|
|
$
|
23,572.8
|
|
|
$
|
22,163.6
|
|
Percentage of assumed to net
|
.5
|
%
|
|
.5
|
%
|
|
.6
|
%
|
|
2017
|
|
2016
|
|
2015
|
||||||
Insurance policy income:
|
|
|
|
|
|
||||||
Direct
|
$
|
2,576.9
|
|
|
$
|
2,553.0
|
|
|
$
|
2,524.3
|
|
Assumed
|
30.4
|
|
|
34.0
|
|
|
38.5
|
|
|||
Ceded
|
(105.0
|
)
|
|
(123.9
|
)
|
|
(133.6
|
)
|
|||
Net premiums
|
$
|
2,502.3
|
|
|
$
|
2,463.1
|
|
|
$
|
2,429.2
|
|
Percentage of assumed to net
|
1.2
|
%
|
|
1.4
|
%
|
|
1.6
|
%
|
3.1
|
3.2
|
3.3
|
4.1
|
4.2
|
4.3
|
4.4
|
4.5
|
4.6
|
10.1
|
10.2*
|
10.3*
|
10.4*
|
10.5*
|
10.6*
|
10.7*
|
10.8*
|
10.9*
|
10.10*
|
10.11*
|
10.12*
|
10.13*
|
10.14*
|
10.15
|
10.16*
|
10.17*
|
10.18*
|
Amended and Restated Employment Agreement dated as of December 18, 2014 between CNO Services, LLC and Christopher J. Nickele,
incorporated by reference to Exhibit 10.17 of our Annual Report on Form 10-K for the year ended December 31, 2014
, as amended by Amendment dated as of August 17, 2017,
incorporated by reference to Exhibit 10.5 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017
, and as further amended by Amendment dated as of October 31, 2017,
incorporated by reference to Exhibit 10.7 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.
|
10.19*
|
Amended and Restated Employment Agreement dated as of December 18, 2014 between CNO Financial Group, Inc. and Edward J. Bonach,
incorporated by reference to Exhibit 10.20 of our Annual Report on Form 10-K for the year ended December 31, 2014
, as amended by Amendment dated as of May 16, 2017,
incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017
, and as further amended by Amendment dated as of August 14, 2017,
incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.
|
10.20*
|
Amended and Restated Employment Agreement dated as of September 30, 2016 between 40|86 Advisors, Inc. and Eric R. Johnson,
incorporated by reference to Exhibit 10.25 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016
, as amended by Amendment dated as of August 10, 2017,
incorporated by reference to Exhibit 10.4 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.
|
10.21*
|
Amended and Restated Employment Agreement dated as of January 12, 2015 between CNO Services, LLC and Matthew J. Zimpfer,
incorporated by reference to Exhibit 10.22 of our Annual Report on Form 10-K for the year ended December 31, 2014
, as amended by Amendment dated as of August 21, 2017,
incorporated by reference to Exhibit 10.6 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.
|
10.22*
|
Amended and Restated Employment Agreement dated as of January 6, 2015 between CNO Services, LLC and Bruce Baude,
incorporated by reference to Exhibit 10.23 of our Annual Report on Form 10-K for the year ended December 31, 2014
, as amended by Amendment dated July 30, 2015,
incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2015
, and as further amended by Amendment dated as of August 11, 2017,
incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017
.
|
10.23
|
10.24
|
Employment Agreement dated as of April 6, 2016 between CNO Financial Group, Inc. and Gary C. Bhojwani,
incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed April 12, 2016
, as amended by Amendment dated as of August 9, 2017,
incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K/A filed on August 11, 2017.
|
10.25*
|
Employment Agreement dated as of April 8, 2016 between CNO Financial Group, Inc. and Erik M. Helding,
incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed April 12, 2016
, as amended by Amendment dated as of August 17, 2017,
incorporated by reference to Exhibit 10.3 of our Current Report on Form 10-Q for the quarter ended September 30, 2017.
|
10.26*
|
10.27*
|
12.1
|
21
|
23.1
|
31.1
|
31.2
|
32.1
|
32.2
|
101.INS
|
XBRL Instance Document.
|
101.SCH
|
XBRL Taxonomy Extension Schema Document.
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document.
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
Page
|
1. Purpose
|
A-3
|
2. Definitions
|
A-3
|
3. Administration
|
A-5
|
4. Stock Subject to Plan
|
A-6
|
5. Eligibility; Per-Person Award Limitations
|
A-7
|
6. Specific Terms of Awards
|
A-7
|
7. Performance-Based Compensation
|
A-12
|
8. Certain Provisions Applicable to Awards
|
A-15
|
9. Change in Control
|
A-16
|
10. Additional Award Forfeiture Provisions
|
A-16
|
11. General Provisions
|
A-18
|
1.
|
Purpose.
The purpose of this Amended and Restated Long-Term Incentive Plan (the
“Plan”
) is to aid CNO Financial Group, Inc., a Delaware corporation (together with its successors and assigns, the
“Company”
), in attracting, retaining, motivating and rewarding certain employees and non-employee directors of the Company or its subsidiaries or affiliates, to provide for equitable and competitive compensation opportunities, to recognize individual contributions and reward achievement of Company goals, and promote the creation of long-term value for stockholders by closely aligning the interests of Participants with those of stockholders. The Plan authorizes stock based incentives for Participants. The Plan was initially established as the Conseco, Inc. 2003 Long-Term Incentive Plan, has been amended from time to time thereafter, and is hereby amended and restated effective upon approval by the stockholders of the Company.
|
2.
|
Definitions.
In addition to the terms defined in Section 1 above and elsewhere in the Plan, the following capitalized terms used in the Plan have the respective meanings set forth in this Section:
|
(a)
|
“
Annual Limit”
shall have the meaning specified in Section 5(b).
|
(b)
|
“
Award”
means any Option, SAR, Restricted Stock, Restricted Stock Unit, Stock granted as a bonus or in lieu of another award, Dividend Equivalent, Other Stock-Based Award or Performance Award, together with any related right or interest, granted to a Participant under the Plan.
|
(c)
|
“
Beneficiary”
means the legal representatives of the Participant’s estate entitled by will or the laws of descent and distribution to receive the benefits under a Participant’s Award upon a Participant’s death, provided that, if and to the extent authorized by the Committee, a Participant may be permitted to designate a Beneficiary, in which case the “Beneficiary” instead will be the person, persons, trust or trusts (if any are then surviving) which have been designated by the Participant in his or her most recent written and duly filed beneficiary designation to receive the benefits specified under the Participant’s Award upon such Participant’s death.
|
(d)
|
“
Board”
means the Company’s Board of Directors.
|
(e)
|
“
Code”
means the Internal Revenue Code of 1986, as amended. References to any provision of the Code or regulation thereunder shall include any successor provisions and regulations, and reference to regulations includes any applicable guidance or pronouncement of the Department of the Treasury and Internal Revenue Service.
|
(f)
|
“
Committee”
means the Human Resources and Compensation Committee of the Board, the composition and governance of which is established in the Committee’s Charter as approved from time to time by the Board and subject to Section 303A.05 of the Listed Company Manual of the New York Stock Exchange, and other corporate governance documents of the Company. No action of the Committee shall be void or deemed to be without authority due to the failure of any member, at the time the action was taken, to meet any qualification standard set forth in the Committee Charter or the Plan. The full Board may perform any function of the Committee hereunder except to the extent limited under Section 303A.05 of the Listed Company Manual, in which case the term “Committee” shall refer to the Board.
|
(g)
|
“
Covered Employee”
means an Eligible Person who is a Covered Employee as specified in Section 11(j).
|
(h)
|
“
Dividend Equivalent”
means a right, granted under this Plan, to receive cash, Stock, other Awards or other property equal in value to all or a specified portion of the dividends paid with respect to a specified number of shares of Stock.
|
(i)
|
“
Effective Date”
means the effective date specified in Section 11(q).
|
(j)
|
“
Eligible Person”
has the meaning specified in Section 5.
|
(k)
|
“
Exchange Act”
means the Securities Exchange Act of 1934, as amended. References to any provision of the Exchange Act or rule (including a proposed rule) thereunder shall include any successor provisions and rules.
|
(l)
|
“Fair Market Value”
means the fair market value of Stock, Awards or other property as determined in good faith by the Committee or under procedures established by the Committee. Unless otherwise determined by the Committee, the Fair Market Value of Stock shall be the officially-quoted closing selling price of the Stock on the principal stock exchange or market on which Stock is traded on the day as of which such value is being determined or, if there is no sale on that day, then on the last previous day on which a sale was reported. Fair Market Value relating to the exercise price or base price of any Non-409A Option or SAR shall conform to requirements under Code Section 409A.
|
(m)
|
“409A Awards”
means Awards that constitute a deferral of compensation under Code Section 409A and regulations thereunder. “
Non-409A Awards
” means Awards other than 409A Awards. Although the Committee retains authority under the Plan to grant Options, SARs and Restricted Stock on terms that will qualify those Awards as 409A Awards, Options, SARs exercisable for Stock, and Restricted Stock will be Non-409A Awards unless otherwise expressly specified by the Committee.
|
(n)
|
“Incentive Stock Option”
or
“ISO”
means any Option designated as an incentive stock option within the meaning of Code Section 422 and qualifying thereunder.
|
(o)
|
“Option”
means a right, granted under the Plan, to purchase Stock.
|
(p)
|
“Other Stock-Based Awards”
means Awards granted to a Participant under Section 6(h).
|
(q)
|
“Participant”
means a person who has been granted an Award under the Plan which remains outstanding, including a person who is no longer an Eligible Person.
|
(r)
|
“Performance Award”
means a conditional right, granted to a Participant under Sections 6(i) and 7, to receive cash, Stock or other Awards or payments.
|
(s)
|
“Restricted Stock”
means Stock granted under the Plan which is subject to certain restrictions and to a risk of forfeiture.
|
(t)
|
“Restricted Stock Unit”
or
“RSU”
means a right, granted under the Plan, to receive Stock, cash or other Awards or a combination thereof at the end of a specified deferral period.
|
(u
)
|
“Retirement”
means, unless otherwise stated in an applicable Award agreement, Participant’s voluntary termination of employment after achieving either (i) 62 years of age or (ii) 60 years of age with at least 10 years of employment with the Company.
|
(v)
|
“Rule 16b-3”
means Rule 16b-3, as from time to time in effect and applicable to Participants, promulgated by the Securities and Exchange Commission under Section 16 of the Exchange Act.
|
(w)
|
“Stock”
means the Company’s Common Stock, par value $0.01 per share, and any other equity securities of the Company that may be substituted or resubstituted for Stock pursuant to Section 11(c).
|
(x)
|
“Stock Appreciation Rights”
or
“
SAR”
means a right granted to a Participant under Section 6(c).
|
(a)
|
Authority of the Committee.
The Plan shall be administered by the Committee, which shall have full and final authority, in each case subject to and consistent with the provisions of the Plan, to select Eligible Persons to become Participants; to grant Awards; to determine the type and number of Awards, the dates on which Awards may be exercised and on which the risk of forfeiture or deferral period relating to Awards shall lapse or terminate, the acceleration of any such dates, the expiration date of any Award, whether, to what extent, and under what circumstances an Award may be settled, or the exercise price of an Award may be paid, in cash, Stock, other Awards, or other property, and other terms and conditions of, and all other matters relating to, Awards; to prescribe documents evidencing or setting terms of Awards (such Award documents need not be identical for each Participant), amendments thereto, and rules and regulations for the administration of the Plan and amendments thereto (including outstanding Awards); to construe and interpret the Plan and Award documents and correct defects, supply omissions or reconcile inconsistencies therein; and to make all other decisions and determinations as the Committee may deem necessary or advisable for the administration of the Plan. Decisions of the Committee with respect to the administration and interpretation of the Plan shall be final, conclusive, and binding upon all persons interested in the Plan, including Participants, Beneficiaries, transferees under Section 11(b) and other persons claiming rights from or through a Participant, and stockholders.
|
(b)
|
Manner of Exercise of Committee Authority.
The express grant of any specific power to the Committee, and the taking of any action by the Committee, shall not be construed as limiting any power or authority of the Committee. The Committee may act through subcommittees, including for purposes of perfecting exemptions under Rule 16b-3 or qualifying Awards under Code Section 162(m) as performance-based compensation, in which case the subcommittee shall be subject to and have authority under the charter applicable to the Committee, and the acts of the subcommittee shall be deemed to be acts of the Committee hereunder. The Committee may delegate the administration of the Plan to one or more officers or employees of the Company, and such administrator(s) may have the authority to execute and distribute Award agreements or other documents evidencing or relating to Awards granted by the Committee under this Plan, to maintain records relating to Awards, to process or oversee the issuance of Stock under Awards, to interpret and administer the terms of Awards, to make grants of Awards to officers (other than any officer subject to Section 16 of the Exchange Act) and employees of the Company (including any prospective officer (other than any such officer who is expected to be subject to Section 16 of the Exchange Act) or employee) subject to an individual maximum annual Award limit as determined and approved at the Compensation Committee’s discretion, and all necessary and appropriate decisions and determinations with respect thereto and to take such other actions as may be necessary or appropriate for the administration of the Plan and of Awards under the Plan, provided that in no case shall any such administrator be authorized (i) to take any action that would result in the loss of an exemption under Rule 16b-3 for Awards granted to or held by Participants who at the time are subject to Section 16 of the Exchange Act in respect of the Company or that would cause Awards intended to qualify as “performance-based compensation” under Code Section 162(m) to fail to so qualify, (ii) to take any action inconsistent with Section 157 and other applicable provisions of the Delaware General Corporation Law, or (iii) to make any determination required to be made by the Committee under the New York Stock Exchange corporate governance standards applicable to listed
|
(c)
|
Limitation of Liability.
The Committee and each member thereof, and any person acting pursuant to authority delegated by the Committee, shall be entitled, in good faith, to rely or act upon any report or other information furnished by any executive officer, other officer or employee of the Company or a subsidiary or affiliate, the Company’s independent auditors, consultants or any other agents assisting in the administration of the Plan. Members of the Committee, any person acting pursuant to authority delegated by the Committee, and any officer or employee of the Company or a subsidiary or affiliate acting at the direction or on behalf of the Committee or a delegee shall not be personally liable for any action or determination taken or made in good faith with respect to the Plan, and shall, to the extent permitted by law, be fully indemnified and protected by the Company with respect to any such action or determination.
|
(a)
|
Overall Number of Shares Available for Delivery.
The total number of shares of Stock reserved for delivery in connection with Awards under this Plan shall be 30,039,505 shares. The total number of shares available is subject to adjustment as provided in Section 11(c). Any shares of Stock delivered under the Plan shall consist of authorized and unissued shares or treasury shares. No more than 10,000,000 shares may be delivered hereunder as ISOs.
|
(b)
|
Share Counting Rules.
The Committee may adopt reasonable counting procedures to ensure appropriate counting, avoid double counting (as, for example, in the case of tandem or substitute awards) and make adjustments in accordance with this Section 4(b). Shares shall be counted against those reserved to the extent such shares have been delivered and are no longer subject to a risk of forfeiture; provided, however, that notwithstanding the above, the number of shares available for issuance under the Plan shall be reduced by 1.25 shares of Stock for every one share of Stock issued in respect of an Award other than an Award of an Option, SAR, or Award that must be settled in cash. To the extent that an Award under the Plan is canceled, expired, forfeited, settled in cash, or otherwise terminated without delivery of shares to the Participant, the shares retained by or returned to the Company will be available under the Plan. The preceding sentence shall not be applicable with respect to (i) the cancellation of an SAR granted in tandem with an Option upon the exercise of the Option or (ii) the cancellation of an Option granted in tandem with an SAR upon the exercise of the SAR. The following shares, however, may not be made available for issuance as Awards under this Plan: (a) shares not issued or delivered as a result of the net settlement of an outstanding Option or SAR, (b) shares used to pay the exercise price or withholding taxes related to an outstanding Award, or (c) shares repurchased on the open market with the proceeds from the exercise of an Option. In addition, in the case of any Award granted in assumption of or in substitution for an award of a company or business acquired by the Company or a subsidiary or affiliate or with which the Company or a subsidiary or affiliate combines, shares issued or issuable in connection with such substitute Award shall not be counted against the number of shares reserved under the Plan.
|
(a)
|
E
ligibility.
Awards may be granted under the Plan only to Eligible Persons. For purposes of the Plan, an “Eligible Person” means (i) an employee of the Company or any subsidiary or affiliate, including any person who has been offered employment by the Company or a subsidiary or affiliate, provided that such prospective employee may not receive any payment or exercise any right relating to an Award until such person has commenced employment with the Company or a subsidiary or affiliate, (ii) any non-employee directors of the Company or (iii) other individuals who perform services for the Company or any subsidiary or affiliate. An employee on leave of absence may be considered as still in the employ of the Company or a subsidiary or affiliate for purposes of eligibility for participation in the Plan, if so determined by the Committee. For purposes of the Plan, a joint venture in which the Company or a subsidiary has a substantial direct or indirect equity investment shall be deemed an affiliate, if so determined by the Committee. Holders of awards who will become Eligible Persons granted by a company or business acquired by the Company or a subsidiary or affiliate, or with which the Company or a subsidiary or affiliate combines, are eligible for grants of substitute awards granted in assumption of or in substitution for such outstanding awards previously granted under the Plan in connection with such acquisition or combination transaction, if so determined by the Committee.
|
(b)
|
Per-Person Award Limitations.
In each calendar year during any part of which the Plan is in effect, an Eligible Person may be granted Awards under each of Section 6(b) through (i) relating to up to his or her Annual Limit (such Annual Limit to apply separately to the type of Award authorized under each specified subsection). A Participant’s Annual Limit, in any year during any part of which the Participant is then eligible under the Plan, shall equal 1,000,000 shares, subject to adjustment as provided in Section 11(c). In the case of an Award which is not valued in a way in which the limitation set forth
in the preceding sentence would operate as an effective limitation satisfying applicable law (including Treasury Regulation 1.162-27(e)(4)), an Eligible Person may not be granted Awards authorizing the earning during any calendar year of an amount that exceeds the Eligible Person’s Annual Limit, which for this purpose shall equal $4 million (this limitation is separate and not affected by the number of Awards granted during such calendar year subject to the limitation in the preceding sentence). For this purpose, (i) “earning” means satisfying performance conditions so that an amount becomes payable, without regard to whether it is to be paid currently or on a deferred basis or continues to be subject to any service requirement or other non-performance condition, and (ii) a Participant’s Annual Limit is used to the extent an amount or number of shares may be potentially earned or paid under an Award, regardless of whether such amount or shares are in fact earned or paid. Additionally, the maximum number of shares of Stock subject to Awards granted during a single calendar year to any non-employee director, taken together with any cash or other fees earned by such non-employee director during such calendar year, shall not exceed (i) $500,000 in total value in the case of non-employee directors other than the Board Chair or Lead Director or (ii) $950,000 in total value in the case of the Board Chair or Lead Director (in each case, calculating the value of any such Awards based on the grant date fair value of such Awards for financial reporting purposes).
|
(a)
|
General.
Awards may be granted on the terms and conditions set forth in this Section 6. In addition, the Committee may impose on any Award or the exercise thereof, at the date of grant or thereafter (subject to Sections 11(e) and 11(k)), such additional terms and conditions, not inconsistent with the provisions of the Plan, as the Committee shall determine, including terms requiring forfeiture of Awards in the event of termination of employment or service by the Participant and terms permitting a Participant to make elections relating to his or her Award. The Committee shall retain full power and discretion with respect to any term or condition of an Award that is not mandatory under the Plan, subject to Section 11(k). The Committee shall require the payment of lawful consideration for an Award to the extent necessary to satisfy the
|
(b)
|
Options.
The Committee is authorized to grant Options to Participants on the following terms and conditions:
|
(i)
|
Exercise Price.
The exercise price per share of Stock purchasable under an Option (including both ISOs and non-qualified Options) shall be determined by the Committee, provided that, notwithstanding anything contained herein to the contrary such exercise price shall be (A) fixed as of the grant date, and (B) not less than the Fair Market Value of a share of Stock on the grant date. Notwithstanding the foregoing, any substitute award granted in assumption of or in substitution for an outstanding award granted by a company or business acquired by the Company or a subsidiary or affiliate, or with which the Company or a subsidiary or affiliate combines, may be granted with an exercise price per share of Stock other than as required above.
|
(ii)
|
No Repricing.
Except for adjustments as permitted by Section 11(c), without the approval of stockholders, the Committee will not amend, replace, substitute, or exchange previously granted Options in a transaction that constitutes a “repricing,” which means any of the following: (i) changing the terms of an Option to lower its exercise price; (ii) any other action that is treated as a “repricing” under generally accepted accounting principles; (iii) repurchasing for cash or canceling an Option at a time when its exercise price is greater than the Fair Market Value of the underlying shares of Stock in exchange for another Award; or (iv) as such term is used in Section 303A.08 of the Listed Company Manual of the New York Stock Exchange.
|
(iii)
|
Option Term; Time and Method of Exercise.
The Committee shall determine the term of each Option, provided that in no event shall the term of any Option exceed a period of ten years from the date of grant. The Committee shall determine the time or times at which or the circumstances under which an Option may be exercised in whole or in part. In addition, the Committee shall determine the methods by which such exercise price may be paid or deemed to be paid and the form of such payment (subject to Sections 11(k) and 11(l)), including, without limitation, cash, Stock (including by withholding Stock deliverable upon exercise), other Awards or awards granted under other plans of the Company or any subsidiary or affiliate, or other property (including through broker-assisted “cashless exercise” arrangements, to the extent permitted by applicable law), and the methods by or forms in which Stock will be delivered or deemed to be delivered in satisfaction of Options to Participants.
|
(iv)
|
ISOs.
Notwithstanding anything to the contrary in this Section 6, in the case of the grant of an Option intending to qualify as an ISO: (i) if the Participant owns stock possessing more than 10 percent of the combined voting power of all classes of stock of the Company (a “10% Shareholder”), the purchase price of such Option must be at least 110 percent of the fair market value of the Common Stock on the date of grant and the Option must expire within a period of not more than five (5) years from the date of grant, and (ii) termination of employment will occur when the person to whom an Award was granted ceases to be an employee (as determined in accordance with Section 3401(c) of the Code and the regulations promulgated thereunder) of the Company and its subsidiaries. Notwithstanding anything in this Section 6 to the contrary, Options designated as ISOs shall not be eligible for treatment under the Code as ISOs to the extent that either (iii) the aggregate fair market value of shares of Common Stock (determined as of the time of grant) with respect to which such Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Subsidiary) exceeds $100,000, taking Options into account in the order in which they were granted, and (iv) such Options otherwise remain
|
(v)
|
Minimum Vesting.
Options may not vest earlier than the first anniversary of the grant date (or the grantee’s commencement of service)(if such grant is made in connection with such commencement), The foregoing minimum vesting condition need not apply (A) in the case of the death, disability or Retirement of the Participant or termination in connection with a Change in Control and (B) with respect to up to an aggregate of five percent of the shares of Stock authorized under the Plan, which may be granted (or regranted upon forfeiture) as Options without regard to such minimum vesting requirements.
|
(c)
|
Stock Appreciation Rights.
The Committee is authorized to grant SARs to Participants on the following terms and conditions:
|
(i)
|
Right to Payment.
An SAR shall confer on the Participant to whom it is granted a right to receive, upon exercise thereof, shares of Stock having a value equal to the excess of (A) the Fair Market Value of one share of Stock on the date of exercise (or, in the case of a “Limited SAR,” the Fair Market Value determined by reference to the change in control price, as defined under the applicable award agreement) over (B) the exercise or settlement price of the SAR as determined by the Committee. Stock Appreciation Rights may be granted to Participants from time to time either in tandem with or as a component of other Awards granted under the Plan (“tandem SARs”) or not in conjunction with other Awards (“freestanding SARs”) and may, but need not, relate to a specific Option granted under Section 6(b). The per share price for exercise or settlement of SARs (including both tandem SARs and freestanding SARs) shall be determined by the Committee, but in the case of SARs that are granted in tandem to an Option shall not be less than the exercise price of the Option and in the case of freestanding SARs shall be (A) fixed as of the grant date, and (B) not less than the Fair Market Value of a share of Stock on the grant date.
|
(ii)
|
No Repricing.
Except for adjustments as permitted by Section 11(c), without the approval of stockholders, the Committee will not amend, replace, substitute, or exchange previously granted SARs in a transaction that constitutes a “repricing,” which means any of the following (i) changing the terms of an SAR to lower its exercise or settlement price; (ii) any other action that is treated as a “repricing” under generally accepted accounting principles; (iii) repurchasing for cash or canceling an SAR at a time when its exercise or settlement price is greater than the Fair Market Value of the underlying shares of Stock in exchange for another Award; or (iv) as such term is used in Section 303A.08 of the Listed Company Manual of the New York Stock Exchange.
|
(iii)
|
Other Terms.
The Committee shall determine the term of each SAR, provided that in no event shall the term of an SAR exceed a period of ten years from the date of grant. The Committee shall determine at the date of grant or thereafter, the time or times at which and the circumstances under which a SAR may be exercised in whole or in part (including based on future service requirements), the method of exercise, method of settlement, method by or forms in which Stock will be delivered or deemed to be delivered to Participants, and whether or not a SAR shall be free-standing or in tandem or combination with any other Award. Limited SARs that may only be exercised in connection with a change in control or termination of service following a change in control as specified by the Committee may be granted on such terms, not inconsistent with this Section 6(c), as the Committee may determine
.
The Committee may require that an outstanding Option be exchanged for an SAR exercisable for Stock having vesting, expiration, and other terms substantially the same as the Option, so long as such exchange will not result in additional accounting expense to the Company.
|
(iv)
|
Minimum Vesting.
SARs may not vest earlier than the first anniversary of the grant date (or the grantee’s commencement of service)(if such grant is made in connection with such commencement), The foregoing minimum vesting condition need not apply (A) in the case of the death, disability or Retirement of the Participant or termination in connection with a Change in Control, and (B) with respect to up to an aggregate of five percent of the shares of Stock authorized under the Plan, which may be granted (or regranted upon forfeiture) as SARs without regard to such minimum vesting requirements.
|
(d)
|
Restricted Stock.
The Committee is authorized to grant Restricted Stock to Participants on the following terms and conditions:
|
(i)
|
Award and Restrictions.
Subject to Section 6(d)(ii), Restricted Stock shall be subject to such restrictions on transferability, risk of forfeiture and other restrictions, if any, as the Committee may impose, which restrictions may lapse separately or in combination at such times, under such circumstances, in such installments or otherwise and under such other circumstances as the Committee may determine at the date of grant or thereafter. Except to the extent restricted under the terms of the Plan and any Award document relating to the Restricted Stock, a Participant granted Restricted Stock shall have all of the rights of a stockholder, including the right to vote the Restricted Stock and the right to receive dividends thereon (subject to any mandatory reinvestment or other requirement imposed by the Committee).
|
(ii)
|
Forfeiture.
Except as otherwise determined by the Committee, upon termination of employment or service during the applicable restriction period, Restricted Stock that is at that time subject to restrictions shall be forfeited and reacquired by the Company; provided that the Committee may provide, by rule or regulation or in any Award document, or may determine in any individual case, that restrictions or forfeiture conditions relating to Restricted Stock will lapse in whole or in part, including in the event of terminations resulting from specified causes.
|
(iii)
|
Limitation on Vesting.
The grant, issuance, retention, vesting and/or settlement of Restricted Stock shall occur at such time and in such installments as determined by the Committee or under criteria established by the Committee. Subject to Section 10, the Committee shall have the right to make the timing of the grant and/or the issuance, ability to retain, vesting and/or settlement of Restricted Stock subject to continued employment, passage of time and/or such performance conditions as deemed appropriate by the Committee; provided that the grant, issuance, retention, vesting and/or settlement of a Restricted Stock Award that is based in whole or in part on performance conditions and/or the level of achievement versus such performance conditions shall be subject to a performance period of not less than one year, and any Award based solely upon continued employment or the passage of time shall vest over a period not less than three years, with no portion vesting in less than one year, from the date the Award is made, provided that such vesting may occur ratably over the three-year period. The foregoing minimum vesting conditions need not apply (A) in the case of the death, disability or Retirement of the Participant or termination in connection with a Change in Control and (B) with respect to up to an aggregate of five percent of the shares of Stock authorized under the Plan, which may be granted (or regranted upon forfeiture) as Restricted Stock or RSUs without regard to such minimum vesting requirements.
|
(iv)
|
Certificates for Stock.
Restricted Stock granted under the Plan may be evidenced in such manner as the Committee shall determine. If certificates representing Restricted Stock are registered in the name of the Participant, the Committee may require that such certificates bear an appropriate legend referring to the terms, conditions and restrictions applicable to such Restricted Stock, that the Company retain physical possession of the certificates, and
|
(v)
|
Dividends and Splits.
As a condition to the grant of an Award of Restricted Stock on or after the Effective Date of the Plan, the Committee shall require that any dividends paid on a share of Restricted Stock shall be held in an account for the benefit of the Participant, to be paid out only upon vesting of such Restricted Stock, or automatically reinvested in additional Restricted Stock, which shall be subject to the same terms as applied to the original Restricted Stock to which it relates. Unless otherwise determined by the Committee, Stock distributed in connection with a Stock split or Stock dividend, and other property distributed as a dividend, shall be subject to restrictions and a risk of forfeiture to the same extent as the Restricted Stock with respect to which such Stock or other property has been distributed.
|
(e)
|
Restricted Stock Units.
The Committee is authorized to grant RSUs to Participants, subject to the following terms and conditions:
|
(i)
|
Award and Restrictions.
Subject to Section 6(e)(ii), RSUs shall be subject to such restrictions on transferability, risk of forfeiture and other restrictions, if any, as the Committee may impose, which restrictions may lapse separately or in combination at such times, under such circumstances (including based on achievement of performance conditions and/or future service requirements), in such installments or otherwise and under such other circumstances as the Committee may determine at the date of grant or thereafter. A Participant granted RSUs shall not have any of the rights of a stockholder, including the right to vote, until Stock shall have been issued in the Participant’s name pursuant to the RSUs, except that the Committee may provide for dividend equivalents pursuant to Section 6(e)(iii) below.
|
(ii)
|
Limitation on Vesting.
The grant, issuance, retention, vesting and/or settlement of RSUs shall occur at such time and in such installments as determined by the Committee or under criteria established by the Committee. Subject to Section 10, the Committee shall have the right to make the timing of the grant and/or the issuance, ability to retain, vesting and/or settlement of RSUs subject to continued employment, passage of time and/or such performance conditions as deemed appropriate by the Committee; provided that the grant, issuance, retention, vesting and/or settlement of an RSU that is based in whole or in part on performance conditions and/or the level of achievement versus such performance conditions shall be subject to a performance period of not less than one year, and any Award based solely upon continued employment or the passage of time shall vest over a period not less than three years from the date the Award is made, provided that such vesting may occur ratably over the three-year period. RSUs may not vest earlier than the first anniversary of the grant date (or the grantee’s commencement of service,if such grant is made in connection with such commencement). The foregoing minimum vesting conditions need not apply (A) in the case of the death, disability or Retirement of the Participant or termination in connection with a Change in Control, and (B) with respect to up to an aggregate of five percent of the shares of Stock authorized under the Plan, which may be granted (or regranted upon forfeiture) as Restricted Stock or RSUs without regard to such minimum vesting requirements.
|
(iii)
|
Dividend Equivalents.
As a condition to the grant of an Award of RSUs on or after the Effective Date of the Plan, Dividend Equivalents on the specified number of shares of Stock covered by an Award of RSUs shall be payable only upon vesting of such RSUs, or deferred with respect to such RSUs, either as a cash deferral or with the amount or value thereof automatically deemed reinvested in additional RSUs, other Awards or other investment vehicles having a Fair Market Value equal to the amount of such dividends, as the Committee shall determine or permit a Participant to elect.
|
(f)
|
Bonus Stock and Awards in Lieu of Obligations.
The Committee is authorized to grant Stock as a bonus, or to grant Stock or other Awards in lieu of obligations of the Company or a subsidiary or affiliate to pay cash or deliver other property under the Plan or under other plans or compensatory arrangements, subject to such terms as shall be determined by the Committee.
|
(g)
|
Dividend Equivalents.
The Committee is authorized to grant Dividend Equivalents to a Participant, which may be awarded on a free-standing basis or in connection with another Award other than an Option, ISO, or SAR. The Committee may provide that Dividend Equivalents shall be held in an account for the benefit of the Participant, to be paid out upon vesting of such Award or shall be deemed to have been reinvested in additional Stock, Awards, or other investment vehicles, and subject to restrictions on transferability, risks of forfeiture and such other terms as the Committee may specify. Notwithstanding the foregoing, the Committee may not payout any dividends or Dividend Equivalents with respect to any unvested Award under this Plan.
|
(h)
|
Other Stock-Based Awards.
The Committee is authorized, subject to limitations under applicable law, to grant to Participants such other Awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, Stock or factors that may influence the value of Stock, including, without limitation, convertible or exchangeable debt securities, other rights convertible or exchangeable into Stock, purchase rights for Stock, Awards with value and payment contingent upon performance of the Company or business units thereof or any other factors designated by the Committee, and Awards valued by reference to the book value of Stock or the value of securities of or the performance of specified subsidiaries or affiliates or other business units. The Committee shall determine the terms and conditions of such Awards. Stock delivered pursuant to an Award in the nature of a purchase right granted under this Section 6(h) shall be purchased for such consideration, paid for at such times, by such methods, and in such forms, including, without limitation, cash, Stock, other Awards, notes, or other property, as the Committee shall determine. Any such other Stock-based Award that is based in whole or in part on performance conditions and/or the level of achievement versus such performance conditions shall be subject to a performance period of not less than one year, and any such other Stock-based Award based solely on continued employment or the passage of time shall vest over a period of not less than three years, with no portion vesting in less than one year, from the date the Award is made, provided that such vesting may occur ratably over the three-year period. The foregoing minimum vesting conditions need not apply (A) in the case of the death, disability or Retirement of the Participant or termination in connection with a Change in Control and (B) with respect to up to an aggregate of five percent of the shares of Stock authorized under the Plan, which may be granted (or regranted upon forfeiture) as other Awards without regard to such minimum vesting requirements. Cash awards, as an element of or supplement to any other Award under the Plan, may also be granted pursuant to this Section 6(h).
|
(i)
|
Performance Awards.
Performance Awards, denominated in cash or in Stock or other Awards, may be granted by the Committee in accordance with Section 7.
|
(a)
|
Performance Awards Generally.
Performance Awards may be denominated as a cash amount, number of shares of Stock, or specified number of other Awards (or a combination) which may be earned upon achievement or satisfaction of performance conditions specified by the Committee. In addition, the Committee may specify that any other Award shall constitute a Performance Award by conditioning the right of a Participant to exercise the Award or have it settled, and the timing thereof, upon achievement or satisfaction of such performance conditions as may be specified by the Committee. The Committee may use such business criteria and other measures of performance as it may deem appropriate in establishing any performance
|
(b)
|
Performance Awards Granted to Covered Employees.
If the Committee determines that a Performance Award to be granted to an Eligible Person who is designated by the Committee as likely to be a Covered Employee should qualify as “performance-based compensation” for purposes of Section 162(m), the grant, exercise and/or settlement of such Performance Award shall be contingent upon achievement of a pre-established performance goal and other terms set forth in this Section 7(b).
|
(i)
|
Performance Goal Generally.
The performance goal for such Performance Awards shall consist of one or more business criteria and a targeted level or levels of performance with respect to each of such criteria, as specified by the Committee consistent with this Section 7(b). The performance goal shall be objective and shall otherwise meet the requirements of Code Section 162(m) and regulations thereunder, including the requirement that the level or levels of performance targeted by the Committee result in the achievement of performance goals being “substantially uncertain.” The Committee may determine that such Performance Awards shall be granted, exercised and/or settled upon achievement of any one performance goal or that two or more of the performance goals must be achieved as a condition to grant, exercise and/or settlement of such Performance Awards. Performance goals may differ for Performance Awards granted to any one Participant or to different Participants.
|
(ii)
|
Business Criteria.
For purposes of this Plan, a “performance goal” shall mean any one or more of the following business criteria, in each case as specified by the Committee: (1) gross or net revenue, premiums collected, new annualized premiums, and investment income, (2) any earnings or net income measure, including earnings from operations, earnings before taxes, earnings before interest and/or taxes and/or depreciation, statutory earnings before realized gains (losses), or net income available to common shareholders, (3) operating earnings per common share (either basic or diluted); (4) return on assets, return on investment, return on capital, return on equity, or return on tangible equity; (5) economic value created including the value of new business; (6) operating margin or profit margin; (7) net interest margin; (8) asset quality; (9) stock price or total stockholder return; and (10) strategic business criteria, consisting of one or more objectives based on meeting specified market penetration, total market capitalization, business retention, new product generation, rate increase actions, geographic business expansion goals, cost targets (including cost of capital), investment portfolio yield, risk-based capital, statutory capital, Best Capital Adequacy Ratio, tax net operating loss utilization, customer satisfaction, employee satisfaction, agency ratings, management of employment practices and employee benefits, supervision of litigation and information technology, and goals relating to acquisitions or divestitures of subsidiaries, affiliates or joint ventures.
The targeted level or levels of performance with respect to such business criteria may be established at such levels and in such terms as the Committee may determine, in its discretion, including in absolute terms, on a per share basis (either basic or diluted), as a goal relative to performance in prior periods, or as a goal compared to the performance of one or more comparable companies or an index covering multiple companies.
|
(iii)
|
Performance Period; Timing for Establishing Performance Goals.
Achievement of performance goals in respect of such Performance Awards shall be measured over a performance period of up to one year or more than one year, as specified by the Committee. A performance goal shall be established not later than the earlier of (A) 90 days after the beginning of any performance period applicable to such Performance Award or (B) the time twenty-five percent of such performance period has elapsed.
|
(iv)
|
Performance Award Pool.
The Committee may establish a Performance Award pool, which shall be an unfunded pool, for purposes of measuring performance of the Company in connection with Performance Awards. The amount of such Performance Award pool shall be based upon the achievement of a performance goal or goals based on one or more of the business criteria set forth in Section 7(b)(ii) during the given performance period, as specified by the Committee in accordance with Section 7(b)(iv). The Committee may specify the amount of the Performance Award pool as a percentage of any of such business criteria, a percentage thereof in excess of a threshold amount, or as another amount which need not bear a strictly mathematical relationship to such business criteria.
|
(v)
|
Settlement of Performance Awards; Other Terms.
Settlement of Performance Awards shall be in cash, Stock, other Awards or other property, in the discretion of the Committee. The Committee may, in its discretion, increase or reduce the amount of a settlement otherwise to be made in connection with such Performance Awards, but may not exercise discretion to increase any such amount payable to a Covered Employee in respect of a Performance Award subject to this Section 7(b). Any settlement which changes the form of payment from that originally specified shall be implemented in a manner such that the Performance Award and other related Awards do not, solely for that reason, fail to qualify as “performance-based compensation” for purposes of Section 162(m). The Committee shall specify the circumstances in which such Performance Awards shall be paid or forfeited in the event of termination of employment by the Participant or other event (including a change in control) prior to the end of a performance period or settlement of such Performance Awards.
|
(vi)
|
Recapture Rights.
If at any time after the date on which a Participant has been granted or becomes vested in an Award pursuant to the achievement of a performance goal under Section 7, the Committee determines that the earlier determination as to the achievement of the performance goal was based on incorrect data and that in fact the performance goal had not been achieved or had been achieved to a lesser extent than originally determined and a portion of an Award would not have been granted, vested or paid, given the correct data, then (i) such portion of the Award that was granted shall be forfeited and any related shares (or if such shares were disposed of the cash equivalent) shall be returned to the Company as provided by the Committee, (ii) such portion of the Award that became vested shall be deemed to be not vested and any related shares (or if such shares were disposed of the cash equivalent) shall be returned to the Company as provided by the Committee, and (iii) such portion of the Award paid to the Participant shall be paid by the Participant to the Company upon notice from the Company as provided by the Committee.
|
(c)
|
Written Determinations.
Determinations by the Committee as to the establishment of performance goals, the amount potentially payable in respect of Performance Awards, the level of actual achievement of the specified performance goals shall be recorded in writing in the case of Performance Awards intended to qualify under Section 162(m). Specifically, the Committee shall certify in writing, in a manner conforming to applicable regulations under Section 162(m), prior to settlement of each such Award granted to a Covered Employee, that the performance
|
(a)
|
Stand-Alone, Additional, Tandem, and Substitute Awards.
Subject to the provisions of Sections 6(b)(ii) and 6(c)(ii), awards granted under the Plan may, in the discretion of the Committee, be granted either alone or in addition to, in tandem with, or in substitution or exchange for, any other Award or any award granted under another plan of the Company, any subsidiary or affiliate, or any business entity to be acquired by the Company or a subsidiary or affiliate, or any other right of a Participant to receive payment from the Company or any subsidiary or affiliate; provided, however, that a 409A Award may not be granted in tandem with a Non-409A Award. Awards granted in addition to or in tandem with other Awards or awards may be granted either as of the same time as or a different time from the grant of such other Awards or awards. Subject to Sections 11(k) and (l), the Committee may determine that, in granting a new Award, the in-the-money value or fair value of any surrendered Award or award or the value of any other right to payment surrendered by the Participant may be applied to reduce the exercise price of any Option, grant price of any SAR, or purchase price of any other Award.
|
(b)
|
Term of Awards.
The term of each Award shall be for such period as may be determined by the Committee, subject to the express limitations set forth in the Plan.
|
(c)
|
Form and Timing of Payment under Awards; Deferrals.
Subject to the terms of the Plan (including Sections 11(k) and (l)) and any applicable Award document, payments to be made by the Company or a subsidiary or affiliate upon the exercise of an Option or other Award or settlement of an Award may be made in such forms as the Committee shall determine, including, without limitation, cash, Stock, other Awards or other property, and may be made in a single payment or transfer, in installments, or on a deferred basis. The settlement of any Award may be accelerated, and cash paid in lieu of Stock in connection with such settlement, in the discretion of the Committee or upon occurrence of one or more specified events, subject to Sections 11(k) and (l). Subject to Section 11(k), installment or deferred payments may be required by the Committee (subject to Section 11(e)) or permitted at the election of the Participant on terms and conditions established by the Committee. Payments may include, without limitation, provisions for the payment or crediting of reasonable interest on installment or deferred payments or the grant or crediting of Dividend Equivalents or other amounts in respect of installment or deferred payments denominated in Stock. In the case of any 409A Award that is vested and no longer subject to a risk of forfeiture (within the meaning of Code Section 83), such Award will be distributed to the Participant, upon application of the Participant, if the Participant has had an unforeseeable emergency within the meaning of Code Sections 409A(a)(2)(A)(vi) and 409A(a)(2)(B)(ii), in accordance with Section 409A(a)(2)(B)(ii).
|
(d)
|
Limitation on Vesting of Certain Awards.
Subject to Section 8, Restricted Stock will vest over a minimum period of three years, with no portion vesting in less than one year, except in the event of a Participant’s death, disability, or retirement, or in the event of a change in control or other special circumstances. The foregoing notwithstanding, Restricted Stock as to which either the grant or vesting is based on, among other things, the achievement of one or more performance conditions generally will vest over a minimum period of one year except in the event of a Participant’s death, disability, or retirement, or in the event of a change in control or other special circumstances, and provided further up to five percent of the shares of Stock authorized under the Plan including non-employee director awards may be granted as Restricted Stock without any minimum vesting requirements. For purposes of this Section 8(d), a performance period that precedes the grant of the Restricted Stock will be treated as part of the
|
(e)
|
Cash Settlement of Awards.
To the extent permitted by the Committee at the time of grant or thereafter, the Company may deliver cash in full or partial satisfaction, payment and/or settlement upon exercise, cancellation, forfeiture or surrender of any Award.
|
9.
|
Change in Control.
The Committee may set forth in any Award Agreement the effect, if any, that a change in control or other, similar transaction shall have on any awards granted under this Plan.
|
10.
|
Additional Award Forfeiture Provisions.
|
(a)
|
Forfeiture of Options and Other Awards and Gains Realized Upon Prior Option Exercises or Award Settlements.
Unless otherwise determined by the Committee, each Award granted hereunder, other than Awards granted to non-employee directors, shall be subject to the following additional forfeiture conditions, to which the Participant, by accepting an Award hereunder, agrees. If any of the events specified in Section 10(b)(i), (ii), or (iii) occurs (a
“Forfeiture Event”
), all of the following forfeitures will result:
|
(i)
|
The unexercised portion of each Option held by the Participant, whether or not vested, and any other Award not then settled will be immediately forfeited and canceled upon the occurrence of the Forfeiture Event; and
|
(ii)
|
The Participant will be obligated to repay to the Company, in cash, within five business days after demand is made therefore by the Company, the total amount of Award Gain (as defined herein) realized by the Participant upon each exercise of an Option or settlement of an Award that occurred on or after (A) the date that is six months prior to the occurrence of the Forfeiture Event, if the Forfeiture Event occurred while the Participant was employed by the Company or a subsidiary or affiliate, or (B) the date that is six months prior to the date the Participant’s employment by the Company or a subsidiary or affiliate terminated, if the Forfeiture Event occurred after the Participant ceased to be so employed. For purposes of this Section, the term “Award Gain” shall mean (i), in respect of a given Option exercise, the product of (X) the Fair Market Value per share of Stock at the date of such exercise (without regard to any subsequent change in the market price of shares) minus the exercise price times (Y) the number of shares as to which the Option was exercised at that date, and (ii), in respect of any other settlement of an Award granted to the Participant, the Fair Market Value of the cash or Stock paid or payable to Participant (regardless of any elective deferral) less any cash or the Fair Market Value of any Stock or property (other than an Award or award which would have itself then been forfeitable hereunder and excluding any payment of tax withholding) paid by the Participant to the Company as a condition of or in connection such settlement.
|
(b)
|
Events Triggering Forfeiture.
The forfeitures specified in Section 10(a) will be triggered upon the occurrence of any one of the following Forfeiture Events at any time during Participant’s employment by the Company or a subsidiary or affiliate, or during the one-year period following termination of such employment:
|
(i)
|
Participant, acting alone or with others, directly or indirectly, (A) engages, either as employee, employer, consultant, advisor, or director, or as an owner, investor, partner, or stockholder unless Participant’s interest is insubstantial, in any business in an area or region in which the Company conducts business at the date the event occurs, which is directly in
|
(ii)
|
Participant discloses, uses, sells, or otherwise transfers, except in the course of employment with or other service to the Company or any subsidiary or affiliate, any confidential or proprietary information of the Company or any subsidiary or affiliate, including but not limited to information regarding the Company’s current and potential customers, organization, employees, finances, and methods of operations and investments, so long as such information has not otherwise been disclosed to the public or is not otherwise in the public domain (other than by Participant’s breach of this provision), except as required by law or pursuant to legal process, or Participant makes statements or representations, or otherwise communicates, directly or indirectly, in writing, orally, or otherwise, or takes any other action which may, directly or indirectly, disparage or be damaging to the Company or any of its subsidiaries or affiliates or their respective officers, directors, employees, advisors, businesses or reputations, except as required by law or pursuant to legal process; or
|
(iii)
|
Participant fails to cooperate with the Company or any subsidiary or affiliate in any way, including, without limitation, by making himself or herself available to testify on behalf of the Company or such subsidiary or affiliate in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, or otherwise fails to assist the Company or any subsidiary or affiliate in any way, including, without limitation, in connection with any such action, suit, or proceeding by providing information and meeting and consulting with members of management of, other representatives of, or counsel to, the Company or such subsidiary or affiliate, as reasonably requested.
|
(c)
|
Agreement Does Not Prohibit Competition or Other Participant Activities.
Although the conditions set forth in this Section 10 shall be deemed to be incorporated into an Award, a Participant is not thereby prohibited from engaging in any activity, including but not limited to competition with the Company and its subsidiaries and affiliates. Rather, the non-occurrence of the Forfeiture Events set forth in Section 10(b) is a condition to the Participant’s right to realize and retain value from his or her compensatory Options and Awards, and the consequence under the Plan if the Participant engages in an activity giving rise to any such Forfeiture Event are the forfeitures specified herein. The Company and Participant shall not be precluded by this provision or otherwise from entering into other agreements concerning the subject matter of Sections 10(a) and 10(b).
|
(d)
|
Committee Discretion.
The Committee may, in its discretion, waive in whole or in part the Company’s right to forfeiture under this Section, but no such waiver shall be effective unless evidenced by a writing signed by a duly authorized officer of the Company. In addition, the Committee may impose additional conditions on Awards, by inclusion of appropriate provisions in the document evidencing or governing any such Award.
|
11.
|
General Provisions.
|
(a)
|
Compliance with Legal and Other Requirements.
The Company may, to the extent deemed necessary or advisable by the Committee and subject to Section 11(k), postpone the issuance or delivery of Stock or payment of other benefits under any Award until completion of such registration or qualification of such Stock or other required action under any federal or state law, rule or regulation, listing or other required action with respect to any stock exchange or automated quotation system upon which the Stock or other securities of the Company are listed or quoted, or compliance with any other obligation of the Company, as the Committee may consider appropriate, and may require any Participant to make such representations, furnish such information and comply with or be subject to such other conditions as it may consider appropriate in connection with the issuance or delivery of Stock or payment of other benefits in compliance with applicable laws, rules, and regulations, listing requirements, or other obligations.
|
(b)
|
Limits on Transferability; Beneficiaries.
No Award or other right or interest of a Participant under the Plan shall be pledged, hypothecated or otherwise encumbered or subject to any lien, obligation or liability of such Participant to any party (other than the Company or a subsidiary or affiliate thereof), or assigned or transferred by such Participant otherwise than by will or the laws of descent and distribution or to a Beneficiary upon the Participant’s death, and such Awards or rights that may be exercisable shall be exercised during the lifetime of the Participant only by the Participant or his or her guardian or legal representative. A Beneficiary, transferee, or other person claiming any rights under the Plan from or through any Participant shall be subject to all terms and conditions of the Plan and any Award document applicable to such Participant, except as otherwise determined by the Committee, and to any additional terms and conditions deemed necessary or appropriate by the Committee.
|
(c)
|
Adjustments.
In the event of any large, special and non-recurring dividend or other distribution (whether in the form of cash or property other than Stock), recapitalization, forward or reverse split, Stock dividend, reorganization, merger, consolidation, spin-off, combination, repurchase, share exchange, liquidation, dissolution or other similar corporate transaction or event, the Committee, in order to prevent dilution or enlargement of a Participant’s rights under this Plan shall, in an equitable manner as determined by the Committee, adjust any or all of (i) the number and kind of shares of Stock or other securities of the Company or other issuer which are subject to the Plan, (ii) the number and kind of shares of Stock or other securities of the Company or other issuer by which annual per-person Award limitations are measured under Section 5, including the share limits applicable to non-employee director Awards under Section 5(c), (iii) the number and kind of shares of Stock or other securities of the Company or other issuer subject to or deliverable in respect of outstanding Awards and (iv) the exercise price, settlement price or purchase price relating to any Award or, if deemed appropriate, the Committee may make provision for a payment of cash or property to the holder of an outstanding Option (subject to Section 11(l)) or other Award. In addition, the Committee is authorized to make adjustments in the terms and conditions of, and the criteria included in, Awards (including performance-based Awards and performance goals and any hypothetical funding pool relating thereto) in recognition of unusual or nonrecurring events (including, without limitation, events described in the preceding sentence, as well as acquisitions and dispositions of businesses and assets, or in response to changes in applicable laws, regulations, or accounting principles) affecting any performance conditions; provided that no such adjustment shall be authorized or made if and to the extent that the existence of such authority (i) would cause Options, SARs, or Performance Awards granted under the Plan to Participants designated by the Committee as Covered Employees and intended to qualify as “performance-based compensation” under Code Section 162(m) and regulations thereunder to otherwise fail to qualify as “performance-based compensation” under Code Section 162(m) and regulations thereunder, or (ii) would cause the Committee to be deemed to have authority to change the targets, within the meaning of Treasury Regulation 1.162-27(e)(4)(vi), under the performance
|
(d)
|
Tax Provisions.
|
(i)
|
Withholding.
The Company and any subsidiary or affiliate is authorized to withhold from any Award granted, any payment relating to an Award under the Plan, including from a distribution of Stock, or any payroll or other payment to a Participant, amounts of withholding and other taxes due or potentially payable in connection with any transaction or event involving an Award, or to require a Participant to remit to the Company an amount in cash or other property (including Stock) to satisfy such withholding before taking any action with respect to an Award, and to take such other action as the Committee may deem advisable to enable the Company and Participants to satisfy obligations for the payment of withholding taxes and other tax obligations relating to any Award, provided that the Committee may allow for additional withholding not to exceed any maximum statutorily permitted amount. This authority shall include authority to withhold or receive Stock or other property and to make cash payments in respect thereof in satisfaction of a Participant’s withholding obligations, either on a mandatory or elective basis in the discretion of the Committee, or in satisfaction of other tax obligations. The Company can delay the delivery to a Participant of Stock under any Award to the extent necessary to allow the Company to determine the amount of withholding to be collected and to collect and process such withholding.
|
(ii)
|
Required Consent to and Notification of Code Section 83(b) Election.
No election under Section 83(b) of the Code (to include in gross income in the year of transfer the amounts specified in Code Section 83(b)) or under a similar provision of the laws of a jurisdiction outside the United States may be made unless expressly permitted by the terms of the Award document or by action of the Committee in writing prior to the making of such election. In any case in which a Participant is permitted to make such an election in connection with an Award, the Participant shall notify the Company of such election within ten days of filing notice of the election with the Internal Revenue Service or other governmental authority, in addition to any filing and notification required pursuant to regulations issued under Code Section 83(b) or other applicable provision.
|
(iii)
|
Requirement of Notification Upon Disqualifying Disposition Under Code Section 421(b).
If any Participant shall make any disposition of shares of Stock delivered pursuant to the exercise of an ISO under the circumstances described in Code Section 421(b) (i.e., a disqualifying disposition), such Participant shall notify the Company of such disposition within ten days thereof.
|
(e)
|
Changes to the Plan.
The Board may amend, suspend or terminate the Plan or the Committee’s authority to grant Awards under the Plan without the consent of stockholders or Participants; provided, however, that any amendment to the Plan shall be submitted to the Company’s stockholders for approval not later than the earliest annual meeting for which the record date is at or after the date of such Board action:
|
(i)
|
If such stockholder approval is required by any federal or state law or regulation or the rules of the New York Stock Exchange or any other stock exchange or automated quotation system on which the Stock may then be listed or quoted; or
|
(ii)
|
If such amendment would materially increase the number of shares reserved for issuance and delivery under the Plan; or
|
(iii)
|
If such amendment would alter the provisions of the Plan restricting the Company’s ability to grant Options or SARs with an exercise price that is not less than the Fair Market Value of Stock; or
|
(iv)
|
In connection with any action to amend or replace previously granted Options or SARs in a transaction that constitutes a “repricing,” as such term defined herein under Sections 6(b)(ii) and 6(c)(ii).
|
(f)
|
Right of Setoff.
The Company or any subsidiary or affiliate may, to the extent permitted by applicable law, deduct from and set off against any amounts the Company or a subsidiary or affiliate may owe to the Participant from time to time (including amounts payable in connection with any Award, owed as wages, fringe benefits, or other compensation owed to the Participant), such amounts as may be owed by the Participant to the Company, including but not limited to amounts owed under Section 10(a), although the Participant shall remain liable for any part of the Participant’s payment obligation not satisfied through such deduction and setoff. By accepting any Award granted hereunder, the Participant agrees to any deduction or setoff under this Section 11(f).
|
(g)
|
Unfunded Status of Awards; Creation of Trusts.
To the extent that any Award is deferred compensation, the Plan is intended to constitute an “unfunded” plan for deferred compensation with respect to such Award. With respect to any payments not yet made to a Participant or obligation to deliver Stock pursuant to an Award, nothing contained in the Plan or any Award shall give any such Participant any rights that are greater than those of a general creditor of the Company; provided that the Committee may authorize the creation of trusts and deposit therein cash, Stock, other Awards or other property, or make other arrangements to meet the Company’s obligations under the Plan. Such trusts or other arrangements shall be consistent with the “unfunded” status of the Plan unless the Committee otherwise determines with the consent of each affected Participant.
|
(h)
|
Nonexclusivity of the Plan.
Neither the adoption of the Plan by the Board nor its submission to the stockholders of the Company for approval shall be construed as creating any limitations on the power of the Board or a committee thereof to adopt such other incentive arrangements, apart from the Plan, as it may deem desirable, including incentive arrangements and awards which do not qualify under Code Section 162(m), and such other arrangements may be either applicable generally or only in specific cases.
|
(i)
|
Payments in the Event of Forfeitures; Fractional Shares.
No fractional shares of Stock shall be issued or delivered pursuant to the Plan or any Award. The Committee shall determine whether cash, other Awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.
|
(j)
|
Compliance with Code Section 162(m).
It is the intent of the Company that Options and SARs granted to Covered Employees and other Awards designated as Awards to Covered Employees subject to Section 7 shall constitute qualified “performance-based compensation” within the meaning of Code Section 162(m) and regulations thereunder, unless otherwise determined by the Committee at the time of allocation of an Award. Accordingly, the terms of Sections 7(b)
|
(k)
|
Certain Limitations on Awards to Ensure Compliance with Code Section 409A.
For purposes of this Plan, references to an award term or event (including any authority or right of the Company or a Participant) being “permitted” under Section 409A mean, for a 409A Award, that the term or event will not cause the Participant to be liable for payment of interest or a tax penalty under Section 409A and, for a Non-409A Award, that the term or event will not cause the Award to be treated as subject to Section 409A. Other provisions of the Plan notwithstanding, the terms of any 409A Award and any Non-409A Award, including any authority of the Company and rights of the Participant with respect to the Award, shall be limited to those terms permitted under Section 409A, and any terms not permitted under Section 409A shall be automatically modified and limited to the extent necessary to conform with Section 409A. For this purpose, other provisions of the Plan notwithstanding, the Company shall have no authority to accelerate distributions relating to 409A Awards in excess of the authority permitted under Section 409A, and any distribution subject to Section 409A(a)(2)(A)(i) (separation from service) to a “key employee” as defined under Section 409A(a)(2)(B)(i), shall not occur earlier than the earliest time permitted under Section 409A(a)(2)(B)(i).
|
(l)
|
Certain Limitations Relating to Accounting Treatment of Awards.
Other provisions of the Plan notwithstanding, the Committee’s authority under the Plan (including under Sections 8(c), 11(c) and 11(d)) is limited to the extent necessary to ensure that any Option or other Award of a type that the Committee has intended to be subject to fixed accounting shall not become subject to “variable” accounting solely due to the existence of such authority, unless the Committee specifically determines that the Award shall remain outstanding despite such “variable” accounting.
|
(m)
|
Governing Law.
The validity, construction, and effect of the Plan, any rules and regulations relating to the Plan and any Award document shall be determined in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of laws, and applicable provisions of federal law.
|
(n)
|
Awards to Participants Outside the United States.
The Committee may modify the terms of any Award under the Plan made to or held by a Participant who is then resident or primarily employed outside of the United States in any manner deemed by the Committee to be necessary or appropriate in order that such Award shall conform to laws, regulations, and customs of the country in which the Participant is then resident or primarily employed, or so that the value and other benefits of the Award to the Participant, as affected by foreign tax laws and other restrictions applicable as a result of the Participant’s residence or employment abroad shall be comparable to the value of such an Award to a Participant who is resident or primarily employed in the United States. An Award may be modified under this Section 11(n) in a manner that is inconsistent with the express terms of the Plan, so long as such modifications will not contravene any applicable law or regulation or result in actual liability under Section 16(b) for the Participant whose Award is modified.
|
(o)
|
Limitation on Rights Conferred under Plan.
Neither the Plan nor any action taken hereunder shall be construed as (i) giving any Eligible Person or Participant the right to continue as an Eligible Person or Participant or in the employ or service of the Company or a subsidiary or affiliate, (ii) interfering in any way with the right of the Company or a subsidiary or affiliate to terminate any Eligible Person’s or Participant’s employment or service at any time (subject to the terms and provisions of any separate written agreements), (iii) giving an Eligible Person or Participant any claim to be granted any Award under the Plan or to be treated uniformly with other Participants and employees, or (iv) conferring on a Participant any of the rights of a stockholder of the Company unless and until the Participant is duly issued or transferred shares of Stock in accordance with the terms of an Award or an Option is duly exercised. Except as expressly provided in the Plan and an Award document, neither the Plan nor any Award document shall confer on any person other than the Company and the Participant any rights or remedies thereunder.
|
(p)
|
Severability; Entire Agreement.
If any of the provisions of the Plan or any Award document is finally held to be invalid, illegal or unenforceable (whether in whole or in part), such provision shall be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability, and the remaining provisions shall not be affected thereby; provided, that, if any of such provisions is finally held to be invalid, illegal, or unenforceable because it exceeds the maximum scope determined to be acceptable to permit such provision to be enforceable, such provision shall be deemed to be modified to the minimum extent necessary to modify such scope in order to make such provision enforceable hereunder. The Plan and any agreements or documents designated by the Committee as setting forth the terms of an Award contain the entire agreement of the parties with respect to the subject matter thereof and supersede all prior agreements, promises, covenants, arrangements, communications, representations and warranties between them, whether written or oral with respect to the subject matter thereof.
|
(q)
|
Plan Effective Date and Termination.
The Plan as hereby amended shall become effective if, and at such time as, the stockholders of the Company have approved it in accordance with applicable law and stock exchange requirements. Unless earlier terminated by action of the Board of Directors, the authority of the Committee to make grants under the Plan shall terminate on the date that is ten years after the latest date upon which stockholders of the Company have approved the Plan, and the Plan will remain in effect until such time as no Stock remains available for delivery under the Plan or as set forth above and the Company has no further rights or obligations under the Plan with respect to outstanding Awards under the Plan.
|
11.
|
Payments Following Termination
.
|
COMPANY:
|
CNO SERVICES, LLC
|
|
/s/ Gary C. Bhojwani
|
Gary C. Bhojwani
|
President
|
|
EXECUTIVE:
|
|
/s/ Yvonne K. Franzese
|
Yvonne K. Franzese
|
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
Pretax income from operations:
|
|
|
|
|
|
|
|
|
|
||||||||||
Net income
|
$
|
175.6
|
|
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
$
|
51.4
|
|
|
$
|
478.0
|
|
Add income tax expense (benefit)
|
304.9
|
|
|
(5.0
|
)
|
|
97.0
|
|
|
123.7
|
|
|
(173.2
|
)
|
|||||
Pretax income from operations
|
480.5
|
|
|
353.2
|
|
|
367.7
|
|
|
175.1
|
|
|
304.8
|
|
|||||
Add fixed charges:
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense on corporate debt
|
46.5
|
|
|
45.8
|
|
|
45.0
|
|
|
43.9
|
|
|
51.3
|
|
|||||
Interest expense on investment borrowings and borrowings related to variable interest entities
|
77.2
|
|
|
70.6
|
|
|
49.9
|
|
|
48.9
|
|
|
54.0
|
|
|||||
Interest added to policyholder account balances
|
105.2
|
|
|
112.9
|
|
|
122.7
|
|
|
173.0
|
|
|
232.5
|
|
|||||
Portion of rental (a)
|
18.7
|
|
|
17.2
|
|
|
14.1
|
|
|
15.1
|
|
|
13.3
|
|
|||||
Fixed charges
|
247.6
|
|
|
246.5
|
|
|
231.7
|
|
|
280.9
|
|
|
351.1
|
|
|||||
Adjusted earnings
|
$
|
728.1
|
|
|
$
|
599.7
|
|
|
$
|
599.4
|
|
|
$
|
456.0
|
|
|
$
|
655.9
|
|
Ratio of earnings to fixed charges
|
2.94X
|
|
|
2.43X
|
|
|
2.59X
|
|
|
1.62X
|
|
|
1.87X
|
|
(a)
|
Interest portion of rental is estimated to be 33 percent.
|
Name
|
State or Other Jurisdiction
|
40|86 Advisors, Inc.
|
DE
|
40|86 Mortgage Capital, Inc.
|
DE
|
American Life and Casualty Marketing Division Co.
|
IA
|
Bankers Conseco Life Insurance Company
|
NY
|
Bankers Life Advisory Services, Inc.
|
IN
|
Bankers Life and Casualty Company
|
IL
|
Bankers Life Securities General Agency, Inc.
|
IN
|
Bankers Life Securities, Inc.
|
IN
|
Business Credit Administration Corp.
|
IN
|
C.P. Real Estate Services Corp.
|
NJ
|
CDOC, Inc.
|
DE
|
CNO Financial Group, Inc.
|
DE
|
CNO Financial Investments Corp.
|
IL
|
CNO Management Services Company
|
TX
|
CNO Services, LLC
|
IN
|
Colonial Penn Life Insurance Company
|
PA
|
Conseco Life Insurance Company of Texas
|
TX
|
Conseco Marketing, L.L.C.
|
IN
|
Design Benefit Plans, Inc.
|
IL
|
Hawthorne Advertising Agency Incorporated
|
PA
|
Illinois General Investment Corp.
|
DE
|
Indiana General Investment Corp.
|
DE
|
K.F. Agency, Inc.
|
IL
|
K.F. Insurance Agency of Massachusetts, Inc.
|
MA
|
Performance Matters Associates, Inc.
|
IN
|
Resource Life Insurance Company
|
IL
|
Washington National Insurance Company
|
IN
|
1.
|
I have reviewed this annual report on Form 10-K of CNO Financial Group, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
1.
|
I have reviewed this annual report on Form 10-K of CNO Financial Group, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
(1)
|
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
(1)
|
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|